

#15
RECEIVED
JAN 14 2003
TECH CENTER 1600 2900
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ent application of: ROBERTSON, et al

No.: 09/380,327

September 3, 1999

Dr: TREATMENT AND DIAGNOSIS OF INFERTILITY
USING TGFBETA OR ACTIVIN

Examiner: Huynh, Phuong

Art Unit: 1644

Docket #: P07407US00/BAS

LETTER TO THE EXAMINER

Honorable Commissioner for Patents
Washington, D.C.

S I R:

In furtherance of the Amendment filed along with the CPA on December 23, 2002 in the above-identified case, Applicants now submit herewith the executed declaration of Dr. David Alexander Clark, M.D., Ph.D. along with the original exhibits.

In light of the submission of the executed document, in combination with the amendments and arguments as submitted on December 23, 2002, Applicants submit that the present case is in condition for immediate allowance, and such action is earnestly solicited.

Respectfully submitted,
LARSON & TAYLOR, PLC

January 10, 2003


B. Aaron Schulman
Registration No. 31877

1199 North Fairfax Street, Suite 900
Alexandria, Virginia 22314
(703) 739-4900



Declaration under U.S.C. § Rule 132

IN THE MATTER OF
US Patent Application No.
09/380,327 by
ROBERTSON et al.

STATUTORY DECLARATION

I, David Alexander Clark of 444 Smith Ave., Burlington in the Province of Ontario, Canada, do solemnly and sincerely declare as follows:

1. _____ I hold the degrees of Doctor of Medicine and Doctor of Philosophy, and am a Diplomate of the American Board of Internal Medicine, a Fellow of the Royal College of Physicians of Canada and a Fellow of the Royal College of Physicians of Edinburgh (UK). I am a Professor (now Emeritus) in the Department of Medicine, with cross appointment in the Departments of Obstetrics and Gynaecology, and Molecular Medicine and Pathology, in the Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada, and a Professor in the Institute of Medical Sciences in the School of Graduate Studies of the University of Toronto. A copy of my *curriculum vitae* is now shown to me and annexed hereto as Exhibit DAC-1.

2. _____ Since 1977, one of my major research interests has been the immunology of pregnancy, in particular the mechanisms underlying immunological rejection of the foeto-placental unit by the maternal immune system. I have published over 100 scientific papers in this field.

3. I am the same David A. Clark who is the first author of the paper entitled "CD56⁺ lymphoid cells in human first trimester pregnancy decidua as a source of novel transforming growth factor- β_2 " (Human Reproduction 1994 9 2270-2277). I am informed that this paper was cited by the Examiner in the Office Action dated 27 August 2002 issued in respect of this application. Other publications from my laboratory are referred to in the publication by Chaouat et al (J. Immunology 1985 134 1594-8), which was also cited in this Office Action.

4. I have read and understood the specification of the present application, US Application No. 09/380327, and the Office Action dated 27 August 2002 issued in respect of this application. I understand that this Office Action has been made final.

5. My understanding of the state of the field in relation to possible immunological causes of infertility and the role of TGF β , as it stood at the priority date, 6 March 1997 is as follows:

Infertility in humans may occur due to

- (i) failure of fertilization,
- (ii) failure of the fertilized ovum to develop into a blastocyst,
- (iii) failure of the blastocyst to implant,
- (iv) failure during the period prior to implantation until formation of a vascularized placenta (i.e. occult losses, chemical pregnancies), or
- (v) failure in the form of spontaneous abortion of a clinically evident pregnancy (i.e. missed menses + positive pregnancy test).

Immunological causes of (i) in 1997 included anti-sperm antibodies. and pro-inflammatory cytokines such as tumor necrosis factor α , IL-1, and interferon γ . Proinflammatory cytokines were found in the peritoneal fluid of women suffering from early endometriosis. This condition proceeds to fibrosis of the fallopian tubes and their ostia; TGF β could contribute to such scarring. Concerning (ii), proinflammatory cytokines, particularly interferon γ , were proposed to arrest embryonic development. Problem (iii) could be produced by similar proinflammatory cytokines.

This is opposite to the teaching from the data of Robertson and Tremellen, in the present specification, which indicates that inflammation is important for implantation. However, proinflammatory cytokines were also viewed as deleterious to trophoblast outgrowth during nidation, and hence could contribute to (iv). TGF β s inhibited trophoblast outgrowth, and were viewed as potentially inhibitory to development. Indeed, Graham and Lala (J. Cell. Physiol. 1991 148 228-234) specifically showed that activation of TGF β 1 by trophoblast cells inhibited their invasive and proliferative properties.

Autoimmunity in the form of autoantibodies, particularly antiphospholipid antibodies was thought important. Rote et al (Biol. Reprod. 1995 53 905-910 and 1997 56 50-58) suggested that certain antiphospholipid antibodies could bind to trophoblast cells, and block their ability to form a placenta. Gleicher et al (Am. J. Reprod. Immunol. 2002 48 252-254 and earlier in Am. J. Obstet Gynecol 1998 159 223-227) suggested that an polyclonal activation of autoantibody production occurred in those patients with autoimmunity and infertility, and is associated with activation of T cells producing proinflammatory Th1-type cytokines which are important in causing the infertility.

There was no information to suggest that any TGF β isoform outside of the embryo *per se* was playing a positive role in fertility. The immunology of spontaneous abortion of an established pregnancy was thought to depend on inhibition of proinflammatory cytokine production by Th2/3 cytokines. The Th2 cytokine of particular importance was considered to be IL-10, although it is now known that IL-6 may also be important. A Th3 cytokine which was a TGF β 2-related molecule of novel structure and properties, which was disclosed in the paper by Clark et al cited by the Examiner, was viewed as particularly important. This cytokine was produced by cells bearing a $\gamma\delta$ T cell receptor able to recognize antigens on trophoblast, unlike conventional T cells with $\alpha\beta$ receptors, which are unable to trigger immune reactions to antigens on trophoblast. The Clark paper is discussed further below.

6. _____ There was no information to support the idea that administering any conventional isoform of TGF β could or would have any beneficial effect on any of the steps required for reproductive success.

7. _____ I am the author of a review article, published in 1998, Clark DA, Coker R, Molecules in focus: Transforming growth factor-beta (TGF- β), Int. J. Biochem. Cell Biol. 1998 30 293-298), a copy of which is annexed hereto as Exhibit DAC-2. This was submitted on 30 July 1996, ie. before the claimed priority date of this application, and accepted on 3 October 1997. This review shows that at that time the only speculated diagnostic or therapeutic role for TGF β in fertility pertained to the novel TGF β 2-related molecules described in Clark et al in recurrent spontaneous miscarriages.

A great deal has happened since 1997, and the only data indicating that exogenous administration of a conventional isoform of TGF β could improve fertility has come from the research of Dr. Sarah Robertson, one of the inventors of the present application.

8. _____ One of the Examiner's substantive objections is that the specification does not constitute an enabling disclosure, and includes subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor, at the time the specification was filed, had possession of the claimed invention. I further understand that this objection results from the Examiner's opinion that the scope of the claims goes beyond what is disclosed in the specification.

9. _____ In particular, the Examiner appears to consider that the specification provides an enabling disclosure only in respect of TGF- β ₁, sperm antigens and MHC Class I, but does not encompass any other type of antigen, or any modified TGF β , or analogue or fragment of TGF β .

The full-length sequences of the different isoforms of TGF- β are known, and the sequences of a variety of fragments and analogues of various TGF- β isoforms are also known. I consider that the information provided in the specification would enable a person of ordinary skill in the art to determine whether any given fragment or analogue is suitable for use in the invention. In particular, intermediates in the processing pathway of activation of latent TGF- β could be used by a person of such ordinary skill to determine if they have the same fertility-enhancing and tolerance promoting effects as those demonstrated by the inventors.

10. I consider that it is clear from the introductory part of the specification, particularly the passage at page 4 line 14 to page 5 line 11 and from the summary of the invention at page 5 lines 25 to 28, that in order for a given molecule of the TGF β superfamily, and in particular a TGF β molecule, to be useful for the purposes of the claimed invention it must have the ability to induce synthesis of granulocyte-macrophage colony stimulating factor (GM-CSF) in uterine epithelial cells. TGF β is a member of a "superfamily" of molecules, which is well recognised in the art, and which includes all of the isoforms of TGF β , and other molecules such as activins, bone morphogenetic proteins, glial cell line-derived neurotrophic factor, and macrophage inhibitory cytokine-1. The specification as lodged therefore clearly demonstrates that TGF β 1, TGF β 2 and activin are all able to trigger the Type II response cascade. The activation of this cascade is known in the art to lead to the stimulation of antigen-presenting dendritic and macrophage cells, which subsequently invade the stromal tissue and increase the intensity of antigen signalling to the lymph nodes, all of which may participate in alleviation of an infertility condition.

11. I have been asked by the applicant's Australian patent attorney, Dr Vivien Santer of Griffith Hack, to consider the following questions:

a) At the priority date, 6 March 1997, would a person familiar with TGF β have considered that it was reasonably predictable that TGF β 1, TGF β 2 and TGF β 3 would have similar effects in most situations?

It was known in March 1997 that different isoforms of TGF β had similar actions in most situations. Any differences related to differences in concentration required to show the effects. For example, for TGF- β 1 and β 2 were immunosuppressive at a similar concentration, but suppression of bone marrow (myeloid) cell growth required a several-fold increase in TGF β 2 concentration compared to TGF β 1 (Nature 1987 329 539-541). Shah et al (J. Cell Sci. 1995 108 983-1002) had suggested that TGF- β 3 might counteract the anti-fibrosis effects of TGF- β 1, but to the best of my knowledge, these data have never been confirmed. During embryogenesis, distinct patterns of expression of different

isoforms had been noted. The meaning of such differences was a matter of speculation, since data from relevant knock-out mice had not been published.

b) Would such a person's opinion have changed between the priority date and date of publication, 11 September 1998?

I do not consider that this opinion would have changed during this period.

c) In particular, would TGF β 1, TGF β 2 and TGF β 3 have been reasonably expected to have a similar effect on fertility?

Caniggia et al (Endocrinology 1997 138 4977-4988) have shown that TGF β 1 and β 3 bound to endoglin on trophoblast, and then would inhibit proliferation by binding to Type I+II receptors; TGF- β 2 bound directly to the latter to produce this inhibition. There was no basis for thinking that conventional isoforms of TGF β should act differently on fertility.

I therefore consider that at the claimed priority date, 6 March 1997, it was accepted in the art that all three isoforms of TGF β have similar biological activities, especially in relation to immunosuppression.

12. I note that the present specification at page 6 lines 11 to 23 states that the three isoforms of TGF β have 70 to 80% sequence homology, and share many biological actions. The passage at page 9 lines 7 to 9 states that

“the specificity of TGF β to be coadministered with the male antigens is at present not entirely clear, and because TGF β ₁ is thought to be responsible whereas TGF β _{2,3} are less important, it is more likely that TGF β ₁ is to be used.”

However, the following passage, from page 9 lines 9 to 17, goes on to make it clear that the invention contemplates that TGF β 2, TGF β 3, activin, or other members of the TGF β superfamily may also be used, and that the invention encompasses modifications of these molecules.

13. The experiments reported in the specification at pages 16 to 29 mainly utilise TGF β 1. However, I note that figure 2 shows that a polyvalent antiserum, which reacts with all three isoforms, totally abolishes the activity of TGF β , whereas a specific anti-TGF β 1 antiserum blocks only 86% of this activity. Figure 4 demonstrates that TGF β 1, TGF β 2 and activin are all able to elicit a GM-CSF response, which is the response stated in the specification to be necessary to start the immune cascade which will alleviate the infertility condition. It is clear from Figure 4 that TGF β 2 was as potent as TGF β 1, and that both of these were much more potent than activin; nonetheless activin did have significant activity.

14. I have been provided with a copy in draft form of a statutory declaration by David Sharkey, which I am informed is to be lodged as part of the response to the Office Action. This declaration reports experiments demonstrating that TGF β 1, TGF β 2 and TGF β 3 are all able to induce an increase in GM-CSF release from human cervical keratinocytes, which are cells of the female reproductive tract. I note that the methods used in these experiments are essentially the same as those described on pages 18 and 19 of the present specification.

15. I note that David Sharkey is a PhD. student at the University of Adelaide, and I therefore consider that he is certainly a person of ordinary skill in the art. Using the methods described in the specification he was able to determine that TGF β 3 did have the necessary activity required for the desired effects on fertility. Indeed, TGF β 3 gave a greater stimulation of GM-CSF production by cervical keratinocytes than TGF β 2.

16. I consider that the Sharkey declaration confirms that using the methods described in the specification TGF β 3 can be identified as suitable for use in the invention, and that these methods would be a matter of routine for a person of ordinary skill in the art.

17. I consider that on the basis of the information provided in the specification, including the experimental results, and on the basis of the general state of the art as it existed at the priority date, it would have been a matter of routine, and would

not have required any inventive effort or undue degree of experimentation, for a person of ordinary skill in the art to have determined that TGF β 3 had the requisite activity to be useful for the purposes of the claimed invention. I similarly consider that such a person of ordinary skill in the art would readily be able to determine whether any other member of the TGF β superfamily was suitable for these purposes.

18. I therefore consider that the specification provides sufficient information for a person of ordinary skill in the art to identify which subtypes of TGF β and members of the TGF β superfamily are suitable for use for the purposes of this invention, and to carry out the invention using the TGF β molecule thus selected. I consider that the person skilled in the art would have regarded TGF β 1, TGF β 2 and TGF β 3 as being functionally interchangeable for all practical purposes for the purposes of the specification.

19. I note that US Patent No. 539825, cited by the Examiner in an obviousness objection, is stated to encompass all of the isoforms of TGF β , namely TGF β 1, TGF β 2, TGF β 3 and TGF β 4 (see Column 5 lines 9 to 11). However, only the use of TGF β 1 is exemplified; see example 3, which refers to TGF β 1 (column 9 line 66) and examples 4 and 6, which do not specify the subtype of TGF β . Notwithstanding this, there is no limitation in the claims to a particular subtype of TGF β , and the Examiner at page 8 of the Office Action relies on this reference to assert that it would be obvious to utilise administration of *any* subtype of TGF β together with an antigen, and to combine this with immunisation of the female parent with a paternal leucocyte antigen.

I also note that in the objection to claims 75 and 76, the Examiner asserts that it would be obvious to use modifications or analogues of TGF β .

20. The Examiner has also objected that the specification does not constitute an enabling disclosure of any antigen other than an MHC Class I antigen on the sperm of the prospective father. I consider that on a fair reading of the specification as a whole, it would be clear to the skilled addressee that it is not necessary that the antigen is actually present on sperm cells; it is merely stated at page 5 lines 31 to 32 that tolerance is elicited "towards male antigens, including paternal MHC Class I antigens". From the passage in

the specification at page 3 lines 24 to 37 it is evident that paternal antigens are present not only in sperm cells but in somatic cells (which are present in ejaculate) and in seminal plasma. At page 8 lines 7 to 9 it is stated that

“the nature of the relevant surface antigens is not entirely clear, but will presumably be those that are particularly antigenic and prominent either on the sperm, or on the conceptus. The most likely candidates are MHC antigens, and more preferably MHC Class I. The most efficient manner of presenting these antigens is in the form that they are naturally present - on any appropriate cell of the intended male parent that expresses them and those cells would include sperm cells and may include leukocytes... This use of cells other than sperm cells will be pertinent where the sperm count of the prospective father is somewhat low. The use of cells other than sperm cells may be preferred where a non-genital route is used... Alternatively the antigens may be presented in purified or semi-purified form, which may or may not be presented on inert or adjuvant carriers...”.

While the experimental examples described in the specification disclose only immunisation by intra-uterine infusion with sperm cells, I consider that it would be abundantly clear to a person of ordinary skill in the art that immunisation by other routes, and with immunogens other than sperm cells, could be used. For example, as stated above the specification states that leukocytes may be used; the reference by Chaouat et al cited by the Examiner discloses immunisation with spleen cells, which are predominantly lymphocytes. The specification also refers to the use of purified or semi-purified antigens.

21. _____ Consequently I consider that a person skilled in the art, provided with the information in the specification, would have no difficulty in using antigens other than MHC Class I antigens present on sperm cells, without the need for any inventive effort or an undue degree of experimentation.

22. _____ I am informed that in a previous office action US Patent No. 5395825 by Feinberg et al was cited as the basis for an objection of lack of novelty. The Examiner has now cited this reference in combination with the publications by Clark et al and by Chaouat et al as the basis for objections that the claimed invention is obvious. The

Examiner asserts that Feinberg teaches a method of treating infertility by administering TGF β together with antigens, such as an ovum, sperm or conceptus, into the reproductive tract of a female to increase the success rate of implantation, and that the TGF β may be administered before, after or simultaneously with male antigen sperm or antigens from the conceptus.

23. _____ In separate rejections, most of the claims are rejected as being obvious over US Patent No. 5395825 by Feinberg et al, in view of the papers by Clark et al and by Chaouat et al referred to above; claims 66, 67 and 71 are rejected as being obvious over this combination of references, together with references by Harlow et al and by Martin-Villa et al; claims 75 and 76 are alleged to be obvious over this combination of references together with papers by Tuan et al or by Lyons et al; claims 83 to 85 are alleged to be obvious in the light of this combination of references together with Grainger et al; and claim 92 is rejected as being obvious over this combination of references together with Heidenreich et al. I have read and understood the references which have been cited by the Examiner.

24. _____ In fact, the specification by Feinberg refers only to the "competence of a conceptus towards uterine implantation (column 3 line 50) and methods of increasing the success rate of *assisted* reproduction (column 3 lines 66 to 67), and is completely silent regarding antigens of any kind, immunisation of the prospective mother, or immune tolerance. The only mention of any immune factor is at column 4 lines 38 to 47, which states that the invention provides methods of contraception and contragestion comprising administering a TGF β *antagonist*, such as antibodies to TGF β , in order to increase the probability that conception will be *prevented*. This is completely opposite to the presently-claimed invention, wherein a TGF β must be administered to increase the probability that a fertilized ovum will succeed in generating a liveborn offspring.

25. _____ I do not consider that the Feinberg specification provides any actual experimental evidence to suggest that

- a) treatment of an ovum or sperm would improve implantation,
- b) the prospective mother would be exposed to sperm of a prospective father

together with TGF β either prior to or after attempted conception, or

- c) the TGF β and antigen of the prospective father should be administered to the prospective mother at different times.

Feinberg suggests that stimulation of fibronectin production by a fertilized ovum by a TGF β should enhance outgrowth of trophoblast which is essential in the process of implantation, which in reality occurs only *in vivo*. However, Feinberg provides experimental evidence only for treatment of the mother *after* implantation. Since Feinberg provides no demonstration that implantation is enhanced, the proposed biological role of a TGF β *in vivo* represents untested speculation.

26. The Clark et al reference, of which I am first author, discloses the up-regulation of release of an endogenous TGF β 2-like molecule from CD56+ cells in decidua during the first trimester of pregnancy, ie. after conception and implantation. The decidua is the inner layer of the wall of the uterus, which envelops the embryo and forms part of the placenta. Consequently this is a tissue of maternal origin, not of foetal or paternal origin. This TGF β 2-related molecule is associated with successful, ie. non-aborting, pregnancy in humans. The Clark paper clearly points out that this TGF β 2-related molecule exhibited different biophysical properties compared to those of conventional 25 kD TGF β 2. In that paper, absence of the novel TGF β 2-like molecule, but not absence of a conventional 25 kD TGF β 2, was linked to recurrent spontaneous abortions. It was further shown in a subsequent publication (Clark et al. Biol Reprod. 1995 52 1380-1388) that the novel TGF β 2-related molecule found in the uterus of a successful pregnancy exhibited very different chemical and biological properties compared to conventional TGF β . A copy of this publication is annexed hereto as Exhibit DAC-3. One would therefore not have expected that administering a conventional TGF β isoform would prove beneficial in preventing infertility due to spontaneous abortions, since the novel TGF β 2-like molecule, described by Clark et al., is *not* a conventional isoform of TGF β .

Therefore this reference does not suggest any role of TGF β prior to implantation, and does not suggest that administration of exogenous TGF β could be used to alleviate an infertility condition.

27. _____ I do not consider that the finding by Chaouat et al, that administration of a female mouse with spleen cells of a histoincompatible mouse increases fetal viability, suggests that immunisation with paternal MHC class I antigens would be useful for treatment of infertility.

The paper cited by the Examiner in fact shows that prevention of spontaneous abortion in DBA/2-mated CBA/J mice could *not* be prevented by immunising the CBA/J female against the Class I MHC of the DBA/2 male. It was necessary to use spleen cells from BALB/c mice. The BALB/c mouse strain is regarded as having the *same* H-2^d Class I MHC antigen as the DBA/2 strain, and from Kiger et al (J. Immunol. 1985 134 2966-2970), it was subsequently known that minor non-MHC antigens on the BALB/c mouse background were required along with H-2^d-associated MHC antigens. Antibodies are rarely if ever made against minor non-MHC antigens. Data from studies in which women were immunised against their husband's HLA-incompatible blood mononuclear cells (e.g. Mowbray JF, Human Reprod. 1988 3 79-82) indicated that an antibody response to MHC was not required for prevention of miscarriages. It was known from Clark et al that immunisation of mice which prevented abortions increased the level of production of the novel TGF β 2-related factor mentioned above, but this should not be taken to indicate that the effect arose from an immune response to the paternal Class I MHC antigens. In fact no published study has shown that immunity to paternal Class I MHC antigens alone can improve the rate of implantation.

28. _____ Feinberg made predictions about the effects of TGF β on implantation. Clark et al and Chaouat et al were describing phenomena occurring *after implantation had been completed*. Indeed, in other publications, Chaouat et al have reported that immunoprevention of spontaneous abortion in the mouse can occur when the treatment is given as late as 3 days after implantation. It would not have been obvious that TGF β treatment of preimplantation embryos would have any effect on the phenomena being

investigated by Clark and by Chaouat. Therefore it could not have been obvious to a person of ordinary skill in the field to combine the disclosure of Feinberg with either or both of the Clark disclosures and the Chaouat disclosure. Nor would it have been obvious to such a skilled person to combine the references by Feinberg, Clark et al and Chaouat et al with any of the additional references cited in items 15 to 18 of the Office Action.

I declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like are punishable by prison or fine or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of any application or patent thereon.

DECLARED at *Hamilton* this *16th* day of *December* 2002
John

David A. Clark.

David A. Clark

Before me:

N. H. Hadler

A person empowered to witness
Statutory Declarations under the
laws of the Province of Ontario,
Canada.

Declaration under U.S.C. § Rule 132

IN THE MATTER OF

US Patent Application No. 09/380,327

by ROBERTSON et al.

EXHIBIT DAC-1

This is Exhibit DAC-1 referred to in the Statutory Declaration by David Alexander CLARK

dated

16 Dec 2002

Before me:



A person empowered to witness Statutory
Declarations under the laws of the Province of
Ontario, Canada.

16/12/02 David A. Clark
DM-1

CURRICULUM VITAE
CLARK, David Alexander

HOME ADDRESS: 444 Smith Avenue,
Burlington, Ontario L7R 2V1,
Canada.

TELEPHONE: -1-(905)-639-4168

BUSINESS ADDRESS: 3V39 McMaster University Medical Center (Hamilton Health
Sciences),
1200 Main Street West,
Hamilton, Ontario, L8N 3Z5, CANADA.

TELEPHONE: -1-(905) 521-2100 Ext. 76376/76375 (McMaster U. Medical Center)
Cell -1-(905)-517-3017
-1-(905)-387-9495 (Hamilton Regional Cancer Center)

EMAIL: clarkd@mcmaster.ca

DATE OF BIRTH: April 26, 1943.
St Thomas, Ontario.

EDUCATION:

University of Western Ontario	1960-67
Rotating Intern, St. Paul's Hospital, Vancouver, British Columbia	1967-68
Junior Assistant Resident in Medicine, Victoria Hospital, London, Ontario, and Lemuel Shattuck Hospital, Boston, Mass., USA	1968-69
Senior Assistant Resident in Medicine, University of Western Ontario, Department of Medicine	1969-70
Clinical Research Fellow in Oncology and Immunology, Tuft's New England Medical Center, Boston, Mass., USA	1970-72

Member Eastern Cooperative Oncology Group	1970-72
--	---------

Graduate Student, Institute of Medical Science, University of Toronto, and Ontario Cancer Institute, Toronto, Canada	1972-76
---	---------

**DEGREES
AND DIPLOMAS:**

M.D., University of Western Ontario (Gold Medalist, summa cum laude)	1967
---	------

L.M.C.C. (Licentiate Medical Council of Canada)	1968
--	------

Diplomate American Board of Internal Medicine, Boston, Mass., USA	1972
---	------

Fellow, Royal College of Physicians and Surgeons of Canada (Internal Medicine)	1974
--	------

Ph.D. (Thesis: Regulation of Cytotoxic T lymphocytes) R.G. Miller, Supervisor, University of Toronto	1977
---	------

Fellow of the Royal College of Physicians (Edinburgh, UK)	2001
--	------

HONOURS:

Ontario Government Scholarship (Ontario Scholar)	1961
---	------

Khaki University and YMCA Scholarship	1961
--	------

University of Western Ontario Board of Governor's Scholarship	1962
--	------

Mathematics Class of 1949 Prize	1962
---------------------------------	------

J.P. Campbell Scholarship in Physiology	1964
--	------

Mosby Histology Prize	1964
-----------------------	------

CIBA Award	1965
Mosby Award	1965
Medical Alumni Gold Medal	1967
Eccles Scholarship, Poulenc Award & Gold Medal	1967
MRC Fellowship	1972-77
MRC Scholarship	1980-84
MRC Scientist Award	1984-88
Fellow, Royal Society of Medicine (London,UK)	1992-
President-elect, American Society for Reproductive Immunology	1995-96
President, ASRI	1996-98
President-elect, International Society for Immunology of Reproduction, (ISIR)	1995-98
President, ISIR	1998-2001
President d'Honneur, ISIR	2001-
Gold Medal of the ISIR	2001
Fellow, Royal College of Physicians (UK)	2002
CURRENT STATUS: Associate Member Obstetrics & Gynecology	11-1984-
Associate Member Molecular Medicine and Pathology	2-1993-
Tenured regular appointment - Medicine	01-1989-02
Emeritus Professor of Medicine, (+ Molecular Medicine & Pathol. + Ob-Gyn. + Graduate Program in Health Sciences) McMaster University	2002-

Professor, Institute of Medical Sciences,
Univ. Toronto Faculty of Graduate Studies 2002-

**PROFESSIONAL
ORGANIZATIONS:**

Vice President ASRI	1986-87
Councillor ASRI - elected	1994-
Councillor ISIR - elected	1986-89
Councillor ISIR - Re-elected	1989-92
Presidential Reappointment to Council	1992-95
President-Elect ASRI	1995-6
President - ASRI	1996-98
Past-President – ASRI	1998-00
President-Elect ISIR	1995-8
President - ISIR	1998-2001
Past-President – ISIR	2001-

EMPLOYMENT HISTORY:

Assistant Professor of Medicine, McMaster University, (Tenured)	1976-82
Associate Professor of Medicine, McMaster University, Hamilton (secondary i.e. cross appointment) Obstetrics/Gynecology)	1982-86 1982-86
Professor of Medicine, McMaster University, Tenured (secondary i.e. cross appointment Obstetrics/Gynecology (secondary appointment) Pathology	1986- 1986- 1993-
Consultant in Medical Oncology, Ontario Cancer Foundation, Hamilton Clinic	1977-
Member, Graduate School Faculty, McMaster University, Hamilton	1977-
Affiliate Staff, Hamilton Civic Hospitals, Hamilton	1976-
Associate Staff, McMaster University Medical Centre, Hamilton	1977-78

Active Staff, McMaster University Medical Centre, Hamilton Health Sciences Corporation, Hamilton	1978-
Associate Member, Reproductive Biology Program	7-1984-
WHO Advisor	11-12-1988
Member, Board of Comprehensive Examination Chairs Graduate Program Faculty of Health Sciences	1998-2004
Chair, Palliative Care Committee McMaster University Medical Center	1980-1990
Member, Research Ethics Board, HHSC	1999-
Member, Pharmacy & Therapy Committee, Hamilton Health Sciences	2001-
Affiliate Scientist, Organ Transplant, Dept. Cell Molec. Biol., Univ. Health Network, U of Toronto	2001-

SCHOLARLY AND PROFESSIONAL ACTIVITIES:

Editorial Boards:	Editorial Board, Journal of Reproductive Immunology	1985-1992
	Editorial Board, American Journal of Reproductive Immunology	1985-
	Associate Editor, Journal of Immunology, Section of Clinical Immunology and Immunopathology	1985-1989
	Editorial Board, Regional Immunology	1987-1992
	American Journal of Reproductive Immunology	1984-

	Associate Editor for North America, American Journal of Reproductive Immunology	1992-
Grant and Personnel Committees:	Member - Applications Committee – Banting Research Foundation	1979-
	Member - MRC Fellowship Panel	1983-1985
	Scientific Officer, MRC Grants Panel for Immunology and Transplantation	1985-1990
	MRC Group Site Review Team	1994
	Member-MRC - PMAC Grants Panel	1995-1998
	-MRC - Senior/Distinguished Scientist Awards Panel	1995-1998
	HED NIH Study Section member	2001-
Executive Position:	6th International Congress of Immunology, Toronto, Canada (Chair, Organizing Committee)	1986
	NCIC Lung Cancer Clinical Trials Committees (2)	1982-86
	Chairman of Local Organizing Committee (3rd International Congress of Reproductive Immunology)	1983-86
	Member of Scientific Committee, Immunology of Normal & Diabetic Pregnancy (Erice, Sicily)	1990
	Program Committee (ASIR) Ethics Committee (ASIR) (Chair of Statistical Analysis Subcommittee)	1990-
	Associate Editor for North America, American Journal of Reprod. Immunol.	1992-
	Program Committee 6th Int. Congress Reprod. Immunol.(Washington, 1995)	1992-95
	Program Committee 1993 ASIR-AAI meeting	

(Denver)	1992-93
Program Committee Annual ASRI meetings	1994-2002
NIH/NICHD Scientific Study Group, Bethesda, Md. USA (ad hoc)	1992-
President-elect, Amer. Soc. Reprod. Immunol.	1995-96
President, ASIR	1996-98
Program Committee - 4th Banff Conference	1996
President-Elect, International Society Reprod. Immunol.	1995-98
NIAID/NIH Task Force on Immunology (Co-Chair)	1997-98
President ISIR	1998-2001
Member, International Scientific Program Committee, 12 th International Congress of Immunology (Montreal, 2004)	2001-2004
Member, NIH HED Study Section	2001-
Editorial Board, Journal of Assisted Reprod. and Genetics	2001-
Safety Monitor, US FDA Immunotherapy Study	2002-
Journal Referee:	
Journal of Immunology	1979-
Regional Immunology	1988-
American Journal of Reproductive Immunology	1983-
Journal of Reproductive Immunology	1983-
Journal of Reproduction and Fertility	1984-
Fertility and Sterility	1986-
Immunopharmacology	1986-
American Journal of Obstetrics & Gynaecology	1988-
Immunology Letters	1984-
Reproduction, Fertility & Development	1989-
Journal of Clinical Immunology	1990-
New England Journal of Medicine	1990-

Biology of Reproduction	1990-
Developmental Biology	1990
Periodicum Biologicum	1990-
Lancet	1992-
Human Reproduction Journals	1992-
Cellular Immunology	1980-
Immunology (BSI, UK)	1999-
Clinical & Experimental Immunol	2001-
Proc. Soc. Exp. Biol. Med.	1983-

External Grant Reviews: World Health Organization
MRC New Zealand
National Cancer Institute of Canada
MRC/CIHR Canada
National Institutes of Health (USA)
Ministry of Health (Ontario, Manitoba, Alberta, & BC)

AREAS OF INTEREST: Reproductive Medicine and Solid Tumor Systemic Therapy:
Consulting
Teaching
Research

COURSES TAUGHT: Discipline Coordinator and
Large Group Leader - Immunology
MD Program 1982-86

Advance Immunobiology (715)
(given alternate years to 739, average
2-4 sessions) 1978-92

Seminar Leader and Course Module
Co-ordinator 1992-97

Module II Coordinator/Leader MS715A
(Yearly) 1997-2001

General Pathology (729)
Seminar Leader 1979-

Immunogenetics (739)
Seminar Leader (given alternate
years to 715, average 2-3 sessions)
(Currently requested in 2001) 1983-97

Reproductive Immunology (777)
Seminar Leader (given when
scheduled, average 2-4 sessions) 1979-

Unit 2 Tutor and Unit 3 Tutor	1996,1998,2000 2001
----------------------------------	------------------------

4ii3 Undergraduate Immunology (Lecturer & Examiner)	1997-
--	-------

SUPERVISORSHIPS:

Master:	R. Slapsys (complete)	1983
	J. Brierley (complete)	1986
	S. Daya (complete)	1986
	F. Merali (complete)	1993
	K. Yu (to begin May 2001)	

Doctoral:	R. Slapsys (complete)	1987
	K. Wright (complete)	1987
	O. Porat (complete)	1991
	A. Cadavid (complete 1998)	1998
	M. Knackstedt (In progress)	1999

Post-Doctoral:	J. Kreck (complete)	1983
	P. Nagarkatti (complete)	1983
	R. Lea (complete)	1988-91
	H. Hirte (complete)	1990
	E. Muzikova (complete)	1993
	S. Wang (complete)	1993
	P. Arck (complete)	1993-96

MD Research Electives:	J. Neiss (complete)	1998
	A. Keil (complete)	2000

Professional:	MD Program (OPD Oncology Rotation in Ambulatory Care, MUMC/HSC)	1987-
	CTU (Medicine Physician)	1988,1990
	Immunotherapy Program for recurrent Pregnancy failure couples (with Dr. Salim Daya)	1988-

Supervisory Committees:	M. Eveleigh (complete)	1980
	M. Chan (")	1982
	S. Gee (")	1979
	K. Rosenthal (")	1979
	K. Wright (")	1980

	P. Ernst	(")	1986
	J. Toles	(")	1986
	M. Romi	(")	1991
	F. Merali	(")	1993
	S. Gyorffy		1994 (resigned)
	A. Cadavid	(")	1998
Student Advisor	F. Dossa	(complete)	1999-02
Student Advisor	A. Duggal	(complete)	1998-01
Student Advisor	C. Chin		2001-
Comp Exam	S. Sweet		1996
Ph.D. Exam	H. Zhong		1997
MSc Defense	L.A. Cohen		1997
Comp Exam	S. Carter		1998
Comp Exam	J. Preston		1999
Comp Exam	N. Sharan		2000
Comp Exam	G. Trentin		2000
Comp Exam	D. Dowlatshahi		2000
Comp Exam	B. Gajewska		2000
Comp Exam	S. Ritz		2000
Comp Exam	P. Margettes		2001
Comp Exam	P. Nair		2002
Comp Exam	D. Alvarez		2002
PhD Transfer Exam.	R. Khadaroo (U of Toronto)		2002

Ph.D. Examiner (written and oral 'viva'): L. Flynn, University College, Dublin,
Ireland 7/2000

CURRENT RESEARCH FUNDING:

Canadian Institutes of Health Research (CIHR)
"Immunopathogenesis of viral hepatitis"
(with G.A. Levy), \$186,417/yr 2000-2005

Bayer-Blood Partnership "Mechanism of transfusion-related
immunomodulation: prevention and exploitation" (with M.
Blajchman) \$ 61,500/yr 2001-2003
[this grant received highest peer-reviewers' score in Canada]

Alexander von Humboldt Foundation 2002
Eu 50,000/yr research award.

ASSIGNED INTELLECTUAL PROPERTY (INVENTIONS):

1. Antagonism of procoagulant as a mechanism of prevention of early pregnancy failure. 2/1999
Clark DA

2. Novel prothrombin cleavage as a basis for diagnosis and treatment in human pregnancy. 5/1999
Clark DA, Weitz J, Hirsh J
3. OX-2 ligands: detection of OX-2 receptor. 5/2000
Clark DA
4. Anti-OX-2 antibody blocks stimulation of tumor growth and metastases by transfused allogeneic white blood cells and allows white cells to stimulate anti-tumor effect in vivo. 11/2000
Clark DA
5. Release of a soluble bioactive OX-2 (CD200) from leukocytes in vitro. 5/2001
Clark DA
6. Immunomodulation of MD1 to prevent fetal loss syndrome, pre-eclampsia, and other LPS-dependent pathology. 7/2001
Clark DA

PATENTS:

1. **Title:** Methods of Modulating Immune Coagulation
International Application #: PCT/CA98/00475
International Application Date: May 15th, 1998
Filing Date: November 15th, 1999
Inventor(s): Levy, Gary A; Clark, David A.
Patent awarded: US 2001 #6403089, Australia 2001
2. **Title:** Methods and Compositions for Immunomodulation
International Application #: PCT/CA98/01038
International Application Date: November 6, 1998
Filing Date: January 21, 2000
CIP: Methods for modulating tumor growth 27/7/2001
CIP: Methods and compositions for modulating fertility 23/8/2001
Inventor(s): Gorczynski, Reginald M.; Clark, David A.
3. **Title:** Methods and Composition for Immunoregulation
U.S. Provisional: 60/189985
Filing Date: May 7, 2000
PCT/CA01/00346 16/3/2001
Inventor(s): Gorczynski, Reginald M & Clark, David A.

CO-INVESTIGATOR ON CLINICAL TRIALS:

- 1: Zaledronate 11
- 2: Zaledronate 10
- 3: Petacc/Tomudex vs 5FU (Astra Zeneca)
- 4: CPT 11 vs Oral Topo 5 days vs Oral Topo 21 days
2nd line management; colon cancer

- 5: NCIC CO 14
6. PA-3(Principal-Investigator)

LIFETIME PUBLICATIONS:

EDITED REVIEWS & BOOK CHAPTERS & OTHER CONTRIBUTIONS

1. Clark, D.A. 1966. Mechanisms of mood. In: University of Western Ontario Medical Journal 36(3):74-84.
2. Clark, D.A. and L. Nathanson. 1972. Cellular immunity in malignant melanoma. In: The Pigment Cell, Vol.I. Edited by V. Riley. Karger Basel, pp 350-359.
3. Clark, D.A. and L. Nathanson. 1972. Patterns of cellular immunity in malignant melanoma. In: Recent Results of Cancer Research. Edited by G. Mathe, Springer-Verlag, pp. 67-78.
4. Nathanson, L. and D.A. Clark. 1973. *In vitro* assay of cell-mediated immunity in BCG therapy of malignant melanoma: a preliminary report. National Cancer Inst. Monogr. 39:221-224.
5. Nathanson, L., Necheles, T.F, Clark, D.A., Silverman, E. and D. Whitten. 1975. HLA-5 masking activity in malignant melanoma. Behring Inst. Mitt. 56:97-103.
6. Phillips, R.A., Clark, D.A., Schilling, R.M. and R.G. Miller. 1975. Quantitation and characterization of effector cells and their progenitors. In: Proc. International Cancer Congress, Florence, Italy. 1974. American Elsevier Publishing Co., New York. Vol.I, pp. 264-269.
7. Miller, R.G., Clark, D.A., Harley, E. and R.A. Phillips. 1975. Quantitation of killer T cell-target interaction: suppressor cells at the effector stage. In: Suppressor Cells in Immunity. International Symposium, May 1975. Eds. S.K. Singhal and N.R. St. C. Sinclair. University of Western Ontario, London, Canada, pp. 50-60.
8. Gee, S.R., Chan, M.A., Clark, D.A. and W.E. Rawls. 1980. Genetically acquired resistance to fatal Pichinde virus infection in the Syrian hamster. In: Genetic Control of Resistance to Infection and Malignancy. An International Symposium of the Canadian Society for Immunology. Eds. E. Skamene, P.A. Konghavn and M. Landy. Academic Press, New York, pp. 345-352.
9. Gee, S.R., Chan, M.A., Clark, D.A. and W.E. Rawls. 1980. Susceptibility to fatal Pichinde virus infection in the Syrian hamster. Proc. of Symposium on Hamster Immune Responsiveness and Experimental Modes of Infectious and Oncologic Diseases, June 3-5, 1980. Eds: J.W. Streilein, D. Hart, J. Stein-Streilein, W. Duncan and R.E. Billingham, pp. 327-328.

10. Clark, D.A. 1982. Impairment of host immunity and survival of the fetus. In: Immunobiology of Transplantation, Cancer, and Pregnancy. P.K. Ray, Editor, Pergamon Press, Inc. New York, pp. 278-304.
11. Clark, D.A., Gauldie, J., Sweeney, G. and S. Safe. 1982. Suppression of immune defences by halogenated aromatic hydrocarbons. In: Proc. Second Annual Ontario Ministry of Environment Technology Transfer Conference, November 24, 1981.
12. Clark, D.A., Slapsys, R.M. and M.R. McDermott. 1982. Active localized suppression of killer T cells by suppressor cells in the genital tract of allopregnant mice. In: Immunology of Reproduction. Eds. K. Bratanov, V.H. Vulchanov, V. Dikov, B. Somlev, R. Georgieva and A. Tornyov. Bulgarian Acad. Sci. Press, pp. 418-421.
13. Clark, D.A. 1982. The Promise of RI. A review of the American Journal of Reproductive Immunology. Nature, 299:504.
14. Clark, D.A., Slapsys, R., Croy, B.A., Rossant, J. and M. McDermott. 1983. Regulation of cytotoxic T cells in pregnant mice. In: Immunology of Reproduction. Eds. T. Wegmann and T.J. Gill. III. Oxford Press, New York, pp. 342-361.
15. Clark, D.A., Sweeney, G. and J. Gauldie. 1983. Suppression of immune defences by halogenated aromatic hydrocarbons. In: Proc. Technology Transfer Conference No. 4, Nov. 29-30, 1983, Ontario Ministry of the Environment, pp. 301-308.
16. Clark, D.A. 1984. Role of hormonal immunoregulation in reproduction. In: Pituitary Function and Immunity. Ed: I. Berczi. CRC Press, Inc., Florida, pp. 261-272.
17. Clark, D.A. 1984. Immunoregulatory mechanisms in pregnancy of animals. In: Reproductive Immunology. Eds: S. Isojima and W.D. Billington. Elsevier Science Publishers, New York, pp. 259-262.
18. Clark, D.A., Gauldie, J. and G. Sweeney. 1984. Dose response, time-course and mechanism for suppression of cytotoxic cell generation by 2,3,7,8-tetrachlorodibenzo (P) dioxin. In: Mechanisms for Biological Effects of Dioxins. Cold Spring Harbour, Banbury Report 18:421-434.
19. Clark, D.A. and R. Slapsys. 1985. Immunoregulatory mechanisms in the uterus and survival of the fetus. In: Contributions to Obstetrics and Gynecology, P.J. Keller, Zurich. Karger Basel, 14:44-53.
20. Clark, D.A. 1985. Maternofetal relations: a minireview. Immunol. Letters 9:239-247.
21. Clark, D.A. 1985. Maternal immune response to the fetus. In: Current Trends in Immunology of Human Reproduction. EOS - Revista di Immunologia ed Immunofarmacologia, eds: F. Dondero and S. Shulman. Vol. VI, pp. 114-117.

22. Wright, K.E., Clark, D.A. and W.E. Rawls. 1985. Pichinde virus infection and differences in lymphocyte responsiveness to lymphokines in two inbred strains of Syrian hamster. In: Genetic Control of Host Resistance to Infection and Malignancy pp. 203-209.
23. Clark, D.A. 1985. Oxford Review of Reprod. Biol. Vol. 6, 1984. J. Reprod. Immunol. A review. Vol. 8, pp. 262-264.
24. Clark, D.A. 1985. Survey of Drug Research in Immunological Disease. Vol. 4. Noncondensed Aromatic derivatives. Part III. Vol. 5. Noncondensed Aromatic Derivatives. Part IV. Ed: V. St. Georgiev. Karger, Basel. Book Review. J.A.C.S. 107:25;7800-7801.
25. Clark, D.A. 1985. Prostaglandin and immunoregulation during pregnancy. Editorial Review. Amer. J. Reprod. Immunol. Microbiol. 9:111-112.
26. Clark, D.A., Sweeney, G.D. and J. Gauldie. 1985. Quantitative assessment of immunotoxicity of haloaromatic hydrocarbons. Key role of the thymus gland in susceptibility to dioxin and implications for definition of "no effect" exposure levels. Proc. Technology Transfer, Conf #6, Dec. 11-12, 1985. Ontario Ministry of the Environment. ISSN 0-825-491.
27. Clark, D.A. and T.G. Wegmann. 1986. Reproductive Immunology. In: Immunology in Canada. Immunology Today Suppl. May, 1986. pp. 28-29.
28. Clark, D.A., Damji, N., Chaput, A., Daya, S., Rosenthal, K.L. and J. Brierley. 1986. Decidua-associated suppressor cells and suppressor factors regulating interleukin 2: their role in the survival of the "fetal allograft". In: Progress in Immunology VI (Eds. B. Cinader, R.G. Miller). Academic Press Inc. pp. 1089-1099.
29. Clark, D.A., Brierley, J., Slapsys, R., Daya, S., Damji, N., Chaput, A. and K. Rosenthal. 1986. Trophoblast-dependent and trophoblast-independent suppressor cells of maternal origin in murine and human decidua. In: Reproductive Immunology, 1986. (Eds. Clark, D.A. and B.A. Croy). Elsevier, Amsterdam pp. 219-226.
30. Daya, S., Lee, S., Underwood, J., Mowbray, J., Craft, I. and D.A. Clark. 1986. Prediction of outcome following transfer of *in vitro* fertilized human embryos by measurement of embryo-associated suppressor factor. 3rd ICRI. In: Reproductive Immunology, 1986. (Eds. Clark, D.A. and B.A. Croy), Elsevier, Amsterdam pp. 277-285.
31. Clark, D.A., Chaput, A., Slapsys, R.M., Brierley, J., Daya, S. and R. Allardyce. 1987. Suppressor cells in the uterus. In: Immunoregulation and Fetal Survival. Eds. T. Wegmann and J. Gill. Oxford Univ. Press, New York, pp. 63-77.
32. Clark, D.A., Chaput, A., Slapsys, R., Brierley, J., Daya, S., Rosenthal, K. and G. Chaouat. 1987. Local intrauterine suppressor cells and suppressor factors in survival of the fetal

- allograft. *In: Reproductive Immunology: materno-fetal relationship. INSERM Colloque. Vol. 154, Paris, pp. 77-88.*
33. Croy, B.A., Crepeau, M., Yamashiro, S. and D.A. Clark. 1987. Further studies on the transfer of Mus caroli embryos to immunodeficient Mus musculus. *In: INSERM Colloque. Vol. 154, Paris, France, pp. 101-112.*
 34. Chaouat, G., Lankar, D., Kolb, J.P. and D.A. Clark. 1987. 2 modes d'avortements d'origine immunitaire chez la souris de laboratoire: mecanismes abortifs, modalites et mecanismes de traitement par immunisation contre un male, relie ou non relie, suivant les differences antigeniques pere-mere. *In: INSERM Colloque, Vol. 154, (Chaouat G, ed), Paris, France, pp. 243-254.*
 35. Clark, D.A. 1987. Current concepts of immunoregulation in implantation. *In: Implantation, (Chapman M.G. and J.G. Grudzinskis, eds), Springer-Verlag, London, pp. 163-175.*
 36. Clark, D.A. 1987. On pre-eclampsia and leukocytes in human decidua. Editorial on Khong's paper, *Amer. J. Reprod. Immunol. Microbiol. 15:9-11.*
 37. Clark, D.A. 1987. Immunology and Birth Defects: Introduction to AJRIM special issue. *Amer. J. Reprod. Immunol. Microbiol. 15:131-132.*
 38. Clark, D.A., Goddard, G. and G.D. Sweeney. 1987. Assessment of Toxicity of Digested and Inhaled Haloaromatic Hydrocarbons. MOE Paper. *In: Proc. 1987 Tech. Transfer Conf. pp. 21-36.*
 39. Clark, D.A. 1988. Pregnancy Immunology. *Year Book of Science. McGraw-Hill, pp.340-344.*
 40. Clark, D.A. 1988. Host immunoregulatory mechanisms and the success of the conceptus fertilized *in vivo* and *in vitro*. *In: Early Pregnancy Loss: Mechanisms and Treatment (Beard R.W. and F. Sharp, eds) Peacock Press. Ashton-Under-Lyne, U.K., pp. 215-227.*
 41. Chaouat, G., Clark, D.A. and T.G. Wegmann. 1988. Genetic aspects of the CBA x DBA/2 and B10 x B10.A models of murine pregnancy failure and its prevention by lymphocyte immunisation. *In: Early Pregnancy Loss: Mechanisms and Treatment (Beard R.W. and F. Sharp, eds) Peacock Press, Ashton-Under-Lyne. U.K. pp.89-102.*
 42. Clark, D.A. and S. Daya. 1988. Macrophages and other migratory cells in endometrium: relevance to endometrial bleeding. *WHO Symposium on "Contraception and Mechanisms of Endometrial Bleeding", (D'Arcangues C., Fraser I., Newton J. and V. Odland, eds), Cambridge University Press, pp. 363-382.*
 43. Clark, D.A., Mowbray, J., Underwood, J. and M. Michel. 1988. On granulated cells in human endometrium. Letter to editor. *Amer. J. Immunol. Microbiol. 14:144-146.*

44. Clark, D.A. and S. Daya. 1988. Immunosuppressive activity in IVF supernatants. Letter to Editor *Amer. J. Reprod. Immunol. Microbiol.* 17:156-157.
45. Clark, D.A. 1989. The Immunology of Recurrent Abortion. Chapter 2. *Adv. in Obstetrics & Gynecology*, (Bonnar J., ed) Vol. 16, Churchill Livingstone, London, pp. 25-42.
46. Lea, R.G. and D.A. Clark. 1989. The immune function of the endometrium. *In: Bailliere's Clinical Obstetrics & Gynecology "Dysfunctional Uterine Bleeding and Menorrhagia"*, (J. O'Drife, ed), Vol.3, pp.293-313.
47. Clark, D.A. and G. Chaouat. 1989. Determinants of embryo survival in the peri- and post-implantation period. *Serono Symposia: Blastocyst Implantation*, Yoshinoga, K. ed., Adams, Boston, pp.171-178.
48. Clark, D.A. 1989. Cytokines and Pregnancy. *In: Current Opinion in Immunology*, (Roitt I., ed), Vol.1, Alden Press, London, pp. 1148-1152.
49. Mogil, R., Guilbert, L., Clark, D.A. and T.G. Wegmann. 1989. Immunological cross talk between fetal placental cells and T lymphocytes. *Cellular Basis of Immune Modulation*, Alan R. Liss, pp.171-174.
50. Clark, D.A. 1989. The origin and role determining success and failure in the post-implantation period. *In: Cellular Signals Controlling Uterine Function*. L.A. Lavia ed., Plenum pp.145-155.
51. Clark, D.A., Banwatt, D.K., Manuel, J., Fulop, G. and B.A. Croy. 1989. SCID mice in reproductive biology. *In: "Current Topics in Microbiology and Immunology"* (M.J. Bosma, R.A. Phillips & W. Schuller, eds), Vol. 152, Springer-Verlag, Heidelberg 1989, pp.227-234.
52. Feld, R., Rapp, E., Pater, J.L., Willan, A., Cormier, Y., Murray, N., Evans, W. K., Hodson, D.I., Clark, D.A., Arnold, A.M., Ayoub, J.I., Wilson, K.S., Latreille, J., Wierzbicki, R.F. and D.P. Hill. 1989. Prolonged survival in patients with advanced non-small cell lung cancer with combination chemotherapy - Report of a Canadian multicentre randomized trial. *In: Treatment and Prevention of Small Cell Lung Cancer*, (Gralla, R.J. & Einhorn, L.H., eds), International Congress and Symposium Series 150, pp.83-93.
53. Chaouat, G., Menu, E., Kinsky, R., Dy, M., Minkowski, M., Dolage, J., Thang, M.N., Clark, D.A. and T.G. Wegmann. 1989. Lymphokines and non-specific cellular lytic effectors at the feto-maternal interface: effect on placental size and survival. *In: Reproductive Immunology 1989*, DW Billington ed, Elsevier, Amsterdam 1989.
54. Clark, D.A. 1990. Decidua-placenta immunologic interactions. *CRC Press. In: Immunology of the Fetus* (Chaouat G., ed). CRC Press 13, Boca Raton, Fl., pp. 162-170.

55. Daya, S. and D.A. Clark. 1990. Immunoregulation at the materno-fetal interface: the role of suppressor cells in preventing fetal allograft rejection. In: Immunology and Allergy Clinic of North America. (N. Gleicher, ed) Vol.10, W.B. Saunders, Philadelphia, pp.49-64.
56. Clark, D.A. 1990. Lymphokines and cytokines affecting reproductive outcome. In: Immunobiology of Normal and Diabetic Pregnancy. (U. di Mario, ed) John Wiley & Sons, Chichester, Chapter 5, pp.79-90.
57. Clark, D.A. 1990. Animal models of normal and aborting pregnancy. In: Immunobiology of Normal and Diabetic Pregnancy. (U. di Mario, ed) John Wiley & Sons, Chichester, Chapter 2, pp.23-37.
58. Clark, D.A. 1990. Are there immune abortions. FORUM 1990. Res. Immunol. (Inst. Pasteur) 141:202-207.
59. Clark, D.A. 1990. Paraimmunology in the decidua? Am. J. Reprod. Immunol. 24:37-39.
60. Clark, D.A. and S. Daya. 1990. Recurrent abortion: is it treatable? CFAS Controversies in Reproductive Endocrinology: an Update for the Clinician. Serono Symposia, Oct/90.
61. Clark, D.A. and S. Daya. 1990. Macrophages and other migratory cells in endometrium: relevance to endometrial bleeding. In: WHO Symposium Contraception and Mechanisms of Endometrial Bleeding, (D'Arcangues C., Fraser I., Newton J. & Odland V., eds), Cambridge University Press, Cambridge, pp.363-382.
62. Clark, D.A. 1990. Commentary on the FORUM. FORUM 1990. Res. Immunol. (Inst. Pasteur) 141:218-226.
63. Chaouat, G., Menu, E., Hoffmann, M., Dy, M., Minkowski, M., Clark, D.A. and T.G. Wegmann. 1990. Lymphokines at the feto-maternal interface affect fetal size and survival. In: Placental Communications: Biochemical, Morphological and Cellular Aspects. L. Cedard, E. Alsat, J. Chalier, G. Chaouat and A. Malassine, eds. Colloque INSERM, John Libbey Eurotext, Paris, Vol. 199, pp.133.
64. Lea, R.G., and Clark, D.A. 1991. Macrophages and migratory cells in endometrium relevant to implantation. (Seppalla W., ed). In: Bailliers Clinic. Obstet. Gynecology Chapter 5. pp.25-59.
65. Clark, D.A., Head, J.R., Drake, B., Fulop, G., Brierley, J., Manuel, J., Banwatt, D. and G. Chaouat. 1991. Role of a factor related to transforming growth factor β 2 in successful pregnancy. In: Molecular Immunology of the Feto-maternal Interface. (Gill. T. & T.G. Wegmann, eds). Oxford University Press pp 294-311.
66. Chaouat, G., Menu, E., Szekeres-Bartho, J., Rebut-Bonneton, C., Bustany, P., Kinsky, R., Clark, D.A. and T.G. Wegmann. 1991. Lymphokines, steroids, placental factors and trophoblast intrinsic resistance to immune cell mediated lysis are involved in pregnancy

- success or immunologically mediated pregnancy failure. In: Molecular Immunology of the Feto-maternal Interface (Gill T. and T.G. Wegmann, eds). Oxford Univ. Press pp 277-293.
67. Clark, D.A. and C. Blair (eds). 1991. NIHCD Conference on Materno-feto Placental Interactions. J. Reprod. Fert. 91:232-244.
 68. Coulam, C. and Clark, D.A., 1991. Report of ASRI Ethics Committee on Treatment of Recurrent Miscarriage. Am. J. Reproductive Immunology. 26:93-95.
 69. Clark, D.A., Lea, R.G., Denburg, J., Banwatt, D., Manuel, J., Damji, N., Underwood, J., Michel, M., Mowbray, J., Daya, S. and G. Chaouat. 1991. TGF- β related suppressor factor in mammalian pregnancy and in recurrent unexplained abortion. In: Proc. INSERM Colloque "Materno-fetal Relationship: Molecular and Cellular Biology", (Chaouat G. ed), John Libbey Eurotext, Paris pp. 171-179.
 70. Clark, D.A. and R.W. Beard. 1991. A morphological and immunological study of human placental bed biopsies in miscarriage. Author's Reply. Brit. J. Obstet. Gynecol. 98:611.
 71. Clark, D.A., Lea, R.G., Podor, T., Daya, S., Banwatt, D., and Harley, C. 1991. Cytokines determining the success or failure of pregnancy. Ann. NY Acad. Sci. 626:524-536.
 72. Daya, S. and D.A. Clark. 1991. Immunology of habitual abortion. SOGC Symposium, June 1991.
 73. Lea, R.G., Harper, J., Banwatt, D., Manuel, J., Daya, S., Porat, O., Craft, I. and D.A. Clark. 1991. Is there an early embryo associated suppressor factor? In: Proc.INSERM Colloque "Materno-fetal Relationship: Molecular and Cellular Biology", (Chaouat G., ed), John Libbey Eurotext, Paris pp 161-168.
 74. Daya, S. and D.A. Clark. 1992. Alloimmunity in normal pregnancy and pregnancy loss. In: Principles of Medical Therapy in Pregnancy, 2nd Edition (N. Gleicher, ed), Appleton & Lange, Norwalk pp 407-413.
 75. Clark, D.A. 1992. Animal Models of Early Pregnancy Loss. In: Immunologic Obstetrics, (Coulam C., Faulk W.P. & J. McIntyre, eds), W.W. Norton, New York pp 428-436.
 76. Coulam, C., Clark, D.A., and A.E. Beer. 1992. Report from the Ethics Committee for Immunotherapy. AJRI 28:3-5.
 77. Daya, S. and D.A. Clark. 1992. *In vitro* fertilization in immunological infertility. Ann. Acad. Med., Singapore. Vol 21:4 pp 525-532.
 78. Clark, D.A. 1992. Uterine cells of immunologic relevance in animal systems. In: Treatise on Reproductive Immunology. (Chaouat, G. ed.) CRC Press, Florida, pp.79-92.

79. Clark, D.A., Lea, R.G., Flanders, K.C., Banwatt, D., and Chaouat, G. 1992. Role of a unique species of TGF- β in preventing rejection of the conceptus during pregnancy. In: Progress in Immunology VIII, Springer-Verlag; Budapest pp. 841-847.
80. Clark, D.A. 1992. Anti-sperm antibodies: do they or don't they? SCOG Symposium. June 1992.
81. Clark, D.A. 1993. Cytokines, decidua and early pregnancy. In: Oxford Reviews of Reprod. Biol. (Milligan, S., ed) Vol. 15, pp. 83-113.
82. Clark, D.A. 1993. Cytokines and uterine bleeding. In: Steroid Hormones and Uterine Bleeding (N. Alexander, C.D. Arcangues, eds). AAAS Press. Washington, pp. 263-275.
83. Clark, D.A. 1993. Paraimmunology & receptors on decidual T-cells: conflict or confirmation? Am. J. Reprod. Immunol. 29:35-38.
84. Clark, D.A. and S. Daya. 1993. Immunological therapies of recurrent pregnancy loss. In: Textbook of Gynecology, (Copeland L.J. ed), W.B. Saunders, Philadelphia pp 231-241.
85. D.A. Clark. 1994. Endometrial molecular and cellular determinants of fertility (and sterility). In: Progress in Infertility. (Behrman, S.J., Patton, G.W., Holtz, G. eds.) Little, Brown & Co. pp.37-44.
86. Daya, S. and D.A. Clark. 1994. Pregnancy and the feto-maternal relationship. In: Immunology and Inflammation. Basic Mechanisms and Clinical Consequences (Sigal et al., eds) Ch 27. pp 547-561.
87. Clark, D.A., and Muzikova E. 1994. Cell Biology of Migratory cells in the endometrium. In: Cellular & Molecular Mechanisms in Female Reproduction. (J.K. Findlay ed). 11:329-344.
88. Clark, D.A. 1994. Maternal aggression against placenta? Am. J. Reprod. Immunol. 31:205-207.
89. Clark, D.A. 1994. Debate: histocompatibility studies in recurrent spontaneous abortion - serotype vs. genotype. Human Reprod. 9:1196-1197.
90. Clark, D.A. 1994. Microfilaria, tolerance and T cells. Lancet. 343:868-869.
91. Clark, D.A. 1994. Does immunological intercourse prevent pre-eclampsia? Lancet. 344:969-970.
92. Clark, D.A. 1994. Stress without distress. Lancet.344:73-74.
93. Coulam, C. and D.A. Clark. 1994. Immunotherapy for recurrent miscarriage. Am. J. Reprod. Immunol. 32:257-260.

94. Clark, D.A., Flanders, K.C., Vince, G., Starkey, P., Hirte, H., Manuel, J., Underwood, J., and Mowbray, J. 1995. Novel transforming growth factor β s (TGF- β 2) in pregnancy and cancer. In: Immunobiology of Reproduction, (Hunt, J. ed) Springer-Verlag, New York. Ch. 9. pp. 125-135.
95. Clark, D.A. 1995. Immunobiological characterization of the trophoblast-decidual interface in human pregnancy. In: Immunology of Human Reproduction. (Kurpysz, M., Fernandez, N., eds). Bios Scientific Publishers Ltd., Oxford, UK. 18:1-11.
96. Lea, R.G., Flanders, K.C., McIntyre S., Michel, M., Mowbray, J., Underwood J., Baird, J.D., and Clark, D.A. 1995. Uterine TGF- β 2 in human normal and pathologic pregnancies. In: INSERM Colloque (Chaouat, G. ed). Annecy, France. p. 115-122.
97. Clark, D.A. 1995. Cytokines. In: McGraw Hill Encyclopaedia of Science and Technology. McGraw Hill.
98. Arck P., Merali, F., and D.A. Clark. 1995. Stress and pregnancy outcome: analysis of mechanisms. In: Early Embryo Development: Uterus preparation and role of cytokines in implantation and labour (Chaoaut, G., ed). INSERM Colloque, p.153-164.
99. Clark, D.A., and Coulam, C.B. 1996. Is there an immunological cause of repeated pregnancy wastage? *Adv. Ob. Gyn.*, Mosby. 3:311-333.
100. Clark, D.A., Daya, S., Coulam, C.B., Gunby, J., and the Recurrent Miscarriage Immunotherapy Trialists Group. 1996. Implications of abnormal human trophoblast karyotype for the evidence-based approach to the understanding, investigation, and treatment of recurrent spontaneous abortion. *Amer. J. Reprod. Immunol.* 35:495-498.
101. Clark, D.A. 1996. Red cell antibodies in pregnancy: Evidence overturned. *Lancet* 347:485-486.
102. Clark, D.A. 1998. Alloimmunity and pregnancy loss. In:(Gleicher, N. ed) Part VIII The Immune System, Third Edition Principles and Practice of Medical Therapy. Appleton & Lang, Satymford CN, pp. 511-520.
103. Clark, D.A., Gunby, J., and Daya, S. 1997. The use of allogeneic leukocytes or IV IgG for the treatment of patients with recurrent spontaneous abortions. *Transfusion Medicine Reviews.* 11(2):85-94.
104. Arck, P., and Clark, D.A. 1998. Immunobiology of the decidua. In: Current Topics of Microbiology & Immunology (L. Olding, Ed.) 222: 45-66.
105. Clark, D.A., Daya S. (1999). Reproductive immunology for the non-immunologist. IN: Textbook of Gynecology (L. Copeland, Ed.) Ch.4:pp.99-110.

106. Clark, D.A., & Daya, S. (1997). Is there hope for IVIG? *Amer. J. Reprod. Immunol.* 39:65-68.
107. Coulam, C.B., Branch, D.W., Clark, D.A., Gleicher, N., Kutteh, W., Lockshin, M.D., and Rote, N.S. (1999) American Society for Reproductive Immunology Report of the Committee for Establishing Criteria for Diagnosis of Reproductive Autoimmune Syndrome. *Amer. J. Reprod. Immunol.* 41:121-132.
108. Clark, D.A. 1998. Immunology of Pregnancy. In: N. Burrows and T.F. Duffy, (eds) *Medical Complications During Pregnancy*. WB Saunders, Philadelphia, 5th edition, pp.431-451.
109. Bothelo, F., and Clark, D.A. 1998. How might pregnancy immunize against breast cancer? *Amer. J. Reprod. Immunol.* 39:279-283.
110. Clark, D.A. 1999 Other immunomodulatory effects of blood transfusion In: *Immunomodulatory Effects of Blood Transfusion* (eds.) Morris, M. Blajchman and E.C. Vamvakas, AABB Press, Bethesda, MD. Chapter 12, pp. 237-252.
111. Clark, D.A. 1999 . From trophoblast antigens and cells to cytokines: visions and realities. In: (Gupta SK (ed)) *Reproductive Immunology*, Narosa, New Delhi, pp.121-131.
112. Robertson, S.A. and Clark, D.A. 1999. Immunology of the reproductive tract and pregnancy. *The Immunologist* 7:38-41.
113. Clark, D.A. 1999. T cells in pregnancy: illusion and reality. *Amer. J. Reprod. Immunol.* 41:233-238.
114. Clark, D.A. 1999. Signaling at the feto maternal interface. *Amer. J. Reprod. Immunol.* 41:169-173.
115. Clark D.A. 1999. Human leukocyte antigen-G: new roles for old? *Amer. J. Reprod. Immunol.* 41:117-120.
116. Coulam, C.B., Branch, D.W., Clark, D.A., Gleicher, N., Kutteh, Wm. Lockshin, M.D., and Rote, N.S. 1999. American Society for Reproductive Immunology: Report of the Committee for establishing criteria for diagnosis of reproductive autoimmune syndrome. *Amer. J. Reprod. Immunol.* 41:121-132.
117. Clark, D.A. 2001 Cytokines. McGraw-Hill, *Encyclopedia of Science & Technology*, 9th edit.
118. Ghazeeri, G.S., Clark, D.A., and Kutteh, W.H. 2001. Immunologic factors in implantation. *Infertility & Reproductive Medicine Clinics of North America*. W.B. Saunders Company (Philadelphia), pp 315-337.
119. Clark, D.A., Yu, G., Levy, G.A., and Gorczynski, R.M. 2001. Procoagulants in fetus

rejection: role of OX-2 (CD200) tolerance signal. *Seminars in Immunology* 13:255-263.

120. Clark, D.A. *Immunology of Pregnancy* 2002. In: Burrows N, Duffy TF (eds), *Medical Complications During Pregnancy*, 6th edition, WB Saunders (in press)

PEER REVIEWED:

1. Lowry, W.S., Clark, D.A. and J.H. Hannemann 1973. Skin cancer and immunosuppression. *Lancet* 1:1290
2. Mukherji, B., Nathanson, L. and D.A. Clark. 1973. Studies of humeral and cell-mediated immunity in human melanoma. *Yale J. Biol. Med.* 46:681-692.
3. Breton, R., Clark, D.A. and L. Nathanson. 1973. The cytochemical detection of concanavalin-A binding on cell surface by scanning electron microscopy. *J. Microscopie* 17:93-96.
4. Clark, D.A., Necheles, T., Nathanson, L. and E. Silverman. 1973. Apparent HLA-5 deficiency in malignant melanoma. *Transplantation* 15:326-328.
5. Mukherji, B., Flowers, A., Nathanson, L. and D.A. Clark. 1974. Heterotransplantation model of malignant melanoma. *Cancer Res.* 34:43-46.
6. Clark, D.A., Necheles, T., Nathanson, L., Whitten, D., Silverman, E. and A. Flowers. 1974. Apparent HLA-5 deficiency in human malignant melanoma. II. HLA-5 masking activity in sera of patients with progressing disease. *Israel. J. Med. Sci.* 10:836-846.
7. Pritchard, K.I., Cowan, D.H., Baker, M.A., Osoba, D., Phillips, R.A. and D.A. Clark. 1975. The use of oral BCG as a single agent in the treatment of metastatic malignant melanoma. *Medical and Paediatric Oncol.* 2:173-1
8. Keystone, E.C., Gladman, D.D., Urowitz, M.B., Clark, D.A., Falk, J.A. and D. Osoba. 1976. Mixed leukocyte reaction in rheumatoid arthritis. *Arth. and Rheum.* 19:532-538.
9. Keystone, E.C., Gladman, D.A., Urowitz, M.B. and D.A. Clark. 1976. The MLR in rheumatoid arthritis: dose response kinetics. *Clin. Immunol. Immunopath.* 5:320-325.
10. Clark, D.A., Phillips, R.A. and R.G. Miller. 1976. Characterization of cells that suppress the cytotoxic activity of T lymphocytes. I. Quantitative measurement of inhibitor cells. *J. Immunol.* 116:1020-1029.
11. Clark, D.A., Phillips, R.A. and R.G. Miller. 1976. Characterization of cells that suppress the cytotoxic activity of T lymphocytes. II. Physical properties, specificity and developmental kinetics of the inhibitory non T cell population. *Cellular Immunology* 34:25-37.

12. Clark, D.A. and M. McDermott. 1978. Impairment of host versus graft reaction in pregnant mice. I. Suppression of T cell generation in lymph nodes draining the uterus. *J. Immunol.* 121:1389-1393.
13. Gee, S.R., Clark, D.A. and W.E. Rawls. 1979. Differences between Syrian hamster strains in natural killer cell activity induced by infection with Pichinde virus. *J. Immunol.* 123:2618-2626.
14. Clark, D.A., McDermott, M.R. and M. Szewczuk. 1980. Impairment of host versus graft reaction in pregnant mice. II. Selective suppression of cytotoxic T cell generation correlates with a soluble suppressor activity and with successful pregnancy. *Cellular Immunology* 52:106-118.
15. McDermott, M.R., Clark, D.A. and J. Bienenstock. 1980. Evidence for a common mucosal immunologic system. II. Influence of the estrous cycle on B immunoblast migration into genital and intestinal tissue. *J. Immunol.* 124:2536-2539.
16. Clark, D.A. 1980. Role of accessory cells in the *in vitro* growth of aggregate-derived murine T cell colonies. *Cellular Immunology* 56:152-162.
17. Clark, D.A. and M.R. McDermott. 1981. Impairment of host versus graft disease in pregnant mice. III. Developmental kinetics, properties and mechanism of induction of suppressor cells during first pregnancy. *J. Immunol.* 127:1267-1273.
18. Clark, D.A., Cinader, B. and S. Koh. 1981. Age-dependent separation of class-specific suppressor cells in thymus of SJL/L mice. *Immunol. Letters* 3:189-194.
19. Gee, S.R., Chan, M.A., Clark, D.A. and W.E. Rawls. 1981. Role of natural killer cells in Pichinde virus infection of Syrian hamsters. *Infection and Immunity* 31:919-928.
20. Clark, D.A., Gauldie, J., Szewczuk, R.M. and G.D. Sweeney. 1981. Enhanced suppressor cell activity as a mechanism of immunosuppression by TCDD. *Proc. Soc. Exp. Biol. Med.* 168:290-299.
21. Tagliabue, A., Befus, A.D., Clark, D.A. and J. Bienenstock. 1982. Characterization of natural killer cells in murine intestinal mucosa. *J. Exp. Med.* 155:1785-1796.
22. Croy, B.A., Rossant, J. and D.A. Clark. 1982. Histological and immunological studies of post implantation death of Mus caroli embryos in the Mus musculus uterus. *J. Reprod. Immunol.* 4:277-293.
23. Slapsys, R.M. and D.A. Clark. 1982. Active suppression of host-vs-graft reaction in pregnant mice. IV. Local suppression cells in decidua and uterine blood. *J. Reprod. Immunol.* 4:355-364.

24. Rossant, J., Croy, B.A., Chapman, V.M., Syracuse, L. and D.A. Clark. 1982. Interspecific chimeras in mammals: a new experimental system. *J. Animal Sci.* 55:5;1241-1248.
25. Eveleigh, M.J., Clark, D.A. and E.L. McCandless. 1982. Carrageenan stimulates the release of dialyzable helper factors. *Immunol. Letters* 5:247-252.
26. Slapsys, R.M. and D.A. Clark. 1982. Active suppression of host vs graft reaction in pregnant mice. V. Kinetics, specificity, and *in vivo* activity of non-T suppressor cells localized to the genital tract of mice during first pregnancy. *Am. J. Reprod. Immunol.* 3:65-71.
27. Chan, M., Clark, D.A. and W.E. Rawls. 1983. Pichinde virus-specific cell-associated suppression of primary footpad swelling in an inbred strain of hamsters. *J. Immunol.* 130:925-931.
28. Croy, B.A., Rossant, J., Clark, D.A. and T.G. Wegmann. 1983. Nonspecific suppression of *in vitro* generation of cytotoxic lymphocytes by allogeneic and xenogeneic embryonic tissues. *Transplantation* 35:627-629.
29. Liao, S.K., Kwong, P., Smith, J., Dent, P.B. and D.A. Clark. 1983. Association of morphological differentiation with enhanced surface antigen expression and susceptibility to natural killer cell lysis in theophylline-treated human melanoma cells. *J. Biol. Resp. Mod.* 2:280-292.
30. Nagarkatti, P.S. and D.A. Clark. 1983. *In vitro* activity and *in vivo* correlates of alloantigen-specific murine suppressor T cells induced by allogeneic pregnancy. *J. Immunol.* 131:638-643.
31. Clark, D.A., Slapsys, R.M., Croy, B.A. and J. Rossant. 1983. Suppressor cell activity in uterine decidua correlates with success or failure of murine pregnancies. *J. Immunol.* 131:540-542.
32. Rossant, J., Croy, B.A., Clark, D.A. and V.M. Chapman. 1983. Interspecific hybrids and chimeras in mice. *J. Exp. Zool.* 228:223-233.
33. Clark, D.A., Sweeney, G., Safe, S., Hancock, E., Kilburn, D.G. and J. Gauldie. 1983. Cellular and genetic basis for suppression of CTL generation by haloaromatic hydrocarbons. *Immunopharmacol.* 6:143-153.
34. Clark, D.A., Slapsys, R., Croy, B.A., Krcek, J. and J. Rossant. 1984. Local active suppression by suppressor cells in decidua: A Review. *Amer. J. Reprod. Immunol.* 5:2;78-83.
35. Croy, B.A., Rossant, J. and D.A. Clark. 1984. Recruitment of cytotoxic cells by ectopic grafts of xenogeneic, but not allogeneic, trophoblast. *Transplantation* 37:1;84-90.

36. Nagarkatti, P.S., Sweeney, G.D., Gauldie, J. and D.A. Clark. 1984. Sensitivity to suppression of cytotoxic T cell generation by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is dependent on the Ah genotype of the murine host. *Toxicol. & Appl. Pharmacol.* 72:169-176.
37. Clark, D.A., McCulloch, P.B., Liao, S.K., Dent, P.B. and A. Fuks. 1984. Sensitivity of human carcinoma cell lines to lysis by blood NK cells correlating with surface expression of CEA. *JNCI* 72:3;505-512.
38. Clark, D.A., Slapsys, R.M., Croy, B.A and J. Rossant. 1984. Immunoregulation of host-versus-graft responses in the uterus. *Immunology Today* 5:111-115.
39. Wright, K., Clark, D.A. and W.E. Rawls. 1984. Differences in lymphocyte responsiveness to lymphokines in two inbred strains of Syrian hamster. *J. Immunol.* 133:1;286-292.
40. Petit, A., Ernst, P., Befus, A.D., Clark, D.A., Rosenthal, K.L., Isizaka, T. and J. Bienenstock. 1984. Murine intestinal intra-epithelial lymphocytes. I. Relationship of a novel Thy 1⁻ Lyt 1⁻ Lyt 2⁺ granulated subpopulation to NK cells and mast cells. *Eur. J. Immunol.* 15:211-215.
41. Clark, D.A. 1984. Local suppressor cells and the success or failure of the "fetal allograft". *Ann. Immunol. (Inst. Pasteur)* 135D:321-324.
42. Clark, D.A. 1984. One key to the gestational voussoir? *Ann. Immunol. (Inst. Pasteur)* 135D:342-344.
43. Daya, S., Clark, D.A., Delvin, C., Jarrell, J. and A. Chaput. 1985. Preliminary characterization of two types of suppressor cells in the human uterus. *Fertil. Steril.* 44:778-785.
44. Croy, B.A., Rossant, J. and D.A. Clark. 1985. Effects of alterations in the immunocompetent status of Mus musculus females on the survival of transferred Mus caroli embryos. *J. Reprod. Fertil.* 74:479-489.
45. Daya, S., Clark, D.A., Delvin, M.C., Jarrell, J. and A. Chaput. 1985. Suppressor cells in human decidua. *Am. J. Obst. Gyn.* 151:267-270.
46. Clark, D.A., Chaput, A., Walker, C. and K.L. Rosenthal. 1985. Active suppression of host vs graft reaction in pregnant mice. VI. Soluble suppressor activity obtained from decidua of allopregnant mice blocks the response to IL-2. *J. Immunol.* 134:1659-1664.
47. Krcek, J. and D.A. Clark. 1985. Localization of a small sized bone marrow subpopulation at the implantation site in the murine fetus. *Amer. J. Reprod. Immunol.* 7:95-98.

48. Ernst, P.B., Petit, A., Befus, A.D., Clark, D.A., Rosenthal, K.L., Ishizaka, T. and J. Bienenstock. 1985. Murine intestinal intraepithelial lymphocytes. II. Comparison of freshly isolated and cultured intraepithelial lymphocytes. *Eur. J. Immunol.* 15:216-221.
49. Clark, D.A., Cinader, B., Rosenthal, K.L., Chaput, A. and S-Y. Koh. 1985. Strain-dependence and cellular aspects of the acceleration of age-dependent shift in class-specific helper and suppressor activity in the thymus of MRL/Mp mice by the LPR gene. *Cell. Immunol.* 96:418-429.
50. Carmen, P.S., Rosenthal, K.L., Ernst, P.B., Clark, D.A., Befus, A.D. and J. Bienenstock 1985. Intraepithelial leukocytes contain a unique subpopulation of NK-like cytotoxic cells active in the defence of gut epithelium to enteric murine coronavirus. *J. Immunol.* 136:1548-1553.
51. Slapsys, R.M., Richards, C.D. and D.A. Clark. 1985. Active suppression of host-versus-graft reaction in pregnant mice. VIII. The uterine decidua-associated suppressor cell is distinct from decidual NK cells. *Cell. Immunol.* 99:140-149.
52. Clark, D.A., Croy, B.A., Rossant, J. and G. Chaouat. 1986. Immune presensitization and local intrauterine defences as determinants of success or failure of murine interspecies pregnancies. *J. Reprod. Fert.* 77:633-643.
53. Clark, D.A., Chaput, A. and D. Tutton. 1986. Active suppression of host-versus-graft reaction in pregnant mice. VII. Spontaneous abortion of allogeneic DBA/2 x CBA/J fetuses in the uterus of CBA/J mice correlates with deficient non-T suppressor cell activity. *J. Immunol.* 136:1668-1675.
54. McDermott, M.R., Horsewood, P., Clark, D.A. and J. Bienenstock. 1986. T lymphocytes in the intestinal epithelium and lamina propria mice. *Immunol.* 57:213-218.
55. Clark, D.A., Slapsys, R., Chaput, A., Walker, C., Brierley, J., Daya, S. and K. Rosenthal. 1986. Immunoregulatory molecules of trophoblast and decidual suppressor cell origin at the materno-fetal interface. *Amer. J. Reprod. Immunol. Microbiol.* 10:100-104.
56. Clark, D.A. and G. Chaouat. 1986. Characterization of the cellular basis for the inhibition of cytotoxic effector cells by murine placenta. *Cell. Immunol.* 102:43-51.
57. Daya, S. and D.A. Clark. 1986. Immunosuppressive factor(s) produced by *in vitro* fertilized human embryos. *New Engl. J. Med.* 315:1551.
58. Daya, S. and D.A. Clark. 1986. Production of immunosuppressor factor(s) by pre-implantation human embryos. *Amer. J. Reprod. Immunol. Microbiol.* 11:98-101.
59. Ernst, P.B., Clark, D.A., Rosenthal, K.L., Befus, A.D. and J. Bienenstock. 1986. Detection and characterization of cytotoxic T lymphocyte precursors in the murine intestinal intraepithelial leukocyte population. *J. Immunol.* 136:2121-2126.

60. Clark, D.A., Mowbray, J., Underwood, J. and H. Lidell. 1987. Histopathologic alterations in the decidua in human spontaneous abortion: loss of cells with large cytoplasmic granules. *Amer. J. Reprod. Immunol. Microbiol.* 13:19-22.
61. Daya, S., Rosenthal, K.L. and D.A. Clark. 1987. Immunosuppressor factor(s) produced by decidua-associated suppressor cells - a proposed mechanism for fetal allograft survival. *Amer. J. Obs. Gyn.* 156:344-350.
62. Brierley, J. and D.A. Clark. 1987. Characterization of hormone-dependent suppressor cells in the uterus of pregnant and pseudopregnant mice. *J. Reprod. Immunol.* 10:201-218.
63. Clark, D.A., Chaouat, G., Guenet, J-L. and N. Kiger. 1987. Local active suppression and successful vaccination against spontaneous abortion in CBA/J mice. *J. Reprod. Immunol.* 10:79-85.
64. Stedronska-Clark, J., Clark, D.A. and W.F. Hendry. 1987. Antisperm antibodies detected by ELISA kit method are not those detected by standard tray agglutination test. *Amer. J. Reprod. Immunol. Microbiol.* 13:76-77.
65. Clark, D.A., Croy, B.A., Wegmann, T.G. and G. Chaouat. 1987. Immunological and para-immunological mechanisms in spontaneous abortion: recent insights in future directions. *J. Reprod. Immunol.* 12:1-12.
66. Evans, W.K., Feld, R., Murray, N., Willan, A., Coy, P., Osoba, D., Clark, D.A., Levitt, M., MacDonald, W. and J. Pater. 1987. A Canadian multicenter randomized trial comparing standard and alternating administration of two-non-cross resistant chemotherapy combinations in patients with extensive small cell lung cancer. *Annals Int. Med.* 107:451-458.
67. Rapp, E., Pater, J.L., Willan, A., Cormier, Y., Murray, N., Evans, W.K., Hodson, I., Clark, D.A., Feld, R., Arnold, A., Ayoub, J.I., Wilson, K.S., Latreille, J., Wierzbiicki, R.F., and D.P. Hill. 1987. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer - report of a Canadian multicentre randomized trial. *J. Clin. Oncol.* 6:663-641.
68. Daya, S. and D.A. Clark. 1988. Identification of two species of suppressive factors of differing molecular weight released by *in vitro* fertilized human oocytes. *Fert. Steril.* 49:360-363.
69. Clark, D.A., Hirte, H.W. and R.N. Buick. 1988. Human ovarian carcinoma: evidence for patient-related differences in susceptibility to cytotoxic effectors that attack different cellular subpopulations within a tumor. *Brit. J. Cancer* 58:415-418.
70. Clark, D.A., Falbo, M., Rowley, R.B., Banwatt, D. and J. Stedronska-Clark. 1988. Active suppression of host-versus-graft reaction in pregnant mice. IX. Soluble suppressor activity

- obtained from allopregnant mouse decidua that blocks the response to interleukin 2 is related to TGF- β . *J. Immunol.* 141:3833-3840.
71. Slapsys, R.M., Younglai, E. and D.A. Clark. 1988. A novel suppressor cell is recruited to decidua by fetal trophoblast-type cells. *Regional Immunol.* 1:182-189.
 72. Michel, M., Underwood, J., Clark, D.A., Mowbray, J. and R.W. Beard. 1989. Histologic and immunologic study of placental bed biopsy tissue of incipiently aborting women. *Am. J. Obs. Gyn.* 161:409-414.
 73. Clark, D.A., Lee, S., Fishell, S., Mahadevan, M., Goodhall, L., Ah-Moye, M., Schechter, O., Stedronska-Clark, J., Daya, S., Underwood, J., Craft, I. and J. Mowbray. 1989. Immunosuppressive activity in human IVF culture supernatants and prediction of outcome of embryo transfer - a multicentre trial. *JIVFET* 1:51-58.
 74. Daya, S., Johnson, P.M. and D.A. Clark. 1989. Trophoblast induction of suppressor type cell activity in human endometrial tissue. *Amer. J. Reprod. Immunol. Microbiol.* 19:65-72
 75. Clark, D.A. and G. Chaouat. 1989. What do we know about spontaneous abortion mechanisms? *Amer. J. Reprod. Immunol. Microbiol.* 19:28-37.
 76. Clark, D.A., Brierley, J., Banwatt, D. and G. Chaouat. 1989. Hormone-induced pre-implantation Lyt 2⁺ murine uterine suppressor cells persist after implantation and may reduce the spontaneous abortion rate in CBA/J mice. *Cell. Immunol.* 123:334-343.
 77. Chaouat, G., Szekeres-Bartho, J., Menu, E., Kinsky, R., Thang, M.-N., Dy, M., Minkowski, M., Clark, D.A. and T.G. Wegmann. 1989. *Immunologie de la relation materno-foetale. Medicine/Sciences, No. special:20-26.*
 78. Michel, M.Z., Zhong, T.Y., Clark, D.A. and R.W. Beard. 1989. A morphological and immunological study of human placental bed biopsies in miscarriage. *Brit. J. Obstet. Gynecol.* 97:984-988.
 79. Chaouat, G., Szekeres-Bartho, J., Menu, E., Kinsky, R., Thang, M.-N., Dy, M., Minkowski, M., Clark, D.A. and T.G. Wegmann. 1989. *Immunologie de la relation materno-foetale. Medicine/Sciences, No. spécial:20-26.*
 80. Chaouat, G., Menu, E., Clark, D.A., Minowsky, M., Dy, M. and T.G. Wegmann. 1990. Control of fetal survival in CBA x DBA/2 mice by lymphokine therapy *J. Reprod. Fert.* 89:447-458.
 81. Clark, D.A., Flanders, K.C., Banwatt, D., Book, W., Manuel, J., Stedronska-Clark, J. and B. Rowley. 1990. Murine pregnancy decidua produces a unique immunosuppressive molecule related to TGF- β 2. *J. Immunol.* 144:3008-3014.

82. Lea, R.G., Daya, S. and D.A. Clark. 1990. Identification of low molecular weight immunosuppressor molecules in human IVF supernatants predictive of implantation as polyamine, possibly spermine. *Fertil. Steril.* 53:875-881.
83. McDougall, J.R., Croy, B.A., Chapeau, C. and D.A. Clark. 1990. Demonstration of a splenic cytotoxic effector cell in mice of genotype SCID/SCID.BG/BG. *Cell. Immunol.* 130:106-117.
84. Porat, O. and D.A. Clark. 1990. Analysis of immunosuppressive molecules associated with murine IVF embryo. *Fertil. Steril* 54:1154-1161.
85. Chaouat, G., Menu, E., Clark, D.A., Dy, M., Minkowski, M., and Wegmann, T.G. 1990. Control of fetal survival in CBA x DBA/2 mice by lymphokine therapy. *J. Reprod. Fert.* 89:447-458.
86. Hirte, H. and D.A. Clark. 1991. Generation of lymphokine-activated killer cells (LAK) in human ovarian carcinoma ascitic fluid: identification of TGF- β as a suppressive factor, *Cancer Immunol. Immunother.* 32:296-302.
87. Clark, D.A. and S. Daya. 1991. Trials and tribulation in the treatment of recurrent spontaneous abortion. *Am. J. Reprod. Immunol.* 25:18-24.
88. Lea, R.G., Porat, O., Daya, S., Fujiwara, K. and D.A. Clark. 1991. The detection of spermine and spermidine in human IVF supernatants and their relation to early embryo associated suppressor activity. *Fertil. Steril.* 56:771-775.
89. Hirte, H.W. and D.A. Clark. 1991. Determinants of susceptibility of human ovarian carcinoma stem cells to lysis by cytokine-activated killer cells. *Cell. Immunol.* 136:215-247.
90. Clark, D.A. 1991. Controversies in reproductive immunology. *Critical Reviews Immunol.* 11:215-247.
91. Clark, D.A. and R.W. Beard. 1991. A morphological and immunological study of human placental bed biopsies in miscarriage. *Brit. J. Obstet. Gynaecol.* 98:611.
92. Zettel, L., Clark, D.A. and P. Ernst. 1991. TGF- β enhances antibody response by a contrasuppression-like mechanism. *International Immunology* 9:975-984.
93. Lea, R.G., Flanders, K.C., Harley, C.B., Manuel, J., Banwatt, D., and Clark, D.A. 1992. Release of a TGF- β 2-related suppressor factor from postimplantation murine decidual tissue can be correlated with the detection of a subpopulation of cells containing RNA for TGF- β 2. *J. Immunol.* 148:778-787.
94. Ohno, I., Lea, R.G., Flanders, K.C., Clark, D.A. Banwatt, D., Dolovich, J., Denburg, J., Harley, C.B., Gauldie, J. and M. Jordana. 1992. Eosinophils in chronically inflamed human

- upper airways tissues express transforming growth factor $\beta 1$ gene (TGF $\beta 1$). J. Clin. Invest. 89:1662-1668.
95. Hirte, H.W., Clark, D.A., O'Connell, G., Rusthoven, J. and J. Mazurka. 1992. Reversal of suppression of lymphokine-activated killer cells by transforming growth factor- β in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody. Cell Immunol. 142:207-216.
 96. Hirte, H.W., Clark, D.A., Mazurka, J., O'Connell, G and J. Rusthoven. 1992. A rapid and simple method for the purification of tumour cells from ascitic fluid of ovarian carcinoma. Gyn. Oncol. 44:223-226.
 97. Clark, D.A., Drake, B., Head, J.R., Stedronska-Clark, J. and D. Banwatt. 1993. Decidua associated suppressor activity and viability of individual implantation sites of allopregnant C3H mice. J. Reprod. Immunol. 17:253-264.
 98. Barr, R.D., Clark, D.A., and Booth, J.D. 1993. Dyspermia in men with localised Hodgkin's disease: a potentially reversible, immune-mediated disorder. Medical Hypotheses 40:165-168.
 99. Lea, R.G., and D. A. Clark. 1993. Effects of decidual cell supernatants and lymphokines on murine trophoblast growth *in vitro*. Biol. Reprod. 48:930-935.
 100. Clark, D.A., D., Banwatt, D., and Chaouat, G., 1993. Effect of prostaglandin synthesis inhibitors on spontaneous and endotoxin-induced abortion in mice. J. Reprod. Immunol. 24:29-44.
 101. Clark, D.A., Banwatt, D., and Croy, B.A. 1993. Murine trophoblast failure and spontaneous abortion. Am. J. Reprod. Immunol. 29:199-205.
 102. Clark, D.A., Banwatt, D., and Chauoat, G. 1993. Stress-triggered abortion in mice is prevented by alloimmunization. Am. J. Reprod. Immunol. 29:141-147.
 103. Yie, S-M., Lobb, D.K., Clark, D.A., and Younglai, E.V. 1994. Identification of a TGF- α like growth factor in human seminal plasma. Fert. Steril. 61:129-135.
 104. Clark, D.A., Quarrington, C., Banwatt, D., Manuel, J., and Fulop, G. 1994. Spontaneous abortion in immunodeficient SCID mice. Am. J. Reprod. Immunol. 32:15-25.
 105. Finotto, S., Ohno, I., Marshall, J.S., Gauldie, J., Denburg, J., Dolovich, J., Clark, D.A., and Jordana, M. 1994. TNF- α production by eosinophils in upper airways inflammation (nasal polyposis). J. Immunol. 153:2278-2289.
 106. Clark, D.A., Chaouat, G., Mogil, R., and Wegmann, T.G. 1994. Prevention of spontaneous abortion in DBA/2-mated CBA/J mice by GM-CSF involves CD8⁺ T cell-dependent suppression of natural effector cells. Cell. Immunol. 154:143-152.

107. The Recurrent Miscarriage Immunotherapy Trialists Group: Coulam, C., Clark, D.A., Collins, J., Scott, J.R., Schlesselman, J.S., Aoki, K., Cauchi, M.N., Lim, D., Christiansen, O.B., Grunnet, N., Cowchock, S., Smith, J.B., Daya, S., Gatenby, P., Camerson, K., Gill, T.J., Ho, H.N., Georgieva, R., Belchev, D., Kilpatrick, D.C., Liston, W., Mowbray, J.F., Underwood, J., Parazzini, F., Crosignani, P.G., Rezenkoff, M.F., and Koyama, F.S. 1994. Worldwide collaborative observational study and meta-analysis on allogenic leukocyte immunotherapy for recurrent spontaneous abortion. *Am. J. Reprod. Immunol.* 32:55-72.
108. Clark, D.A. 1994. Intralipid as treatment for recurrent unexplained abortion? *Am. J. Reprod. Immunol.* 32:290-293.
109. Clark, D.A., Vince, G., Flanders, K.C., Hirte, H., and Starkey, P. 1994. CD56⁺ lymphoid cells in human first trimester pregnancy decidua as a source of novel TGF- β 2-related immunosuppressive factors. *Human Reprod.* 9:2270-2277.
110. Arck, P., Merali, F., Manuel, J., Chaouat, G., and Clark, D.A. 1995. Stress triggered abortion: inhibition of protective suppression and promotion of tumour necrosis factor- α (TNF- α) release as a mechanism triggering resorptions in mice. *Am. J. Reprod. Immunol.* 33:74-80.
111. Lea, R.G., Underwood, J., Flanders, K.C., Hirte, H., Banwatt, D., Ohno, I., Michel, M., Daya, S., Harley, C., Mowbray, J.F., and Clark, D.A. 1995. A subset of patients with recurrent spontaneous abortion is deficient in transforming growth factor β 2 producing "suppressor cells" in decidua near the placental attachment site. *Am. J. Reprod. Immunol.* 34:52-64.
112. Lea, R.G., Stewart, F., Allen, W.R., Ohno, I. and D.A. Clark. 1995. Accumulation of chromotrope 2R positive cells accumulate in the equine endometrium during early pregnancy and express TGF- β 2. *J. Reprod. Fert.* 103:339-347.
113. Muzikova, E., and Clark, D.A. 1995. Polyamines may increase percentage of IVF murine oocytes that develop into blastocysts. *Human Reprod.* 10:1172-1177.
114. Muzikova, E., and D.A. Clark. 1995. Is spontaneous resorption in the DBA/2-mated CBA/J mouse due to a defect in "seed" or in "soil"? *Am. J. Reprod. Immunol.* 33:81-85.
115. Clark, D.A., Flanders, K.C., Hirte, H., Dasch, J.R., Coker, R., McAnulty, R.J., and Laurent, G.J. 1995. Characterization of murine pregnancy decidua TGF- β . I. TGF- β 2-like molecules of unusual molecular size released in bioactive form. *Biol. Reprod.* 52:1380-1388.
116. Arck, P., Merali, F., Stead, R., Chaouat, G. and Clark, D.A. 1995. Stress-triggered abortion: inhibition of protective suppressor mechanisms and promotion of TNF- α release via neurotransmitter. *Amer. J. of Reprod. Immunol.* 33:74-80.

117. Arck, P., Merali, F., Stanisz, A., Stead, R., Chaouat, G., Manuel, J., and Clark, D.A. 1995. Stress-induced murine abortion associated with substance P-dependent alteration in cytokines in maternal uterine decidua. *Biol. Reprod.* 53:814-819.
118. Clark, D.A., Arck, P., Jalali, R., Merali, F., Manuel, J., Chaouat, G., Underwood, J., and Mowbray, J. 1996. Psycho-neuro-cytokine/endocrine pathway in immunoregulation during pregnancy. *Am. J. Reprod. Immunol.* 35:330-337.
119. Merali, F.S., Arck, P.C., Beaman, K. and Clark, D.A. 1996. Transforming growth factor- β 2-related-decidual suppressor factor is not related to TJ6 protein. *Am. J. Reproductive Immunology* 35:342-347.
120. Coulam, C.B., Stephenson, M., Stern, J.J. and Clark D.A. 1996. Immunotherapy for recurrent pregnancy loss: Analysis of results from clinical trials. *Amer. J. Reprod. Immunol.* 35:352-359.
121. Jalali, G.R., Arck, P.C., Chaouat, G., Underwood, J.L., Surridge, S., Clark, D.A., and Mowbray, J.F. 1996. Immunosuppressive properties of monoclonal antibodies and human polyclonal alloantibodies to the R80K protein of trophoblast. *Amer. J. Reprod. Immunol.* 36:129-134.
122. Clark, D.A., Delcros, J.-G. and Craft I. 1996. High levels of spermine in IVF medium as a negative predictor of subsequent success of embryo transfer. *J. Assisted Reprod. Genetics* 13:464-467.
123. Arck, P.C., Merali, F., Chaouat, G. and Clark, D.A. 1996. Inhibition of immunoprotective CD8+ cells as a basis for stress-triggered substance P-mediated abortion in mice. *Cell Immunol.* 171:226-230.
124. Clark, D.A., Wang, S., Rogers, P., Vince, G. and Affandi, B. 1996. Endometrial lymphomyeloid cells in abnormal uterine bleeding due to norplant. *Human Reprod.* 11:1438-1444.
125. Cadavid, A.P., Guilbert, L.J., Jalali, G.R., Underwood, J.L., Mowbray, J.F., and Clark, D.A. 1997. Human cytotrophoblastic cells absorb the NK blocking activity of monoclonal BA11. *Amer. J. Reprod. Immunol.* 37:73-78.
126. Markert, U., Arck, P.C., McBey, B.A., Manuel, J., Croy, B.A., Marshall, J.S., Chaouat, G. and Clark, D.A. 1997. Stress-triggered abortions are associated with alterations of granulated cells in the decidua. *Am. J. of Reprod. Immunol.* 37:94-100.
127. Clark, D.A., Merali, F., Hoskin, D., Steele-Norwood, D., Arck, P.C., Murgita R., Croitoru, K., Hirte, H. 1997. Murine pregnancy decidua-associated suppressor cells in abortion prone DBA/2-mated CBA/J mice that produce transforming growth factor β 2-related immunosuppressive molecules express a bone-marrow-derived natural suppressor cell marker and $\gamma\delta$ T cell receptor. *Biol. Reprod.* 56:1351-1360.

128. Arck, P.C., Ferrick, D.A., Steele-Norwood, D., Croitoru, K and Clark, D.A. 1997. Regulation of abortion $\gamma\delta$ T cells. *Am. J. Reprod. Immunol.* 37:87-93.
129. Arck, P.C., Ferrick, D.A., Steele-Norwood, D., Croitoru, K. and Clark D.A. 1997. Murine T cell determination of pregnancy outcome. I. Effects of strain, $\alpha\beta$ T cell receptor, $\gamma\delta$ cell receptor and $\gamma\delta$ T cell subsets. *Am. J. Reprod. Immunol.* 37:492-502.
130. Arck, P.C., Troutt, A.B., and Clark, D.A. 1997. Soluble receptors neutralizing TNF- α and IL1 block stress-triggered murine abortion *Am. J. Reprod. Immunol.* 37:262-266.
131. Mowbray, J.F., Jalali, R., Chaouat, G., Clark, D.A. Underwood, J., Allen, W.R., Mathias, S. 1997. Maternal response to paternal trophoblast antigens. *Amer. J. Reprod. Immunol.* 37:421-426.
132. Clark, D.A. and Coker R. 1998. Molecules in Focus, Transforming growth factor β . *Int. J. Biochem. & Cell Biol.* 30:1-6.
133. Lea, R.G., McIntyre, S., Ohno, I., Baird, J.D., and Clark, D.A. 1997. Tumour necrosis factor- α mRNA positive cells in spontaneous resorption in rodents. *Amer. J. Reprod. Immunol.* 39:50-57.
134. Coulam, C.B., Clark, D.A., Beer, A.E., Kutteh, W.H., Silver, R., Kwak, J., Stephenson, M. 1997. Current clinical options for diagnosis & treatment of recurrent spontaneous abortion (from the Clinical Guidelines Recommendation Committee for Diagnosis and Treatment of Recurrent Spontaneous abortion). *Amer. J. Reprod. Immunol.* 38:57-74.
135. Clark, D.A., Merali, F., Steele-Norwood, D., Hoskin, D., Arck, P.C., Murgita, R., Croitoru, K. and Hirte, H. 1997. Decidua-associated suppressor cells in abortion-prone DBA/2 mated CDA/J mice that release bioactive transforming growth factor β 2-related immunosuppressive molecules express a bone-marrow-derived natural suppressor cell marker and $\gamma\delta$ T cell receptor. *Biol. Reprod.* 56:1351-1360.
136. Clark, D.A., Chaouat, G., Arck, P.C., Mittruecker, H.W. and Levy, G.A. 1998. The Cutting Edge: Cytokine-dependent abortion in CBA X DBA/2 mice is mediated by the procoagulant fgl2 prothrombinase. *J. Immunol* 160:545-549.
136. Daya, S., Gunby, J. and Clark, D.A. 1998. Intravenous immunoglobulin therapy for recurrent spontaneous abortion: A meta-analysis. *Amer. J. Reprod. Immunol.* 39:69-76.
137. Clark, D.A., Arck, P.C., Chaouat, G. 1999. Why did your mother reject you? Immunogenetic determinants of the response to environmental selective pressure expressed at the uterine level. *Amer. J. Reprod. Immunol.* 41:5-22.
139. Lea, R.G., Riles, S.C., Antipatis, C., Hannah, L., Ashworth, C.J., Clark, D.A. and Critchley, H.D. 1998. Cytokines, apoptosis regulatory genes and abnormal pregnancy. *Amer. J.*

- Reprod. Immunol. 42:100-109.
141. Clark, D.A., Ding, J., Coulam, C.B., August, C., Chaouat, G. and Levy, G.A., 1999. The emerging role of immunoregulation of fibrinogen-related procoagulant fgl2 in the success or spontaneous abortion of early pregnancy in mice and humans. *Amer. J. Reprod. Immunol.* 42:37-43.
 142. Arck, P., Dietl, J., Clark, D.A. 1999. From the decidual cell internet: Trophoblast recognizing T cells. *Biol. Reprod.* 60:227-233.
 142. Daya, S., Gunby, J., Porter, F., Scott, J. and Clark, D.A. 1999. Critical analysis of intravenous immunoglobulin therapy for recurrent miscarriage. *Human Reprod. Update* 5:475-482.
 142. Clark D.A. 1999. Recurrent miscarriage: Immunological causes. *Medscape Women's Health.* (Published).
<http://www.medscape.com/Medscape/WomensHealth/journal/1999/V04.n03/wh3153.clar/wh313.clar.01.html>
 145. Clark, D.A. 1999. Hard Sciences versus Phenomenology in Reproductive Immunology. *Critical Reviews in Immunology.* 19:509-539.
 146. Arck, P.C., Ferrick, D.A., Steele-Norwood, D., Egan, P.J., Croitoru, K., Carding, S., Dietl, J., and Clark, D.A. 1999. Murine T cell determinants of pregnancy outcome. II. Distinct Th1 and Th2/3 populations of V γ 1+ δ 6+ T cells influence success or failure of pregnancy in CBA X DBA/2 matings. *Cell. Immunol.* 196:71-79.
 147. Niess, J.H., Manuel J., Markert, U.R. and Clark, D.A. 2000. Ly49D transfected NK cells show reduced interleukin-10 production in response to H-2^d and increased lytic activity: implication by interaction using class I MHC alloantigen⁺ target cells in pregnancy. *Amer. J. Reprod.. Immunol.* 44:47-51.
 148. Lea, R.G., Riley, S.C., Antipatis, C., Hannah, L., Ashworth, C.J., Clark, D.A., & Critchley, H.D. 2000. Cytokines, apoptosis regulatory genes & abnormal pregnancy. *Amer. J. Reprod. Immunol.* 42:100-109.
 149. Gorczynski, R.M., Chen, Z., Clark, D.A., Hu, J., Kai, U., Li, X., Tsang, W., & Hadidi, S. 2000. Regulation of gene expression of murine MD-1 regulates subsequent T. Cell Activation and cytokine production. *J. Immunol.* 165:1925-1932..
 150. Gorczynski, R.M., Yu, G., and Clark, D.A. 2000. Receptor engagement on cells expressing a ligand for the tolerance-inducing molecule OX2 induces an immunoregulatory population which inhibits alloreactivity in vitro and in vivo. *J. Immunol.* 165:4854-4860.
 151. Clark, D.A., Ding, J-W., Yu, G., Levy, G.A., and Gorczynski, R.M. 2001. Fgl2 prothrombinase expression in trophoblasts and decidua triggers abortion but may be countered by OX-2. *Molecular Human Reproduction* 7:185-194.

152. Clark, D.A., and Croitoru, K. 2001. Th1/Th2,3 imbalance due to cytokine-producing NK, $\gamma\delta$ T and NK- $\gamma\delta$ T cells in murine pregnancy decidua in success or failure of pregnancy. *Amer. J. Reprod. Immunol.* 45:257-265.
153. Chaouat, G., and Clark, D.A. 2001. Fas/Fas ligand interaction at the placental interface is not required for the success of allogeneic pregnancy in anti-paternal MHC-preimmunized mice. *Amer. J. Reprod. Immunol.* 45:108-115.
154. Gorczynski, R.M., Johnson, N., Yu, G., and Clark, D.A. 2001. Does successful allopregnancy mimic transplantation tolerance ? *Graft* 4:338-345.
155. Clark, D.A., Coulam, C.B., Daya S., and Chaouat, G. 2001. Unexplained sporadic and recurrent miscarriage in the new millennium: a critical analysis of immune mechanisms and treatments. *Human Reprod. Update* 7:501-511.
156. Knackstedt, M., Ding, J-W., Arck, P.C., Hertwig, K., Coulam, C.B., August, C., Lea, R., Dudenhausen, J.W., Gorczynski, R.M., Levy, G.A., and Clark, D.A. 2001. Activation of a novel prothrombinase, fgl2, as a basis for the pregnancy complications spontaneous abortion and pre-eclampsia. *Amer. J. Reprod. Immunol.* 46:196-210.
157. Clark, D.A., Chaouat, G., Gorczynski, R.M. 2002. Thinking outside the box: mechanisms of environmental selective pressures on the outcome of the materno-fetal relationship. *Amer. J. Reprod. Immunol.* 47:275-282.
158. Gorczynski, R.M., Hadidi, S., Yu, G., Clark, D.A. 2002. The same immunoregulatory molecules contribute to successful transplantation and pregnancy. *Amer. J. Reprod. Immunol.* 47:18-26.
159. Merger, M., Barojevic, R., Steele-Norwood, D., Clark, D.A., Viney, J.L., Riddell, R., Maria, D. and Croitoru, K. 2002. Defining the roles of perforin, Fas/FasL and TNF α in T cell-induced mucosal damage in the mouse intestine. *Gut* (in press.)
160. Chan, C.W.Y., Chan, M.W.C., Liu M, Fung L, Cole, E.H., Leibowitz, J.L., Marsden PA, Clark, D.A., Levy, G.A. 2002. Kinetic analysis of a unique direct prothrombinase, fgl2, and identification of a serine residue critical for the prothrombinase activity. *J. Immunol.* 168:5170-5177.
161. Clark, D.A., Yu, G., Arck, P.C., Levy, G.A., Gorczynski, R.M. 2002. MD-1 is a critical part of the mechanism causing Th1-cytokine-triggered murine fetal loss syndrome. *Amer. J. Reprod. Immunol.* (in press).
164. Knackstedt MK, Zencleusen AC, Hertwig K, Hagen E, Dudenhausen JW, Clark DA, Arck PC. 2002. Th1 cytokines and the prothrombinase fgl2 in stress-triggered and inflammatory Abortions. *Amer. J. Reprod. Immunol.* (in press)
162. Clark DA. 2002. Is there any evidence for immunologically-mediated or immunologically

-modifiable early pregnancy failure ? J. Assist. Reprod. Genet. (in press)

163. Liu, M., Leibowitz, J.L., Clark, D.A., Ning, Q., Ding, J.W., Pereira B., Belyavski, M., Fung, L., Marsden P., and Levy, G.A. 2002. Murine fgl2 prothrombinase transcriptional regulation: contribution of Sp1, variants of Sp3, Ets family members, and Stat3. Eur. J Biochem. (submitted).
164. Marsden, P., Fung, L.S., Mendicino, M., Ghandekar, A., Miller, T., Chan, C., Chan, M., He, W., Gorczynski, R., Grant, D., Clark, D.A., Phillips, M.J., and Levy, G.A. 2002. Targeted disruption of fgl2/fibroleukin prevents immunologically mediated thrombosis associated with xenotransplantation and fulminant viral hepatitis. J Clin Invest (in revision).

ABSTRACTS:

1. Nathanson, L., Clark, D.A. and R. Schwartz. 1972. Cellular immunity in malignant melanoma. In: International Cancer Conference and 8th International Pigment Cell Conference Proceedings, pp 78.
2. Clark, D.A. and L. Nathanson. 1972. Cellular immunity in malignant melanoma. Proc. Amer. Assoc. Cancer Res. 13:79.
3. Necheles, R.F., Clark, D.A., Nathanson, L., Whitten, D. and E. Silverman. 1973. HL-A blocking activity in disseminated malignant melanoma. Clin. Res. 21:650.
4. Nathanson, L., Necheles, T.F., Clark, D.A., Silverman, E. and D. Whitten. 1974. HL-A masking activity in malignant melanoma. Proc. Amer. Assoc. Cancer Res. 15:72.
5. Clark, D.A., Phillips, R.A. and R.G. Miller. 1975. Quantitative estimates of killer and inhibitor cells of cell-mediated immunity by Cr⁵¹ release. Federation Proceedings 34:993.
6. Clark, D.A., Phillips, R.A. and R.G. Miller. 1976. Properties of cells suppressing lysis of ⁵¹Cr-labelled targets by sensitized T lymphocytes. II. Physical properties, specificity and developmental kinetics of the inhibitory non T cell population. Cell. Immunol. 34:25-37.
7. Clark, D.A. and M. McDermott. 1978. Active suppression of host vs graft reaction in pregnant mice. Federation Proceedings 37:1646.
8. Clark, D.A. and M. McDermott. 1978. Active suppression of host vs graft reaction in pregnant mice. Canadian Fed. Biol. Soc. 21:86.
9. Clark, D.A. 1979. *In vitro* growth of T lymphocyte colonies requires accessory cells. In Vitro 15:222.

10. Gee, S.R., Clark, D.A. and W.E. Rawls. 1979. The role of NK cells in Pichinde virus infection of Syrian hamsters. *Fed. Proc.* 38:1158.
11. Gee, S.R., Clark, D.A. and W.E. Rawls. 1979. Natural killer (NK) cell activity in Syrian hamsters. *Hamster Society Satellite Symposium*. FASEB, Dallas, Texas.
12. Clark, D.A. and M. Szewczuk. 1979. Cellular and soluble suppressors of cytotoxic T cell generation in pregnant mice. *Can. Fed. Biol. Soc.* 22:49.
13. Gee, S.R., Chan, M.A., Clark, D.A. and W.E. Rawls. 1980. Effect of route of inoculation on Pichinde virus infection in the Syrian hamster. *Fed. Proc.* 39:1151.
14. Clark, D.A., McDermott, M. and M. Szewczuk. 1980. Suppression of host versus graft reaction in allogeneically mated mice. *Can. Fed. Biol. Soc.* 23:89.
15. Clark, D.A., Gauldie, J., Sweeney, G.D. and M. Szewczuk. 1980. Selective inhibition of murine T cell function by TCDD. *Can. Fed. Biol. Soc.* 23:88.
16. Eveleigh, M.J., Clark, D.A. and E.L. McCandless. 1980. Immunomodulating properties of carrageenans. *Can. Fed. Biol. Soc.* 23:155.
17. Clark, D.A. 1980. Cellular and soluble suppressors of host versus graft reaction in mice during first pregnancy. *Proc. 4th Int. Congress Immunol.* 16.5.10, Poster and Workshop.
18. Croy, A., Rossant, J. and D.A. Clark. 1981. Is there maternal immune rejection of the fetus in failed murine interspecies pregnancy? *J. Reprod. Immunol., Suppl.* S32a.
19. Clark, D.A., Gauldie, J., Sweeney, G. and M.R. Szewczuk. 1981. Selective suppression of cytotoxic T cell (CTL) generation by halogenated aromatic hydrocarbons. *Fed. Proc.* 40:3, #4918.
20. Croy, B.A., Rossant, J. and D.A. Clark. 1981. Is there maternal immune rejection of the fetus in failed murine interspecies pregnancy? *Proc. Can. Fed. Biol. Soc.* 24:140, #160.
21. Slapsys, R.M. and D.A. Clark. 1981. Active localized suppression of CTL generation in allopregnant mice. *Proc. Can. Fed. Biol. Soc.* 24:141, #163.
22. Chan, M.A., Gee, S.R., Clark, D.A. and W.E. Rawls. 1981. Pichinde-virus induced suppression of primary footpad swelling in Syrian hamsters. *Proc. Can. Fed. Biol. Soc.* 24:273, 3689.
23. Clark, D.A. and P.B. McCulloch. 1981. Effect of CEA production on the sensitivity of human tumor cells to lysis by natural killer cells. *Proc. Roy. Coll. Surg, Canada*, #125.
24. Rawls, W.E., Gee, S.R., Chan, M.A. and D.A. Clark. 1981. NK cells as targets for Pichinde virus replication. *Proc. Abstracts Fifth Int. Congress on Virology*, August, 1981.

25. Tagliabue, A., Befus, A.D., Clark, D.A. and J. Bienenstock. 1982. Characterization of natural killer cells in the murine intestinal mucosa. Ninth Int. RES Congress. February 1982.
26. Clark, D.A., McCulloch, P.B., Dent, P.B. and S.K. Liao. 1982. Effect of CEA production on the sensitivity of human tumor cells to lysis by natural killer cells. *Proc. Amer. Soc. Clin. Oncol.* 1:35;C-136.
27. Slapsys, R. and D.A. Clark. 1982. Active localized suppression of cytotoxic T cells (CTL) in allopregnant mice. *Fed. Proc.* 41:426.
28. Croy, B.A., Rossant, J. and D.A. Clark. 1982. Maternal immune rejection of the fetus in failed murine interspecies pregnancy. *Fed. Proc.* 41:426.
29. Bienenstock, J., Tagliabue, A., Befus, A.D. and D.A. Clark. 1982. Natural killer cell heterogeneity: characteristics of murine intestinal cells. *Fed. Proc.* 41:316.
30. McDermott, M.R., Clark, D.A. and J. Bienenstock. 1982. Selective localization of mesenteric T lymphoblasts in intestinal respiratory and reproductive tissues. *Fed. Proc.* 41:607.
31. Croy, B.A., Rossant, J. and D.A. Clark. 1982. The role of trophoblast in immune protection of the fetus. *Proc. Can. Fed. Biol. Soc.* 25:26;96.
32. Clark, D.A., McCulloch, P.B., Dent, P.B. and S.K. Liao. 1982. Effect of CEA production in the sensitivity of human tumor cells to lysis by natural killer cells. *Proc. Can. Fed. Biol. Soc.* 25:112, #437.
33. Slapsys, R.M. and D.A. Clark. 1982. Active localized suppression of CTL generation in allopregnant mice. *Proc. Can. Fed. Biol. Soc.* 25:26, #95.
34. Clark, D.A. and R.M. Slapsys. 1982. Active suppression of killer T cells by suppressor cells localized in the genital tract of allopregnant mice. *In: Proc. Immunol. of Reproduction Symposium.* June, 1982. *Amer. J. Reprod. Immunol.* 2:166.
35. Petit, A., Ernst, P., Rosenthal, K., Clark, D.A., Befus, D., Ishizaka, T. and J. Bienenstock. 1983. Murine intestinal intraepithelial lymphocytes (IEL) and their relationship to T cells, NK cells and mast cells. *Fed. Proc.* 42, #802.
36. Levine, M., Browman, G., Bush, H., Clark, D., Figueredo, A., Gowing, J., Hryniuk, W., McCulloch, P., Skillings, J., Tanser, C. and D. White. 1983. A pilot study of short, intensive, adjuvant chemotherapy for stage III breast carcinoma. *Proc. Amer. Soc. Clin. Oncol.* 2:101, #395.

37. Croy, B.A., Rossant, J. and D.A. Clark. 1983. Comparison of immune responses to ectopic grafts of allogeneic and xenogeneic murine trophoblast. *Proc. Can. Fed. Biol. Soc.* 26:193, #132.
38. Clark, D.A. and P.S. Nagarkatti. 1983. *In vitro* properties and *in vivo* correlates of suppressor T cells induced by allogeneic murine pregnancy. *Proc. Can. Fed. Biol. Soc.* 26:128.
39. Slapsys, R.M., Croy, B.A., Rossant, J. and D.A. Clark. 1983. Active localized suppression of cytotoxic T cell generation in the murine uterus correlates with successful pregnancy. *Proc. Can. Fed. Biol. Soc.* 26:193, #131.
40. Liao, S.K., Kwong, P.C., Smith, L.W., Dent, P.B. and D.A. Clark. 1983. Association of morphological differentiation with enhanced histocompatibility antigen expression and susceptibility to natural killer cell lysis in theophylline-treated human malignant melanoma cells. *Proc. Can. Fed. Biol. Soc.* 26:192.
41. Slapsys, R.M., Nagarkatti, P.S., Rossant, J., Croy, B.A. and D.A. Clark. 1983. Properties and significance of two distinct types of suppressor cells associated with murine pregnancy. *Proc. 5th Int. Congress Immunol., Kyoto, Japan.*
42. Croy, B.A., Rossant, J. and D.A. Clark. 1983. Comparison of immune responses to ectopic grafts of allogeneic and xenogeneic murine trophoblast. *Proc. 5th Int. Congress Immunol., Kyoto, Japan.*
43. Croy, B.A., Rossant, J. and D.A. Clark. 1983. Studies of cytotoxic cells in dying embryos in the Mus caroli-Mus musculus pregnancy model system. *J. Reprod. Immunol. Suppl.* 1:74.
44. Clark, D.A., Croy, B.A., Rossant, J. and R.M. Slapsys. 1983. Active localized suppression of cytotoxic T cell generation in the murine uterus correlates with successful pregnancy. *J. Reprod. Immunol. Suppl.* 1:76.
45. Ernst, P.B., Clark, D.A., Befus, A.D., Rosenthal, K. and J. Bienenstock. 1984. Cytotoxic T-lymphocyte precursors (CTLp) from murine intestinal intraepithelial lymphocytes (IEL). *Fed. Proc.*
46. Ernst, P., Clark, D.A., Befus, D., Rosenthal, K.L. and J. Bienenstock. 1984. Cytotoxic T-cell precursors (CTLp) from murine intestinal Lyt 2+ intraepithelial lymphocytes (IEL). *Can. Fed. Biol. Soc.* 27:110; #78.
47. Clark, D.A., Slapsys, R.M., Croy, B.A., Chaput, A., Tutton, D. and J. Rossant. 1984. Role of local intrauterine suppression in the protection of the antigen-bearing fetus. *Can. Fed. Biol. Soc.* 27:25; #93.

48. Wright, K.E., Clark, D.A. and W.R. Rawls. 1984. Differences in lymphocyte responsiveness to lymphokines in two inbred strains of Syrian hamster. *Can. Fed. Biol. Soc.* 27:112; 386.
49. Slapsys, R.M. and D.A. Clark. 1984. Uterine decidual suppressor cells and decidual NK cells represent two distinct populations. *Can. Fed. Biol. Soc.* 27:136, 3184.
50. Clark, D.A., Gauldie, J. and G.D. Sweeney. 1984. Immunoregulation by dioxin and related haloaromatic hydrocarbons. *J. Leucocyte Biol.* 36(3)392.
51. Clark, D.A., Slapsys, R.M., Chaput, A., Walker, C., Rosenthal, K., Croy, B.A. and J. Rossant. 1984. Immunoregulatory mechanisms in the uterus and survival of the fetus. *Amer. J. Reprod. Immunol.* 6:56.
52. Slapsys, R.M., Beeson, J. and D.A. Clark. 1984. The role of the trophoblast in the localization of decidua-associated suppressor cells. *Amer. J. Reprod. Immunol.* 6:66.
53. Daya, S., Clark, D.A., Devlin, M.C., Jarrell, J. and A. Chaput. 1984. Suppressor cells in human decidua. *SOGC.*
54. Daya, S., Clark, D.A., Devlin, C., Jarrell, J. and A. Chaput. 1984. Suppressor cells in human decidua and endometrium. *CFAS Meeting.*
55. Goodyear, M., Hryniuk, W., Clark, D.A., Figueredo, A., Levine, M. and P. McCulloch. 1985. Relationship of dose-intensity (DI) to outcome in chemotherapy of advanced breast carcinoma. *ASCO.*
56. Brierley, J. and D.A. Clark. 1985. Identification of a trophoblastic-independent, hormone-dependent suppressor cell in the uterus of pregnant and pseudopregnant mice. *Fed. Proc.* 44:1884.
57. Slapsys, R., Beeson, J. and D.A. Clark. 1985. Recruitment of a trophoblast-dependent suppressor cell to the implantation site of allopregnant mice. *Fed. Proc.* 44:1880.
58. Brierley, J. and D.A. Clark. 1985. Identification of a trophoblast-independent hormone-regulated suppressor cell in the endometrium of pregnant and pseudopregnant mice. *CFBS.*
59. Goodyear, M., Hryniuk, W., Figueredo, A., Levine, M., McCulloch, P., Clark, D.A. and J. Kotalik. 1985. Dose intensity as a predictor of response and survival in the treatment of advanced breast cancer with chemotherapy. *OCTRF Tenth Clinical Cancer Research Conference. Clin. & Invest. Med.* 8:A163; #R758.
60. Daya, S., Clark, D.A., Devlin, C., Jarrell, J. and A. Chaput. 1985. Suppressor cells - a requirement for successful pregnancy? *SOGC.*

61. Daya, S. and D.A. Clark. 1985. Suppressor cells - a requirement for successful pregnancy? XIth World Congress of Gynecology and Obstetrics, West Berlin.
62. Evans, W.K., Murray, N., Feld, R., Coy, P., Clark, D.A., Levitt, M., Shelley, W. and J. Pater. 1985. Canadian multicenter randomized trial comparing standard (SD) and alternating (A) combination chemotherapy in extensive small cell lung cancer (SCLC). Fourth World Congress on Lung Cancer. Toronto. August, 1985. Clin. Invest. Med. 8:A163; #R756.
63. Brierley, J. and D.A. Clark. 1986. Characterization of a hormone-dependent suppressor cell in the uterus of pregnant and pseudopregnant mice. FASEB Fed. Proc. 45:499.
64. Conway, C.M. and D.A. Clark. 1986. Decidua-associated suppressor activity in allopregnant mice: correlation with gestational age and litter size. 3rd ICRI. J. Reprod. Immunol. Suppl. June, 1986, p. 127.
65. Brierley, J. and D.A. Clark. 1986. Pre-implantation immunoregulatory mechanisms in the uterus of pregnant mice. 6th ICI 1.21.6, p. 733.
66. Clark, D.A., Cinader, B., Rosenthal, K.L., Koh, S-Y. and A. Chaput. 1986. Strain-dependence and cellular aspects of the acceleration of age-dependent shift in class-specific helper and suppressor activity in the thymus of MRL/Mp mice by the LPR gene. 6th ICI 1.62.6, p. 78.
67. Clark, D.A., Brierley, J., Daya, S., Slapsys, R., Chaput, A., Rosenthal, K., Chaouat, G. and N. Kiger. 1986. Intrauterine suppressor cells and the success for failure of murine and human pregnancy. XII World Congress on Fertility and Sterility. Singapore. Oct. 26-31, 1986.
68. Chaouat, G. and D.A. Clark. 1986. Another model of murine spontaneous abortion and immunological treatment. 3rd ICRI. J. Reprod. Immunol. Suppl. June, 1986, p. 135.
69. Clark, D.A., Brierley, J., Slapsys, R., Daya, S., Damji, N., Chaput, A. and K. Rosenthal. 1986. Trophoblast-dependent and trophoblast-independent suppressor cells of maternal origin in murine and human decidua. 3rd ICRI. J. Reprod. Immunol. Suppl. June, 1986, p. 22.
70. Brierley, J. and D.A. Clark. 1986. Characterization of a hormone-dependent suppressor cell in the uterus of pregnant and pseudopregnant mice. 3rd ICRI. J. Reprod. Immunol. Suppl. June, 1986, p. 118.
71. Slapsys, R.M., Beeson, J.H. and D.A. Clark. 1986. Localization of the trophoblast-dependent decidua-associated suppressor cell. 3rd ICRI. J. Reprod. Immunol. Suppl. June, 1986, p. 121.
72. Daya, S., Rosenthal, K. and D.A. Clark. 1986. Modification of endometrial suppressor cell function by trophoblast products. 3rd ICRI. J. Reprod. Immunol. Suppl. June, 1986, p. 164.

73. Daya, S., Johnson, P.M. and D.A. Clark 1986. Mechanism of activation of suppressor cells in the endometrium of the human uterus. 3rd ICRI. J. Reprod. Immunol. Suppl. June, 1986, p. 164
74. Clark, D.A., Slapsys, R., Brierley, J., Chaput, A. and S. Daya. 1986. Suppressor cells in the uterus of mice and humans. Proc. Anat. Soc. U.K. J. Anat. p. 11.
75. Carman, P.S., Ernst, P., Rosenthal, K.L., Clark, D.A., Befus, A.D. and J. Bienenstock. 1986. NK activity against enteric murine coronavirus mediated by intestinal intraepithelial leukocytes. 6th ICI. 1.41.34, p. 45.
76. Slapsys, R., Beeson, J.H. and D.A. Clark. 1986. Trophoblast-dependent localization of decidua-associated suppressor cells. 6th ICI. 6.21.13, p. 735.
77. Chaouat, G., Clark, D.A. and M. Marloie. 1986. Another model of murine spontaneous abortion and its treatment. 6th ICI. 6.21.42, p. 740.
78. Clark, D.A., Brierley, J., Daya, S., Slapsys, R., Chaput, A., Rosenthal, K., Croy, B.A., Chaouat, G., Kiger, N., Underwood, J., Mowbray, J. and C. Conway. 1986. Physiological significance of decidual cells and fetal survival. CDS Annual Symposium, Bangkok, Thailand. Oct. 20-24/86.
79. Sauder, D.N., Guy, D., Damji, N., Orr, F.W. and D.A. Clark. 1986. *In vivo* and *in vitro* effects of epidermal thymocyte activating factor on tumor growth and tumor cell chemotaxis. AFCR.
80. Daya, S. and D.A. Clark. 1987. Molecular weight determination of embryo associated suppressor factor. Proc. SOGC, 43:43.
81. Croitoru, K., Carman, S., Sozzani, S., Ernst, P.B., Rosenthal, K.L., Clark, D.A. and J. Bienenstock. 1987. Modulation of intestinal anti-viral NK activity. Gastroenterology, Vol.92, No. 5, Part 2.
82. Clark, D.A., Brierley, J., Rosenthal, K., Denburg, J. and G. Fulop. 1988. Natural Immunity and Rejection of the Fetal "Allograft". CSI Spring Meeting.
83. Schechter, O., Stedronska-Clark, J., Hamilton, M., Linnemeyer, P. and D.A. Clark. 1988. Analysis of immunosuppressive activity associated with IVF embryos. Amer. J. Reprod. Immunol. Microbiol. 16:113.
84. Lee, S., Clark, D.A., Daya, S., Fishel, S., Mahadevan, M., Goodall, H., Mason, B.A. and M. Ah-Moye. 1988. Immunosuppressive activity in human IVF culture supernatants. Human Reproduction, ESRHE 141:23.
85. Lea, R.G. and D.A. Clark. 1988. *In vitro* studies of murine blastocyst implantation. 3rd Banff meeting on Materno-fetal Interface.

86. Chaouat, G., Menu, E., Hofman, M., Dy, M., Minkowski, M., Clark, D.A. and T.G. Wegmann. 1990. Lymphokines at the feto-maternal interface affect fetal size and survival. *Placenta* 10:482.
87. Lea, R.G., Harley, C.B. and D.A. Clark. 1990. The detection of RNA for TGF- β 2 in murine post-implantation decidual tissue correlated with the detection of a pregnancy associated suppressor factor. Canadian Society of Immunology 1990 (Abs.)
88. Clark, D.A., Manuel, J. and D.K. Banwatt. 1990. Cytokines and spontaneous abortion in CBA/J mice. Canadian Society of Immunology 1990 (Abs.).
89. MacDougall, J.R., Croy, B.A., Chapeau, C. and D.A. Clark. 1990. Assessment of cellular immune responses in mice of genotype scid/scid.bg/bg. Canadian Society of Immunology 1990 (Abs.)
90. Clark, D.A., Manuel, J. and D.K. Banwatt. 1990. Cytokines and spontaneous abortion in CBA/J mice. *FASEB J.* 4:A1888.
91. Lea, R.G., Harley, C.B. and D.A. Clark. 1990. The detection of RNA for TGF- β 2 in murine post-implantation decidual tissue correlated with the detection of a pregnancy associated suppressor factor. *FASEB J.* 4:A1865.
92. Porat, O. and D.A. Clark. 1990. Analysis of immunosuppressive molecules associated with IVF embryos. Israel Fertility Society 1990 (Abs.).
92. Lea, R.G., Harley, C.B. and D.A. Clark. 1990. The detection of RNA for TGF- β 2 in post-implantation decidual tissue correlates with the detection of a pregnancy associated suppressor factor. European Federation of Immunological Societies 1990 (Abs.)
94. Clark, D.A., Lea, R.G., Podor, T., Daya, S., Banwatt, D. and C. Harley. 1990. Cytokines determining the success or failure of pregnancy. VII World Congress on Human Reproduction, Helsinki (Abs.)
95. Clark, D.A. 1990. Success and failure of the fetal allograft. *Am J Reprod Immunol.* 22:81 (Abs.)
96. Zettel, L.A., Clark, D.A., and P.B. Ernst. 1990. Identification of TGF- β as a novel contra-suppressive factor. *FASEB J.* 4:A1708.
97. Lea, R.G., Flanders, K.C., Harley, C.B. and D.A. Clark. 1990. The release of a TGF- β 2-related factor by decidual suppressor cells. BSI/MFIG Meeting, Edinburgh 1990 (Abs.).
98. Murray N. Coppin, C., Rapp, E., Pater, J., Cormier, Y., Evans, W., Hodson D., Clark, D., Feld, R., Arnold, A., Ayoub, J., Wilson, K., Latreille, J., Wierzbicki, R. and D. Hill. 1990.

- The Canadian multicenter trial in non-small-cell lung cancer (NSCLC): an analysis of drug delivery. ASCO Annual Meeting 1990 (Abs.).
99. Clark, D.A. and S. Daya. 1990. Recurrent abortion: is it treatable? CFAS Controversies in Reproductive Endocrinology: An Update for the Clinician. Serono Symposia, Oct/90.
 100. Ernst P.B., Clark, D.A., Lea, R. and L. Zettel. 1990. Transforming growth factor β production in the normal and inflamed murine small intestine. 3rd Annual Gastroenteric Biology Conference 1990 (Abs.)
 101. Hirte, H.W. and D.A. Clark. 1990. Identification of a factor in ascitic fluid of human ovarian carcinoma suppressing generation of lymphokine-activated killer cells as transforming growth factor β (TGF- β). Society for Biological Therapy 1990 (Abs. #26).
 102. Lea, R.G., Allen, W.R., Ohno, I., Jordana, M. and D.A. Clark. 1991. The expression of TGF- β subtypes in pregnancy associated tissues. Canadian Society Immunology 1991 (Abs.)
 103. Clark, D.A., Banwatt, D., Manuel, J., Fulop, G. and G. Chaouat. 1991. Two models of spontaneous abortion (fetal rejection): common pathogenetic features and distinct triggers. Canadian Society Immunology 1991 (Abs.)
 104. Ohno, I., Lea, R.G., Dolovich, J., Clark, D., Jordana, M. and J. Gauldie. 1991. The expression of TGF- β subtypes in nasal polyposis tissues. Canadian Society Immunology 1991 (Abs.).
 105. Clark, D.A. and S. Daya. 1991. Immunotherapy for unexplained recurrent abortion: problems of proving efficacy/inefficacy. Am. J. Reprod. Immunol. 25:60.
 106. Daya, S., Gunby, J., Jalali, G.R., Underwood, J.L., Mowbray, J.F., and D.A. Clark. 1991. Trophoblast induction of suppressor-type cell activity in human endometrial tissues is dependent on IgG bound to antigenic sites. Am. J. Reprod. Immunol. 25:49.
 107. Clark, D.A., Banwatt, D., Manuel, J., Fulop, G. and G. Chaouat. 1991. Two models of spontaneous abortion (fetal rejection): common pathogenic features and distinct triggers. British Society for Immunology 1991.
 108. Daya, S. and D.A. Clark. 1991. Immunology of habitual abortion. SOGC Symposium, June 1991.
 109. Sinclair, S.B., Baca-Estrada, M.E., Croitoru, K., Lea, R., Clark, D.A., Riddell, R.H. and P.B. Ernst. 1992. TGF- β production by eosinophils in inflamed human intestine. Gastroenterology. Vol.102:A696.
 110. Clark, D.A., Banwatt, D., Fulop, G., Quarrington, C. and B.A.Croy 1992. Genetic aspects of spontaneous abortion (resorption) in normal and immunodeficient (SCID) mice. AJRI 27:48-49.

111. Clark, D.A, Manuel, J. and Banwatt D. 1992. Immunotherapy of stress-triggered abortion in mice. *Am. J. Reprod. Immunol.* 27:35.
112. Lea, R.G., Ohno, I., Finotto, S., Flanders, K., Jordana, M., Gauldie, J., and Clark, D.A. 1992. The expression and release of TNF- α & TGF- β 2 by murine uterine tissues in normal and aborting pregnancies. *EOS* 12:113.
113. Clark, D.A., Christmas, S., Johnson, P.M., and Banwatt, D. 1992. Failure to detect TGF- β 2 mRNA or TGF- β suppressive activity associated with human CD3 decidual leucocyte clones. *EOS* 12:82.
114. Clark, D.A., Chaouat, G., Banwatt, D., and Manuel, J. 1992. Effect of prostaglandin synthesis inhibitors on spontaneous and endotoxin-induced abortion in mice. *Am. J. Reprod. Immunol.* 27:35.
115. Clark, D.A., Lea, R.G., Chaouat, G., Pearce, M., and Abrams, J. 1992. CD8⁺ suppressor cells and GM-CSF in the CBA-DBA/2 murine recurrent spontaneous abortion model. *EOS* 12:82.
116. Clark, D.A., Lea, R.G., Underwood, J., Michel, M., Flanders, K.C., Harley, C., Daya, S., Hirte, H., and Mowbray, J. 1992. A subset of recurrent first trimester-aborting women show subnormal TGF- β 2 suppressor activity near the implantation site associated with miscarriage. *EOS* 12:83.
117. Clark, D.A. 1992. Anti-sperm antibodies: do they or don't they? SCOG Symposium. June 1992.
118. Clark, D.A., Flanders, K.C., Starkey, P., Vince, G., and H.Hirte. 1993. Murine and human decidua-associated natural suppressor cells release a novel type of TGF- β 2. *J. Immunol.* 150:4A.
119. Yie, S.M., Lobb, D., Clark, D.A., and Younglai, E.V. 1993. Human sperm produce growth factors. AFS/CFAS 49th Ann.Mtg. Oct.93.
120. Vince, C., Starkey P., Hirte, H., Flanders, K., and Clark D.A. 1993. TGF- β production by large granular lymphocytes from human decidua. MFIG meeting BSI April 1993, Liverpool.
121. Yie, S.M., Lobb, D., Clark, D.A., and Younglai, E.V. 1993. Human Sperm Produce Growth Factors. *Am. Fertil. Soc. (Abs).*
122. Clark, D.A., Manuel, J., and Whyte, T. 1994. TGF- β 2-producing suppressor cells may explain remission of autoimmune arthritis in pregnancy. *Am. J. Reprod. Immunol.* 31:226 (Abs).

123. Merali, F., Manuel, J., Arck, P., and Clark, D.A. 1994. Do murine decidual natural suppressor cells synthesize novel TGF- β 2-related suppressor factor? *Am. J. Reprod. Immunol.* 31:230 (Abs).
124. Arck, P., Merali, F., Manuel, J., Chaouat, G., and Clark, D.A. 1994. Mechanism(s) of stress-triggered abortion in mice. *Am. J. Reprod. Immunol.* 31:221 (Abs)
125. Clark, D.A. 1994. Stress, abortion, parturition: role of immune system. INSERM Colloque, Annecy, France. (Abs).
126. Arck, P., Merali, F. and D.A. Clark. 1994. Stress and pregnancy outcome: analysis of mechanisms. INSERM Colloque, Annecy, France. (Abs)
127. Merali, F., Manuel, J., Arck, P., and Clark, D.A. 1994. Do murine decidual natural suppressor cells synthesize novel TGF- β 2-related suppressor factor? *Am. J. Reprod. Immunol.* 31:230 (Abs.).
128. Merali, F., Manuel, J., Arck, P. and Clark, D.A. 1994. Is the novel TGF- β 2-related suppressor factor synthesized by murine decidual natural suppressor cells? INSERM Colloque, Annecy, France. (Abs.)
129. Clark, D.A., Arck, P., Jalali, R., Merali, F., Manuel, J., Chaouat, G., Underwood, J., and Mowbray, J. 1995. Psycho-neuro-cytokine/endocrine pathway in immunoregulation during pregnancy. *Am. J. Reprod. Immunol.* 33:431 (Abs).
130. Merali, F., Arck, P., Manuel, J., Beaman, K., Flanders, K. and D.A. Clark. 1995. TGF- β 2-related DSF: is it TJ6 or not TJ6? *Am. J. Reprod. Immunol.* 33:453 (Abs).
131. Arck, P., Merali, F., Stanis, A., Stead, R., Chaoaut, G. and D.A. Clark. 1995. Stress-induced murine abortion may be prevented via depletion of neurotransmitter substance P. *Am. J. Reprod. Immunol.* 33:464.
132. Arck, P., Merali, F., Stanis, A., Chaouat, G. and D.A. Clark. 1995. Influence of stress on immunoregulation during pregnancy. AAI (Abstr. of 9th ICI) (Abs).
133. Merali, F., Arck, P., Chaouat, G., Manuel, J. and D.A. Clark. 1995. TGF- β 2-related suppressor factor: secreted or synthesized? AAI (Abstr. of 9th ICI) (Abs).
134. Merali, F., Arck, P., Manuel, J., and D.A. Clark. 1995. Is the novel TGF β -2-related suppressor factor synthesized by murine decidual natural suppressor cells? Insem Colloque, Annecy, France (Abs.).
135. Arck, P., Merali, F., Stanis, A., Stead, R., Chaouat, G. and Clark, D.A. 1995. Stress-triggered abortion: inhibition of protective suppressor mechanisms and promotion of TNF- α release via neurotransmitter substance P. *Amer. J. Reprod. Immunol.* 33:464.

136. Clark, D.A. and Chaouat, G. 1996. Cytokines abort the fetal parasite. Société Canadienne d'Immunologie - Réunion du Printemps 1996, March 22-25, 1996, Le Chantecler - Sainte-Adèle, Québec.
137. Clark, D.A. 1996. $\gamma\delta$ T cells and outcome of early pregnancy. Third International Meeting "Mechanisms in Local Immunity" & Third Meeting of Alps-Adria Society for Immunology of Reproduction, September 26-28, 1996. Opatija, Croatia.
138. Clark, D.A., Manuel, J., Arck, P.C., and Whyte, A. 1996. Is remission of collagen-induced arthritis in pregnant DBA/1 mice relevant to remission of rheumatoid arthritis in human pregnancy? *Amer. J. Reprod. Immunol.* 35:464.
139. Arck, P.C., Ferrick, D.A., Steele-Norwood, D., and Clark, D.A. 1996. T cell involvement in pathogenesis and prevention of stress-triggered abortion in mice. *Amer. J. Reprod. Immunol.* 35:454.
140. Clark, D.A., and Chaouat, G. 1996. Spontaneous abortion in DBA/2-mated mice is due to cytokines and not trophoblast killing by asialogm1+ NK cells or NO-producing macrophages. *Amer. J. Reprod. Immunol.* 35:454.
141. Markert, U.M., Arck, P.C., McBey, B.A., Manuel, J., Chaouat, G., Marshall, J., Croy, B.A. and Clark, D.A. 1996. Stress triggered abortions are associated with alterations of granulated cells in the decidua. *Amer. J. Reprod. Immunol.* 35:455.
142. Clark, D.A. 1996. $\gamma\delta$ T cells as determinants of pregnancy success or failure: return of the "fetal allograft"? *Amer. J. Reprod. Immunol.* 35:447.
143. Cadavid, A.P., Clark, D.A., Guilbert, L.J., Jalali, G.R., Underwood, J.L., Mowbray, J.F. 1996. Murine monoclonal BA11 antibody to the human syncytiotrophoblast R80K antigen binds to cytotrophoblast and inhibits lysis of K562 cells without binding to the target cell. *Amer. J. Reprod. Immunol.* 35:461.
143. Clark, D.A. 1996. Chemotherapy for metastatic breast cancer: Dose intensity without toxicity. Guidelines or clinical trial? Controversies in the Etiology, Detection and Treatment of Breast Cancer: 1996. May 2-3, 1996, The Old Mill, Toronto, Ontario. Canada.
144. Clark, D.A., Arck, P. and G. Chaouat. 1996. Decidual immunocyte-placental interaction. *Placenta* 17:A7.
145. Clark, D.A., Arck, P.C., Ferrick, D.A., and Croitoru, K. 1997. Maternal uterine T cell determination of survival of the fetus QUA parasite. *J. Aller. and Clin. Immunol.* 99:S506;2047.
146. Clark, D.A. 1997. Presidential Address: Paradigm Lost, Paradigm Gained. *Amer. J. Reprod. Immunol.* 37:347

147. Arck, P.C., Quarrington, C., Mak, T, and Clark, D.A. 1997. TNF- α P55 receptor knockout mice demonstrate two distinct types of endotoxin-induced rejection of embryo *qua* parasite. *Amer. J. Reprod. Immunol.* 37:347.
148. M. Merger, D.A. Clark, D. Steele-Norwood, R. Borojevic, R.H. Riddell, K. Croitoru. 1998. Anti-CD3 induced T cell enteropathy is not dependent on TNF- α mediated pathways. *Amer. Gastroenterological Assoc. Ann. Mtg., New Orleans, May 1998.*
149. Clark, D.A., Arck, P.C., Steele-Norwood, D., Croitoru, K., Levy, G.A. & Chaouat G. 1998. Th1/Th2 balance determines outcome of pregnancy via FGL2 prothrombinase-triggered inflammation. *Amer. Assoc. Immunol. FASEB J.* 12: A880.
150. Arck, P.C., Steele-Norwood, D., Dietl, J. and Clark, D.A. 1998. Two distinct populations of V(1⁺ T cells determine success or failure of pregnancy in CBA/J x DBA/2J mice. 1998 Meeting of the American Society Reproductive Immunology. Chicago, IL, May 9-12, 1998. *Amer. J. Reprod. Immunol.* 39:296.
151. Clark, D.A., Manuel, J., Stampfli, M.R., Kirpilani, H., Jordana, M., Gauldie, J. 1998. Trophoblast barrier to maternal cytokines and the Barker hypothesis. 1998 Meeting of the American Society Reproductive Immunology. Chicago, IL, May 9-12, 1998. *Amer. J. Reprod. Immunol.* 39:299.
152. Clark, D.A., 1998. Immunopathology of early pregnancy. Fourth International Meeting "Mechanisms in Local Immunity. 4th Meeting of Alps Adria Society for Immunology of Reproduction. Opatija, Croatia. Sept. 16-19, 1998. *Period. Biol.* 100 Suppl.
153. Clark, D.A., 1998. Tom Wegmann Memorial Lecture: From trophoblast antigens and cells to cytokines: Visions and realities. 7th International Congress of Reproductive Immunology, New Delhi, India, October 27-30, 1998. *Amer. J. Reprod. Immunol.* 40(4):242 (9).
154. Clark, D.A., Steele-Norwood, D., Croitoru, K. (1998). Th1/Th2,3 NK Cells: Regulation of FGL2 prothrombinase-mediated abortions? 10th International Congress of Immunology, New Delhi, India, November 1-6, 1998.
155. Clark, D.A., 1998. How did your mother reject you? Let me count the ways. *Amer. J. Reprod. Immunol.* 39:298.
156. Clark, D.A., Ding, J.W., Steele-Norwood, Croitoru, K., Arck, P.C., Coulam, C.B., Chaouat, G., and Levy, G.A. 1998. At the Interface: Prevention and promotion of prothrombin activation determines the fate of chromosomally normal embryos. *Period. Biol.* 100 (3): S9-1.
157. Chaouat, G., and Clark, D.A. 1998. NK & T cells in immune abortion and local cytokine networks. *Period. Biol.* 100 (3): S8-3.

158. Lea, R.G., Hannah, L., Antipatis, C., Riley, S.C., Clark, D.A., Ashworth, C.J., Tulppala, M. 1998. Cytokines, apoptosis regulatory genes and abnormal pregnancy. *Period. Biol.* 100 (3) S9-4.
159. Chaouat, G., Cayol, V., Mairowitz, V., and Clark, D.A. 1998. Local immune suppression and placento-maternal regulation of materno-fetal tolerance. *Am J Reprod Immunol.* 40:246
160. Kieslich, C., Arck, P.C., Klapp, B.F., Marx, L., Coulam, C., Clark, D.A. 1999. Increased human decidual mast cells might be associated with stress-triggered abortion rather than chromosomal abnormalities of the embryo. *Amer. J. Reprod. Immunol.* 41:384.
161. Clark, D.A., Chaouat, G., Ding, J.W., August, C., Coulam, C.B., Levy, G.A. 1999. FGL2 in pregnancy: A novel prothrombinase at the fetomaternal interface may prevent bleeding and cause abortions. *Amer. J. Reprod. Immunol.* 41:374.
162. Neiss, H.J., Manuel, J., Markert, U.R. and Clark, D.A. 1999. Interleukin 10 production of Ly49D positive rat natural killer cells (NK cells) in pregnancy. *Am. J. Reprod. Immunol.* 41:394.
163. Clark, D.A., Ding, J.W., Yu, K., Levy, G.A., Gorczynski, R.M. 1999. Unexplained recurrent abortions associated with up-regulation of a novel prothrombinase on trophoblast and in decidua, are inhibited by maternal $\gamma\delta$ T cells that produce Th2 and Th3 cytokines in response to the novel tolerance-promoting molecule OX-2, expressed at these sites. *Amer. Soc. For Reproductive Medicine*, 55th Annual Meeting, September 25-30, 1999, Toronto, Ontario, Canada..
164. Clark, D.A., Yu, K., Levy, G.A., Gorczynski, R.M. 2000. The OX-2 tolerance signal molecule at the fetomaternal interface determines pregnancy outcome. *Amer. Soc. Reprod. Immunol.* June 10-13, 2000, Jacksonville, FLA. *Amer. J. Reprod. Immunol.* 43:326
165. Knackstedt M, Johnson N, Arck P, Ding JW, Levy GA, Gorczynski RM, Clark DA. 2000. Immune coagulation in preeclampsia. *Amer. J. Reprod. Immunol.* 43:329
166. Clark, D.A., Ding, J.W., Yu, K., Coulam, C.B., August, C., Levy, G.A., Gorczynski, R.M. 2000. The immunoregulatory tolerance-promoting molecule OX-2 expressed at the maternal-fetal interface prevents spontaneous abortions. 6th Congress of the Adria-Alps Society of Immunology of Reproduction. June 27-30, 2000 Pecs, Hungary.
167. Knackstedt, M., Johnson, N., Yu, K., Ding, J.W., Levy, G.A., Gorczynski, R., Clark, D.A. 2000. Immune coagulation in preeclampsia. *FASEB J.* 14(6): A1248.
168. Clark, D.A. Reliable decision making in evidence-based oncology. 2001. Canadian Association of Medical Oncologists/National Cancer Institute of Canada, Annual meeting.
169. Clark, D.A., Yu, G., Hadidi, S., Levy, G.A., Gorczynski, R.M. 2001. LPS plays key role in

- Th1 cytosine-dependent murine abortions. *Amer. J. Reprod. Immunol.* 45;356.
170. Clark DA, Manuel J, Gorczynski RM, Blajchman M. 2001. Labile CD200 tolerance signal important in transfusion-related immunomodulation (TRIM) prevention of recurrent miscarriages. *Amer. J. Reprod. Immunol.* 45;361.
 171. Knackstedt M, Zenclussen A, Hagen E, Hertwig K, Dudenhausen JW, Clark DA, Arck PC. 2001. Analysis of TNF- α , fgl2 and apoptosis in murine abortions. *Amer. J. Reprod. Immunol.* 45;349.
 172. Keil A, Yu K, Manuel J, Levy GA, Gorczynski RM, Clark DA. 2001. The 'tolerance-promoting' molecule OX-2 is expressed in fetal trophoblast cells that cocoon the 'fetal allografts' and may prevent pregnancy loss caused by activation of fgl2 prothrombinase. *Amer. J. Reprod. Immunol.* 45;343.
 173. Clark DA. 2001. New insights into the molecular basis for success or failure of early pregnancy. *J. Japan Soc. Immunol. Reprod.* 16:40-43
 173. Clark DA, Gorczynski RM, Levy GA. 2002. One signal to abort, or 3 for safety ? Definition of the molecular matrix- the importance of danger and its immunotherapeutic antithesis. *Amer. J. Reprod. Immunol.* 47:356
 174. Knackstedt MK, Dudenhausen J, Clark D, Arck PC. 2002. Th1 cytokines and the Prothrombinase fgl2 in stress-triggered and inflammatory abortions. *Amer. J. Reprod. Immunol.* 47:347.
 175. Clark DA, Gorczynski RM, Levy GA. 2002. Not Th1 nor Th2 but "danger" for whom the belle tolls. *Amer. J. Reprod. Immunol.* 48:140

PRESENTATIONS AT MEETINGS:

Invited:	American Society for Immunology of Reproduction, Park City, Utah (Keynote Speaker)	06-1983
	University of Liverpool, Department of Immunology (Speaker) (Evidence for Immune Rejection of the Fetus)	04-1984
	King's College Cambridge, British Society of Immunology (Lecturer)(Suppressor Cells and Success of the Fetal Allograft)	04-1984
	Institut Curie, Paris, France,	

(Speaker)(Pregnancy Immunology)	04-1984
Cold Spring Harbor Symposium "Biological Mechanisms of Dioxin Action" (given by Dr. Sweeney due to previous commitment to speak in England)	06-1984
Canadian Society for Immunology, Symposium on Immunology of Reproduction (Symposium Speaker)	06-1984
Gordon Conference on Mammalian Genital Tract (Speaker) (Pregnancy Immunology)	07-1984
RES Society Minisymposium on Immunotoxicology (Speaker)	10-1984
International Congress on Reproductive Immunology, Tel Aviv (Symposium Speaker)	10-1984
Minisymposium of Reproductive Immunology, Paris, France (Speaker)	10-1984
6th International Symposium on Immunology of Reproduction, Varna (Speaker)	05-1985
Anatomical Society of Great Britain, University of Southampton, U.K. (Pregnancy Immunology)	01-1986
Inserm Colloque, Paris, France, Immunology of Reproduction (Speaker and Member of Scientific Committee)	12-1986
Implantation Meeting, Guy's Hospital, London (Speaker) (Current concepts of immunoregulation of implantation)(Speaker)	04-1987
Philadelphia, Spring Symposium in Clinical Applications of Reproductive Immunology (Immunological aspects of pregnancy and IVF failure and their treatment)	

- (Clinical approaches to infertility and recurrent abortion)(Speaker) 05-1987
- Gordon Conference
"Are immunosuppressors and growth stimulating factors the same?" (Speaker) 07-1988
- Methodist Centre for Transplantation & Immunology of Reproduction Conference
"Can animal models help?" panel discussion - immunotherapy of recurrent abortion (Speaker) 08-1988
- WHO Conference -
"Contraception and mechanisms of endometrial bleeding;macrophages and other migratory cells in endometrium; relevance to endometrial bleeding" (Speaker) 11-1988
- 3rd Banff Conference on the Materno-fetal Interface
"Role of factor related to transforming growth factor β 2 in successful pregnancy" (Speaker) 01-1989
- European Molecular Biology Organization
Basel Institute for Immunology
"SCID mice in reproductive biology" (Speaker) 02-1989
- University of Ottawa Ob-Gyn, 1989
update in Reproductive and Infertility
"Immunology for Obstetricians & Gynecologists" (Speaker) 05-1989
- St Mary's Hospital Medical School,
London U.K. Aleck Bourne Lecture
"The Immunology of Pregnancy Failure" (Speaker) 05-1989
- Society of Obstetricians and Gynaecologists of Canada, Quebec City
"Key role of local intrauterine suppression in preventing rejection of the conceptus" (Speaker) 06-1989
- Wichita Conference - Cellular signals controlling uterine function, University of Kansas,
"The origin and role of cytokines determining success and failure in the

post-implantation period" (Speaker)	09-1989
Erice Conference, Sicily - 1st International Symposium on "Immunobiology of Normal and Diabetic Pregnancy" (Speaker)	03-1990
Walter Heap Centennial Symposium on Embryo Transfer, Guelph, "Cytokines in post-implantation success of the embryo" (Speaker)	04-1990
American Society for the Immunology of Reproduction, Chicago, "Success and Failure of the Fetal Allograft" (Speaker)	06-1990
VII World Congress on Human Reproduction Helsinki, Finland, "Cytokines determining the success or failure of pregnancy" (Speaker)	07-1990
Institute of Molecular Genetics, Dept. of Immunology, Prague, "Role of a TGF- β 2-like factor in preventing rejection by LAK cells" (Speaker)	07-1990
Institute of Physiology, Prague, "Role of polyamines in the success or failure of <i>in vitro</i> fertilized embryos" (Speaker)	07-1990
Serono Symposia USA, Ville d'Esterel, Quebec, "Controversies in Reproductive Endocrinology: An Update for the Clinician" (Speaker)	10-1990
American Academy of Dermatology, Atlanta, Georgia, "Organization of the Immune System" (Speaker)	12-1990
INSERM Colloque, Paris, "TGF- β in human and mouse reproduction" and "Is there an early embryo suppressor factor?" (Speaker) (declined; post-doc. sent to give talks)	12-1990
St. Justine Center for Clinical Investigation and Research, Montreal, Quebec	

- "Immunotherapy for Recurrent Miscarriage"
(Speaker) 04-1991
- Society for Obstetricians & Gynecologists of
Canada, Toronto
"Immunology and Reproduction: Basic and
Applied" (Speaker) 06-1991
- American Society for Reproductive Immunology
Symposium, Virginia, USA
"Immunotherapy for Unexplained Recurrent
Abortion: Problems in Proving Efficacy/Inefficacy"
(Speaker and Symposium Chairperson) 06-1991
- Chicago Medical School,
University of Health Sciences, Chicago, Ill. USA
"Mechanisms of Suppression of Abortion (Rejection
of the Fetoplacental Unit): of Mice and Women".
(Speaker) 11-1991
- University of Western Ontario
"Role of transforming growth factor β on the
regulation of trophoblast cell invasiveness, growth
and differentiation". (Speaker) 04-1992
- National Institutes of Health,
Contraceptive Development Branch, NICHD,
Bethesda, Md., USA
"Cytokines: role in regulation of endometrial bleeding.
(Speaker) 05-1992
- Colleges Biosciences Association
George Brown College,
Toronto, Ontario
"Immunology made simple - 1992 edition".
(Speaker) 06-1992
- Canadian Society of Obstetricians &
Gynecologists, 48th Annual Meeting,
Vancouver, B.C.
"Anti-sperm antibodies: do they or don't they?"
"Objectives: Immunology for the Obstetrician
Gynecologist". (Speaker) 06-1992
- University of Toronto
"TGF- β in pregnancy and cancer" (Speaker) 06-1992

- 8th International Congress of Immunology,
Budapest, Hungary
"Role of a unique species of TGF- β in
preventing rejection of the conceptus during pregnancy".
(Speaker) 08-1992
- T Cell Sciences (Boston)
"Novel form(s) of TGF- β in pregnancy and cancer"
(Speaker) 09-1992
- National Research Council,
Biotechnology Institute, Montreal
"Murine pregnancy decidua produces a unique
immunosuppressive molecule related to TGF- β 2"
(Speaker) 11-1992
- Endocrinology of Embryo-endometrial
Interactions, Bordeaux, France Satellite Symposium
of the 9th International Congress of Endocrinology
(N.I.C.E.92) Bordeaux, France
"Cytokines: molecular language for "yes"
and "no". Invited speaker (declined due
to lack of travel funds). 09-1992
- Ontario Thoracic Society
"Should you treat non-operable, non-small cell lung
cancer?" (Speaker) 02-1993
- AAI FASEB Meeting (Denver)
"Murine and human decidua-associated natural
suppressor cells release a novel type of TGF- β 2".
(Minisymposium Speaker) 05-1993
- SCID Mouse Workshop
University of Guelph, Guelph, Ont.
"Abortion in SCID mice" (Speaker) 06-1993
- Meta-analysis of immunotherapy of recurrent
miscarriage (Washington, DC)
(Speaker & Chairperson) 07-1993
- Serono Symposia, Boston, MA
"Novel transforming growth factor β 's in
pregnancy and cancer" (Speaker) 08-1993

RT Weaver Day, Hamilton, Ont "Identification of suppressor cells in decidua that produce novel species of TGF- β suppressor factor in successful human pregnancies" (Speaker)	11-1993
British Society for Immunology "Mechanism of pregnancy - induced remission of arthritis" (Speaker)	12-1993
University of Newcastle upon Tyne "TGF- β 's in pregnancy and cancer". (Speaker)	01-1994
University of Cambridge, UK "Novel TGF β 's in the uterus". (Speaker)	01-1994
University of Oxford, UK "TGF- β 's in pregnancy and cancer". (Speaker)	01-1994
Guy's Hospital Medical School, London, UK "Pregnancy and Arthritis". (Speaker)	01-1994
Mohawk College Health Sciences Education Current Topics of Interest in Immunology "Review of the Immune System". (Speaker)	04-1994
INSERM-Merieux Colloque, France "Effect of immune status on stress- induced abortion". (Speaker)	05-1994
Sunnybrook Hospital Oncology Dept. "Is dose intensity dose insanity? The problem of Stage IV breast cancer". (Speaker)	02-1995
MFIG-BSI Symposium, "Psycho-neuroimmunological mechanisms in spontaneous abortion: of mice, women & James Mowbray St. Mary's Hospital, London, UK. (Speaker)	04-1995
6th International Society for Immunology of Reproduction, Washington, D.C., USA Local & systemic effects of pregnancy- related TGF β (Symposium Speaker)	07-1995

- 9th International Congress of Immunology,
San Francisco, USA
"At the interface: uterine immunoregulation during
pregnancy" (Symposium Speaker) 07-1995
- The 16th Annual ASRI Meeting "γδ T cells as
determinants of pregnancy success or failure:
return of the "fetal allograft?"
(Symposium Speaker) 06-1996
- The 13th Rochester Trophoblast Conference
and, The Thomas G. Wegmann Memorial Symposium
on Reproductive Immunology, Banff, Alberta
"αβ and γδ T cells and reproductive success/failure"
(Symposium Speaker & Member of Organizing
Committee) 09-1996
- Third International Meeting "Mechanisms in Local
Immunity" Third Meeting of Alps-Adria Society for
Immunology of Reproduction
"γδ T cells and outcome of early pregnancy"
(Chair and Symposium Speaker) 09-1996
- AAAAI/AAI/CIS Joint Meeting, San Francisco
"Maternal Uterine T Cell Determination of Survival
of the Fetus *QUA* Parasite
(Invited Symposium Speaker & Chair) 02-1997
- 17th Annual Meeting of ASRI, Vancouver
"Paradigm Lost, Paradigm Gained"
(Invited Speaker) 06-1997
- Czech Academy of Science
"Paradigm shifts in immunology of reproduction:
New insights on role of T cells and on mechanisms
causing pregnancy failure"
(Invited Speaker) 07-1997
- AAI Annual Meeting, San Francisco
"Maternal uterine T cell determination of survival
Of the fetus *qua* parasite"
(Invited Speaker and Chair) 04-1998
- 18th Annual Meeting of American Society
Reproductive Immunology
"Why did your mother reject you"?

(Invited Speaker)	05-1998
Fourth Meeting of Alps Adria Society for Immunology of Reproduction, Opatija, Croatia "Immunopathology of early pregnancy" (Invited Speaker and Chair)	09-1998
7th ICRI, New Delhi, India Tom Wegmann Memorial Horation "From trophoblast antigens and cells to cytokines: visions and realities" (Invited Plenary Speaker)	10-1998
VII International Congress of Reproductive Immunology "Immunological Contraception" Dr. B.R. Ambedkar Centre, New Delhi, India (Symposium Speaker)	10-1998
10th ICI New Delhi, India Th1/Th2,3 NK Cells: Regulation of FGL2 prothrombinase-mediated abortions? (Invited Chair & Speaker)	11-1998
10th International Congress of Immunology New Delhi, India "Immune regulation of maternal fetal interactions" (Invited Speaker and Chair - "Reproductive Immunology)	10-1998
American Society Reproductive Immunology 19 th Annual Meeting "Molecular mechanism in immunologically- modifiable pregnancy failure" (Speaker)	06-1999
Frontiers in Reproduction Symposium, Wood's Hole 19 th Annual Meeting NICHD/NIH (Invited Speaker)	07-1999
10 th International Congress Mucosal Immunology Amsterdam, The Netherlands (Declined)	7-1999
European Placenta Meeting, Austria (Declined)	9-1999

- European Congress in Immunology & Pregnancy
 "Exploring the maternal fetal interface"
 Rome, (Lead Speaker) 10-1999
- MRC Group on Organ Injury, University Health Network,
 The Toronto General Div.
 "Transplantation tolerance mechanisms as a basis for
 successful pregnancy"
 Toronto (Invited Speaker) 10-1999
- Dartmouth Medical Centre,
 "Maternal Recognition of the Fetal Allograft: Identification
 Of Immunogenetic Determinants determining rejection or
 Tolerance"
 Lebanon, New Hampshire
 (Invited Speaker) 03-2000
- "Immunomodulation in Recurrent Abortion, Crohn's
 Disease, and Rheumatoid Arthritis
 Clinical and Molecular Basis of Transfusion-Induced
 Immunomodulation
 Washington D.C. (Invited Speaker) 03-2000
- "The immunoregulatory tolerance-promoting molecule
 OX-2 expressed at the maternal-fetal interface prevents
 spontaneous abortions" (Invited Speaker and Chair)
 6th Congress of the AASRI
 Pecs, Hungary 06-2000
- The Centre for Human Reproduction
 Chicago, Illinois
 "Behind the evidence of evidence based medicine
 as applied to obstetrics & gynecology. Would
 you believe this?" (Invited CME speaker) 11-2000
- The Centre for Human Reproduction
 New York City, New York
 "TRIM: transfusion-induced immunomodulation
 as a treatment modality in infertility and recurrent
 miscarriage. What do we really know?"
 (Invited CME speaker) 11-2000
- University of Rome (Italy),
 "New insights into molecular pathogenesis of human
 pregnancy success and failure derived from studies of
 mouse models".

(Invited speaker)	6-2001
VIII International Congress of Reproductive Immunology: Presidential Plenary Address "Thinking outside the box"	7-2001
Annual meeting of Japan Society for Immunology of Reproduction (Tokyo): (Invited International Lecturer) "New Insights into the Molecular Basis for Success or Failure of Early Pregnancy"	12-2001
Dept. Immunology/Microbiol. Chicago Medical School "New Insights into the Molecular Basis for Success or Failure of Early Pregnancy"	2-2002
Annual meeting of Czech Society for Immunology of Reproduction. "Danger and the fetomaternal interface" (Invited speaker: declined)	5-2002
Annual Meeting of the American Society for Reproductive Immunology (Chicago). "Molecular basis for 'danger' at the feto-maternal interface and its immunotherapeutic antithesis."	6-2002
8 th Congress of AASIR (Weimar, Germany) "Not Th1 nor Th2 but 'danger' for whom the belle tolls"	9-2002
Brown University-Lingpong Meeting (Providence, RI) "Danger at the fetomaternal interface: the molecules and messengers."	11-2002

ADMINISTRATIVE RESPONSIBILITIES:

Department:	Promotion & Tenure Committee (member) MVIP Executive & Education Committees (member) Palliative Care Committee (Chairman) Clinical Program Management (member) Quality Assurance Sub-Committee (member) Library Users Committee (member)
University:	<i>Ad Hoc</i> CAWAR Committee (member) CAUWAR Reevaluation Committee <i>Ad Hoc</i> Pension and MUFF Committees Pension Trust Committee

Pension Surplus Distribution Committee

Faculty:

Clinical Faculty Association (President)
 Faculty Association (CFA Representative)
 Regional Medical Associates (Member of Board)

HHSC:

Research Ethics Board (Member)
 Pharmacy and Therapeutics Committee (member)

MEMBERSHIPS IN PROFESSIONAL SOCIETIES:

Royal College of Physicians & Surgeons of Canada (Fellow)	1974-
Canadian Society for Immunology	1977-
Canadian Oncology Society	1978-
American Association of Immunologists	1978-
Royal Society of Medicine - London	1979-
Fellow	1992-
American Society for Reproductive Immunology	1983-
International Society for Immunology of Reproduction	1984-
Canadian Society for Clinical Investigation	1985-
Canadian Fertility & Andrology Society	1986-
British Society for Immunology	1988-
Canadian Association of Medical Oncologists	1991-
Society for the Study of Reproduction	1992-
American Society for Reproductive Medicine (Fellow)	1999-
Royal College of Physicians (Edinburgh, UK)(Fellow)	elected installed
	2001 2002

Declaration under U.S.C. § Rule 132

IN THE MATTER OF

US Patent Application No. 09/380,327
by ROBERTSON et al.

EXHIBIT DAC-2

This is Exhibit DAC-2 referred to in the Statutory Declaration by David Alexander CLARK

dated 16 Dec 2002

Before me:



A person empowered to witness Statutory
Declarations under the laws of the Province of
Ontario, Canada.



PERGAMON

The International Journal of Biochemistry & Cell Biology 30 (1998) 293–298

*The
International
Journal of
Biochemistry
& Cell Biology*

16/12/02 David A Clark
Dir-2

Molecules in focus

Transforming growth factor-beta (TGF- β)

David A. Clark^{a,*}, Robina Coker^b

^a*Mucosal Immunology Group, Molecular Immunology Inflammation Programme, Departments of Medicine, Pathology, Obstetrics and Gynecology, McMaster University, 1200 Main St. West, Hamilton, Ont., Canada L8N 3Z5.*

^b*Centre for Cardiopulmonary Biochemistry and Respiratory Medicine, University College London Medical School, 5 University St., London WC1E 6JJ, UK*

Received 30 July 1996; accepted 3 October 1997

Abstract

The TGF- β family of cytokines are ubiquitous, multifunctional and essential to survival. They play important roles in growth and development, inflammation and repair and host immunity. The mammalian TGF- β isoforms (TGF- β_1 , β_2 and β_3) are secreted as latent precursors and have multiple cell surface receptors of which at least two mediate signal transduction. Autocrine and paracrine effects of TGF- β 's can be modified by extracellular matrix, neighbouring cells and other cytokines. The vital role of the TGF- β family is illustrated by the fact that approximately 50% of TGF- β_1 gene knockout mice die in utero and the remainder succumb to uncontrolled inflammation after birth. TGF- β_2 and TGF- β_3 gene knockout mice are not yet described. More recently, novel TGF- β -like molecules have been described which share some of the properties of the mammalian TGF- β isoforms. The role of TGF- β in homeostatic and pathogenic processes suggests numerous applications in the diagnosis and treatment of various diseases characterised by inflammation and fibrosis. © 1998 Published by Elsevier Science Ltd. All rights reserved.

1. Introduction

Supernatants conditioned by tumor cells may enable phenotypically normal rat kidney fibroblasts (NRK cells) to grow as colonies in semisolid agar, a feature of malignant cells. Two cytokines mediate this effect, transforming growth factor (TGF)- α (5 kDa) and TGF- β (25 kDa) [11]. The 'gold standard' defining TGF- β is the ability to

promote colony formation by NRK cells in semi-solid medium in the presence of TGF- α or its equivalent, epidermal growth factor. However, the commonest bioassay for TGF- β is the inhibition of mink lung epithelial cell growth.

2. Structure

At least 23 distinct genes code for the TGF- β superfamily [1] and there exist at least five TGF- β isoforms. The amino acid sequence of TGF- β 's is highly conserved between species. This article

* Corresponding author. Tel.: +1-905-5212100; fax: +1-905-5214971; e-mail: clarkd@csu.fhs.mcmaster.ca.




Fig. 1. Synthesis and secretion of TGF- β : From gene to released product. Details of intracellular processing is shown for TGF- β_1 for which most information is available. Other TGF- β isoforms are believed to follow a similar sequence. *aa denotes amino acid.

focuses on mammals where three TGF- β isoforms are described. The bioactive molecule is a homodimer of two 12.5 kDa peptides joined by a sulphidryl bond to form a 25 kDa molecule (TGF- $\beta_{1,1}$, - $\beta_{2,2}$, or - $\beta_{3,3}$). Heterodimers (e.g. TGF- $\beta_{1,2}$ and - $\beta_{2,3}$) may also form. Some bioactive TGF- β 's have atypical molecular weights. These include 120/90 kDa glioblastoma-derived factors, 40 and 30 kDa molecules in human breast cancer cell homogenates and 30–32 kDa and 15–20 kDa factors released by uterine lining cells of pregnant mice [2]. These atypical molecules differ functionally from the TGF- β_{1-3} isoforms and may therefore offer valuable insight into the structure–function relationships of the TGF- β isoforms.

3. Synthesis and degradation

The synthesis of latent TGF- β is illustrated in Fig. 1. The details of intracellular processing are most completely defined for TGF- β_1 . The TGF- β_1 and - β_3 genes span 100 kb and - β_2 , 70 kb. The cleavage of pro-TGF- β is mediated by endopeptidases such as furin [4] to yield the 12.5 kDa monomer. The cleaved fragment dimerizes to form a 75 kDa latency binding peptide which assists in folding of the 25 kDa dimer and remains associated to form the latent complex. A 135 kDa latency binding peptide bearing mannose-rich carbohydrate may attach to the complexed latency peptide dimer. The latent complex may be stored in α granules in platelets (the largest reservoir of TGF- β in the body), or may be secreted. Secretion is enhanced by the carbohydrate. It is unclear if TGF- β 's of atypical molecular weight arise from different genes than do the 25 kDa TGF- β_{1-3} or from a different processing of the same pro-peptide.

On release, latent TGF- β may bind to a cell membrane-associated mannose-6-phosphate receptor or to extracellular matrix, as illustrated in Fig. 2. Release of bioactive TGF- β by neoplastic and non-neoplastic cells (such as macrophages and immunosuppressor cells) may occur by activation of latent TGF- β by simultaneously released serine protease(s) [5]. Similar enzymatic

processes may explain activation of latent TGF- β where one type of cell produces latent TGF- β (e.g. vascular endothelial cells) and a second cell type (e.g. pericytes) causes activation. Several different enzymes may activate latent TGF- β bound to extracellular matrix proteins.

Bioactive TGF- β 's may bind to matrix, to α_2 -macroglobulin and to decorin (all of which usually inhibit activity), or to carriers such as albumin and newly synthesized IgG (which does not inhibit activity). α_2 -macroglobulin may facilitate TGF- β action on cells bearing α_2 -macroglobulin receptors. TGF- β - α_2 -macroglobulin complexes are taken up via hepatic mannose-6 phosphate/insulin-like growth factor II receptors and possibly catabolized. Bioactive TGF- β 's may also be degraded by proteases and elastases released at sites of inflammation [2]. TGF- β may be excreted in the urine.

4. Biological functions

The TGF- β 's play roles in adult and embryonic growth and development, in inflammation and repair including angiogenesis and in regulation of host resistance mechanisms. TGF- β 's have both autocrine and paracrine effects. Biological effects are mediated via receptors. Six different receptors have now been described, the most recent being endoglin [7, 13]. The receptors may be subdivided into those which mediate an intracellular signal and those which store and/or present TGF- β 's to signaling receptors. Type II receptors, to which TGF- β is bound, associate with type I receptors to form a signaling complex. The signal appears to proceed via a series of MAD peptides [3] and can result in inhibition or stimulation. For example, adaptive responses (cytotoxic T-cells, delayed-type hypersensitivity/cellular immunity T-cells and helper T-cells) may be inhibited as may be the activity of natural effector cells such as macrophages, natural killer cells and natural cytotoxic cells which contribute to host resistance. Epithelial and endothelial cell growth *in vitro* is also inhibited. In general, mesenchymal cells are stimulated by TGF- β 's but the receptor(s) which mediate proliferation and




Fig. 2. Extracellular pathways of TGF- β : From release of latent form to action on receptors and catabolism. For details, see text.

synthesis of matrix proteins such as procollagen, together with the promotion of monocyte and neutrophil influx into inflammatory sites, are not

yet clearly defined. Epithelial tumor cells lacking type I and II receptors are unusual in that they proliferate in response to TGF- β 's. It is possible

that type V receptors (which have kinase activity as do type II receptors) mediate some of these effects. Neutrophil influx into tissues may be inhibited by TGF- β , rather than stimulated, as in TGF- β -mediated prevention of reperfusion injury. The response depends on TGF- β concentration and TGF- β -mediated alteration in fibronectin production [2,10]. Similarly, dose-dependent reversal of TGF- β effects on endothelial cell growth have been attributed to variations in surface receptor phenotype and modulation of acidic fibroblast growth factor receptors [8].

Whilst the pro-inflammatory and fibrogenic effects of TGF- β have been called the 'dark side' of its character, TGF- β enhances wound strength and stimulates epithelial cell growth *in vivo*. This contrasts with the inhibitory effect seen *in vitro* and promotes healing. Epithelial cells in this regenerative setting resemble malignant tumor cells which usually proliferate in response to TGF- β . TGF- β can stimulate as well as inhibit immune responses [2,6,12]. TGF- β_1 gene knock-out mice establish the importance of TGF- β 's in normal homeostasis. TGF- β_1 gene knock-out embryos have a 50% intrauterine death rate and the homozygous progeny develop a fatal inflammatory syndrome by 3 to 6 weeks of age. No studies of TGF- β_2 or TGF- β_3 knock-out mice have yet been reported.

Several factors appear to influence the response to bioactive TGF- β s. The potency of TGF- β_1 , - β_2 and - β_3 is similar in stimulating NRK cell colony formation but TGF- β_2 is much less inhibitory to bone marrow cell growth compared with TGF- β_1 on a per molecule basis and TGF- β_3 is three to five times more potent in stimulating osteoblast growth and collagen synthesis. Particular TGF- β isoforms are required for certain embryological events (e.g. TGF- β_3 for murine palate development). The structure of the TGF- β molecule and the nature of TGF- β binding proteins and receptors which lack kinases needed for direct cell signaling are important. Endoglin mediates the growth inhibitory response to TGF- β_1 and - β_3 on cells such as fetal trophoblasts and may inhibit trophoblast invasion of maternal uterine tissues [13]. TGF- β binding proteins such

as endoglin present the TGF- β molecule to the receptors with signaling activity. Invasive cells such as fetal trophoblasts produce metalloproteinases which may liberate and activate inactive matrix-associated TGF- β . Other cytokines may also enhance or inhibit the effects of TGF- β [9]. TGF- β_3 may be less fibrogenic *in vivo* and antagonize the fibrogenic effects of TGF- β_1 and - β_2 [12]. As an illustration of the role of the cellular environment on response, replication of NRK fibroblasts or epithelial cells grown as anchorage-dependent monolayers in culture is inhibited by TGF- β , but is stimulated when the same cells are grown in an anchorage-independent manner. *In vivo*, TGF- β enhances wound reepithelialization. These observations have led to the concept that cytokines and matrix proteins act together as a molecular language modulating target cell responses. Defining these interactions should facilitate our understanding of seemingly paradoxical effects. It is also clear that one cytokine may modify receptors for the same type of cytokine and receptors for other cytokines on target cells.

5. Possible medical applications

Applications of TGF- β 's remain speculative. Enhancing wound healing and healing of lesions in inflammatory bowel disease appears promising. Recombinant simian TGF- β_2 has been used systemically as an immunosuppressant (e.g. for multiple sclerosis where enhanced TGF- β levels herald remission) but may entail renal toxicity. The commercial use of TGF- β_{1-3} is therefore still awaited. TGF- β 's may prevent post-ischemia reperfusion injury and could be valuable following myocardial injury and cerebrovascular ischaemia. Some women appear to 'reject' their embryos due to subnormal production of atypical TGF- β_2 -like molecules, suggesting diagnostic and therapeutic approaches. Inhibition of TGF- β could be useful in arresting development of pathologic states associated with fibrosis such as liver cirrhosis, pulmonary fibrosis, scleroderma, chronic pancreatitis and nephritis. TGF- β levels may be elevated by hemorrhage or infection, and could provide useful therapeutic targets. In sum-

mary, the TGF- β family constitute a fascinating set of molecules greatly expanded by the recent discovery of TGF- β 's with atypical molecular weights and distinct functional properties the potential of which remains to be tapped.

References

- [1] D.W. Burt, A.S. Law, Evolution of the transforming growth factor-beta superfamily, *Prog. Growth Factor Res.* 5 (1994) 99–118.
- [2] D.A. Clark, K.C. Flanders, H. Hirte, J.R. Dasch, R. McAnulty, R.J. McAnulty, G.J. Laurent, Characterization of murine pregnancy decidua transforming growth factor β . I. Transforming growth factor β_2 -like molecules of unusual molecular size released in bioactive form, *Biol. Reprod.* 52 (1995) 1380–1388.
- [3] R. Derynck, Y. Zhang, Intracellular signalling. The Mad way to do it, *Current Biol.* 63 (1996) 1226–1229.
- [4] C.M. Dubois, M.-H. Laprise, F. Blanchette, L.E. Leduc, R. Leduc, Processing of transforming growth factor β_1 precursor by human furin convertase, *J. Biol. Chem.* 270 (1995) 10618–10624.
- [5] M. Horimoto, J. Kato, R. Takimoto, T. Terui, Y. Mogi, Y. Niitsu, Identification of a transforming growth factor beta-1 activator derived from a human gastric cancer cell line, *Br. J. Cancer* 72 (1995) 676–682.
- [6] S. Kondo, K. Isobe, N. Ishiguro, I. Nakashima, T. Miura, Transforming growth factor- β_1 enhances the generation of allospecific cytotoxic T-lymphocytes, *Immunology* 79 (1993) 459–464.
- [7] Q. Liu, S.S. Huang, J.S. Huang, Kinase activity of the type V transforming growth factor β receptor, *J. Biol. Chem.* 269 (1994) 9221–9226.
- [8] Y. Moyen, M. Kan, G.H. Sao, W.L. McKehan, J.D. Sato, Bifunctional effects of transforming growth factor- β (TGF- β) on endothelial cell growth correlate with phenotypes of TGF- β binding sites, *Exp. Cell Res.* 191 (1990) 229–304.
- [9] C. Nathan, M. Sporn, Cytokines in context, *J. Cell Biol.* 113 (1991) 981–986.
- [10] T. Parekh, B. Saxena, J. Reibman, B.N. Cronstein, L.I. Gold, Neutrophil chemotaxis in response to TGF- β isoforms (TGF- β_1 , TGF- β_2 , TGF- β_3) is mediated by fibronectin, *J. Immunol.* 152 (1994) 2456–2466.
- [11] A.B. Roberts, M.B. Sporn, Peptide growth factors and their receptors, in: *Handbook of Experimental Pharmacology*, vol. 95, part 1, 1990, pp. 419–472.
- [12] M. Shaw, D.M. Foreman, M.W. Ferguson, Neutralization of TGF- β_1 and TGF- β_2 or exogenous addition of TGF- β_3 to cutaneous rat wound reduces scarring, *J. Cell Sci.* 108 (1995) 985–1002.
- [13] I. Caniggia, C.V. Taylor, J.W. Ritchie, S.J. Lye, M. Letarte, Endoglin regulates trophoblast differentiation along the invasive pathway in human villous explants Placenta, *J. Immunol.* 138 (1997) 4977–4988.

Declaration under U.S.C. § Rule 132

IN THE MATTER OF

US Patent Application No. 09/380,327
by ROBERTSON et al.

EXHIBIT DAC-3

This is Exhibit DAC-3 referred to in the Statutory Declaration by David Alexander CLARK

dated

16 Dec 2002

Before me:



A person empowered to witness Statutory
Declarations under the laws of the Province of
Ontario, Canada.

16/12/82 David A Clark
DR23

Characterization of Murine Pregnancy Decidua Transforming Growth Factor β . I. Transforming Growth Factor β 2-Like Molecules of Unusual Molecular Size Released In Bioactive Form¹

DAVID A. CLARK,^{2,3} KATHLEEN C. FLANDERS,⁵ HAL HIRTE,³ JAMES R. DASCH,⁴ ROBINA COKER,⁶
ROBIN J. McANULTY,⁶ and GEOFFREY J. LAURENT⁶

Molecular Virology-Immunology Program,³ McMaster University, Hamilton, Ontario, Canada L8N 3Z5
Celtrix Pharmaceuticals,⁴ Santa Clara, California

Laboratory of Chemoprevention,⁵ NCI-NIH Bldg. 41, Bethesda, Maryland

Biochemistry Unit,⁶ National Heart and Lung Institute, London SW3, United Kingdom

ABSTRACT

A novel type of bioactive transforming growth factor β 2 (TGF β 2)-related immunosuppressive activity, lower in molecular mass (20–23 kDa) than a conventional TGF β 2 standard (25 kDa), has been shown to be released by non-T non-B suppressor cells of murine decidua into fetal bovine serum (FBS)-containing tissue culture medium during a 48-h incubation at 37°C. Substitution of a serum-free medium has allowed direct PAGE-Western blotting and the demonstration in supernatant (prior to incubation at 37°C) of a TGF β 2-immunoreactive doublet at a higher molecular mass (26 and 27 kDa) than the standard but with apparent immunosuppressive activity. When decidua were incubated in serum-free medium at 37°C, immunosuppressive activity in the supernatant increased to peak at 18 h in association with the appearance of the previously described lower molecular mass species of molecule. The doublet did not appear to be the result of glycosylation of a conventional 25-kDa TGF β 2 and could be converted into the lower molecular mass form by incubation for 18 h at 37°C, with pH 4.5 but not with pH 7.5 buffer; this incubation in the absence of decidual cells was not accompanied by increased immunosuppressive activity. This transformation could be blocked by a brief heating of the supernatant to 80°C for 10 min to destroy enzymes present in supernatant prior to mixing with the acidic buffer, but biologic activity neutralizable by anti-TGF β 2 was retained. These data suggest that TGF β 2-like immunoregulatory activity in murine decidua is biologically active and that the size of the molecules may be modified by local enzymatic activity. The immunosuppressive factor was shown to be capable of stimulating procollagen production by confluent human fibroblasts assayed by HPLC measurement of hydroxyproline; but, in comparison to an authentic TGF β 2 standard, the potency was much lower. On this basis, it would be possible to have local active immunosuppression without stimulation of fibrosis in implantation site decidua.

INTRODUCTION

We recently described a transforming growth factor β 2 (TGF β 2)-related molecule produced by small-sized non-T suppressor cells at the implantation site in murine decidua [1, 2]. A major peak of suppressive activity, purified by HPLC using a molecular sieving column and high potassium-acetic acid (pH 2.9) buffer, proved by Western blotting and electroelution to have a molecular mass slightly lower than that of a purified TGF β standard [1, 2]. Nevertheless, these molecules were able to stimulate anchorage-independent growth of normal rat kidney (NRK) fibroblasts in semisolid medium in the presence of epidermal growth factor (EGF); the bioactivity of these molecules was neutralized by anti-TGF β 2; and release of the activity correlated closely with expression of TGF β 2 mRNA by small lymphocytic suppressor cells in decidua [1, 3]. Two problems with these data have been identified. First, the supernatants were generated by incubation of disaggregated decidua at 37°C for 48 h in tissue culture medium containing 10% non-heat-

inactivated fetal bovine serum (FBS): latent TGF β might have been activated by enzymes during the incubation period, and/or conventional TGF β might have been modified so as to have a lower molecular mass. Indeed, Wollenberg found that incubating radioiodinated TGF β 1 with proteases and elastases generated fragments in the size range of our activity as defined by PAGE-Western blots and electroelution [4]. A second problem related to the use of medium containing 10% FBS was the high protein concentration, which made it difficult to determine the size of the molecules by Western blotting without a preliminary HPLC purification: the acid buffer conditions could have modified the TGF β species present in decidual supernatants.

In this paper, we show that our TGF β 2-related activity is present in serum-free medium incubated with decidua. Active TGF β 2 was present in the medium in which the cells were suspended, without incubation at 37°C (time = 0), as a doublet with molecular masses slightly greater than that of TGF β 2. This doublet did not appear to reflect glycosylation of a conventional 25-kDa TGF β 2. With incubation of the decidual tissue, activity increased and peaked at 18 h, and this was associated with increased antigenic and biologic activity at the lower molecular mass (20–23 kDa) and an alteration in the doublet. Bioactivity included immu-

Accepted January 28, 1995.

Received September 19, 1995.

¹Supported by a grant from the Medical Research Council of Canada (MT6447).

²Correspondence: Professor David A. Clark, Rm. 3V39, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5.




FIG. 1. NRK fibroblast assay for TGF β . Upper panel: Relationship of colorimetric end point to colony count performed with a microscope. No significant difference was detected by Student's *t*-test for paired samples ($p > 0.5$, 4 replicates per group). Error bars represent ± 1 SEM. Addition of rabbit anti-TGF β antibody, 10 μ g/ml, completely abrogated growth-stimulating effect of TGF β at all test concentrations (data not shown). Lower panel: comparison dose response of TGF β 1 (solid squares) to TGF β 2 (solid inverted triangles). Error bars represent ± 1 SEM, 4 replicates per point.

have found this to directly correlate with colony formation and to provide a less tedious assay. Briefly, 25 μ l tetrazolium (MTT; Sigma, 5 mg/ml in PBS) was added to each well, and samples were incubated at 37°C for 4 h. Then 100 μ l extraction buffer (20% [w/v] SDS in 50% dimethylformamide in distilled water containing 2% glacial acetic acid and 2.5% 1 N HCl, pH 4.7) was added to each well to solubilize formazan generated by the viable cells. After overnight incubation at 37°C, the OD of each well at 570 nm was determined by means of an EMAX ELISA reader (Molecular Devices, Palo Alto, CA) using a reference OD of 630 nm. The difference in OD was proportional to the number of colonies present as shown in Figure 1 (upper panel). Purified TGF β 1 obtained from R & D Systems (Minneapolis, MN) was routinely used to generate a standard curve, as the result was not different from that obtained with porcine TGF β 2 (as shown in Fig. 1, lower panel) and the latter was in short supply.

Affinity column- and HPLC-purified immunosuppressive activity was also tested for its ability to stimulate procollagen production by fibroblasts through use of a method described previously [10]. Briefly, human fetal lung fibroblasts (HFL-1, obtained from ATCC) were cultured to confluence in 12-well plates with DMEM-5% newborn calf serum (NCS). They were then preincubated for 24 h with medium containing 4 mM glutamine, 50 μ g/ml ascorbic acid, 0.2 mM proline, and 2% NCS. The medium was replaced with medium containing the HPLC fraction or TGF β 2 (either natural porcine or recombinant simian). The cells were incubated for a further 24 h before harvesting. After harvesting, proteins in the cell layer and medium were precipitated with 67% ethanol and the samples filtered (0.65 μ m). The ethanol-insoluble fraction was then hydrolysed in 6 M hydrochloric acid, and the hydroxyproline present was measured by HPLC as an index of procollagen content. A dose-response curve was generated for natural porcine TGF β 2. These results were then compared with the response to human recombinant TGF β 2 (in PBS or HPLC buffer) and to the purified decidual factor at dilutions of 1/10 and 1/20. The effect of HPLC buffer at 1/10 and 1/20 was also tested.

Modification of Supernatants

Serum-free conditioned supernatants were treated with *N*-glycanase (Sigma and Genzyme, Boston, MA) or endoglycosidase H (Genzyme) by the method of Sha et al. [11] prior to Western blotting to determine whether the position of the TGF β 2-like bands could be shifted. Briefly, 250 μ l supernatant was added to 100 μ l 10 mM EDTA, 0.2% SDS, 0.1 M 2-mercaptoethanol, and 1% NP-40 buffer containing 1.25 mU of *N*-glycanase, and incubation was conducted for 18 h at 37°C. For endoglycosidase F, a buffer containing 50 mM Na acetate, 2 mM CaCl₂, 2 mM EDTA, and Tris-HCl, pH 4.5, was used. The material was lyophilized and stored at 4°C until reconstitution in concentrated form in SDS buffer for PAGE-Western blotting.

In some experiments, the supernatants were heated at 80°C for 10 min (to activate any latent TGF β and to inactivate endogenous enzymes [12]), and the effect of subsequent incubation at 37°C at acid pH was studied. Latent TGF β was also activated in some experiments by addition of 5–10 μ l of 1 N HCl to 100 μ l supernatant (pH reached 2.0) at room temperature for 30 min [13] and then neutralizing to pH 7.2 by addition of 2 N NaOH.

Statistics

The significance of the difference between means was determined by Student's *t*-test.

RESULTS

Activity in Serum-Free Medium

Figure 2 illustrates the typical increase in suppressive activity in serum-free supernatants incubated for different times

nosuppression, stimulation of NRK fibroblast colony formation, and, to a lesser degree, stimulation of procollagen synthesis. The data are compatible with production and generation of novel bioactive TGF β 2-like molecules by murine pregnancy decidua.

MATERIALS AND METHODS

Mice and Supernatants

Female C3H/HeJ mice were obtained from the Jackson Laboratory (Bar Harbor, ME) and mated with similarly obtained DBA/2 males as previously described. Day 0.5 was defined as the morning the vaginal sperm plug was sighted. On Days 12.4–14.5 of pregnancy, the animals were killed, the uteruses removed and opened, and the placentae peeled from the underlying decidua. The decidua was then harvested by scraping down to muscle and was disaggregated by passage through a 60-mesh stainless steel screen [1]. Details concerning cell yields and viability have been reported previously [1]. All procedures were carried out through use of α -MEM (Grand Island Biological Company, Burlington, ON, Canada) containing 10 mM HEPES and antibiotics but with 1 mg/ml (0.1%) BSA (Sigma, St. Louis, MO) in place of FBS. Usually one uterine decidua per milliliter was cultured in a Falcon #2057 (Los Angeles, CA) tube for varying time periods. Zero time (t0) supernatant (no 37°C incubation) was obtained by spinning down the cells in the 1-ml resuspension volume before incubation; t6, t12, t18, t24, t36, and t48 supernatants were similarly obtained by harvesting the 1-ml cell-free supernatant after the indicated time at 37°C in 5% CO₂. The t0 sample was at room temperature for approximately 30 min and would be expected to contain free TGF β as well as molecules released from matrix and from cells disrupted during the disaggregation procedure.

Fractionation of Supernatants and Western Blotting

Serum-free conditioned medium was concentrated by speed vacuum centrifugation, and a 5–10-times concentrated sample was separated by HPLC using a TSKG2000 analytical column run at 1 ml per min as previously described [1]. Elution buffer was 0.05 M KCl, 0.58% acetic acid (pH 2.9); the reduction in concentration of KCl from 0.1 M made it easier to analyze speed vacuum-concentrated HPLC fractions by PAGE-Western blots. Western blotting of unseparated supernatant and HPLC fractions was done as described previously using a rabbit antibody specific for a peptide corresponding to amino acids 50–75 of TGF β 2 [1, 3, 5]. Prestained high molecular mass standards were obtained from Bethesda Research Labs (Bethesda, MD), and purified porcine TGF β 2 was obtained from R & D Systems (Minneapolis, MN). In some experiments, supernatant was applied to a 5-ml column containing Reactibeads (Pierce Chemical Company, Rockford, IL) to which the 3C7 murine monoclonal anti-TGF β 2 antibody had been attached [6]. The

3C7 antibody is known to neutralize murine decidua-associated suppressive activity by at least 75% [1]. Briefly, approximately 45 mg of purified antibody was dialyzed overnight against 0.05 M borate, 0.1 M NaCl buffer, pH 8.5. Reactigel 6X was washed with ice-cold deionized H₂O; 15 ml of packed gel was mixed with the antibody. After 29 h at room temperature, the gel was centrifuged and the supernatant removed. Twenty milliliters of 0.15 M glycine in 0.1 M bicarbonate buffer, pH 8.3, was added for 4 h to quench any residual active sites on the gel. The gel was washed with 3 alternating cycles of 0.1 M acetate + 0.5 M NaCl buffer (pH 4.3) and 0.1 M bicarbonate + 0.5 M NaCl buffer (pH 8.3). Coupling efficiency was estimated to be approximately 95%. The 3C7-coated beads were loaded into a column, and decidua supernatant was added and incubated for 30 min at 22°C. Then the affinity column was washed with PBS until no optical density (OD) at 280 nm (OD 280) activity could be detected and was eluted with 0.1 M glycine, pH 2.9. One-milliliter fractions were collected and tested for OD 280 activity, antigenic activity as revealed by Western blotting, and biological activity as described below.

Bioassays

Immunosuppression was assessed through use of the murine CTL generation assay system previously described [1, 3]. Percentage ⁵¹Cr-release values (P) were converted into the N_{at} parameter linearly related to CTL number from the formula,

$$N_{at} = \ln(1 - P/100).$$

Percentage suppression was calculated from 100–100 (N_{at} with supernatant/N_{at} in medium or buffer control) [3]. Recombinant human TGF β 2 standard and 3C7 murine monoclonal neutralizing antibody were kindly supplied by Celtrix Pharmaceuticals (Santa Clara, CA).

In some experiments, TGF β activity was assayed by a modification of the NRK rat kidney fibroblast colony formation assay [1, 7–9]. The TGF β assay employed the NRK-49F rat kidney fibroblasts (ATCC, Rockville, MD), which form colonies in semisolid medium containing EGF when TGF β is added. NRK fibroblasts were maintained in monolayer culture in DMEM/F12 medium (Gibco, Grand Island, NY) containing 3% FBS (Gibco), 5 μ g/ml insulin, 10 μ g/ml transferrin, 5 ng/ml EGF, 5×10^{-5} M phosphoethanolamine, 100 IU/ml penicillin, 100 μ g/ml streptomycin, and 2.5 μ g/ml amphotericin B (all additives from Sigma). The fibroblasts were harvested by trypsinization, and 500 cells in 50 μ l preheated medium containing 0.3% low-melting-point agarose were plated in culture wells of a 96-well plate over a layer of 100 μ l medium containing 1% low-melting-point agarose that had gelled at 4°C. After the NRK fibroblast aliquot had been similarly gelled, 50 μ l of control or test sample was added and the plates were incubated at 37°C in a 5% CO₂ incubator for 7 days. Colony growth was determined by means of the colorimetric endpoint (through use of a modification of the method of Hansen et al. [8]), as we

16. Kovacina KS, Steele-Perkins G, Purchio AF, Lioubin M, Miyazono K, Heldin CH, Roth RA. Interactions of recombinant and platelet transforming growth factor- β 1 precursor with the insulin-like growth factor II/mannose 6-phosphate receptor. *Biochem Biophys Res Commun* 1989; 160:393-403.
17. Huber D, Philipp J, Fontana A. Protease inhibitors interfere with the transforming growth factor- β -dependent but not the transforming growth factor- β -independent pathway of tumour cell-mediated immunosuppression. *J Immunol* 1992; 148:277-284.
18. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Hien UL, Liotta LA, Falay V, Kehrl JH, Fauci AS. Transforming growth factor type β : rapid induction of fibrosis and angiogenesis *in vivo* and stimulation of collagen formation *in vitro*. *Proc Natl Acad Sci USA* 1986; 83:4162-4171.
19. Coker RK, McAnulty RJ, Laurent GJ. Transforming growth factor β 1, β 2 and β 3 isoforms all stimulate procollagen synthesis and reduce degradation by human fetal lung fibroblasts. *Am J Resp Crit Care Med* 1994; 149:A627 (abstract).
20. Flanders KC, Thompson NL, Cissel DS, Van Obberghen-Schilling E, Baker CC, Kass ME, Ellingsworth LR, Roberts AB, Sporn MB. Transforming growth factor- β 1: histochemical localization with antibodies to different epitopes. *J Cell Biol* 1989; 108:653-660.
21. Clark DA, Flanders KC, Starkey P, Vince G, Hirte H. Murine and human decidua-associated natural suppressor cells release a novel type of TGF- β 2. *J Immunol* 1993; 150:4A (abstract).
22. Hoskin DW, Brooks-Kaiser JC, Kaiser M, Murgita RA. Reactivity of monoclonal antibody 1E5.B5 with a novel phenotypic marker expressed on a murine natural suppressor cell subset. *Hybridoma* 1992; 11:203-215.
23. Merali F, Manuel J, Arck P, Clark DA. Do murine decidua natural suppressor cells synthesize novel TGF- β 2-related suppressor factor? *Am J Reprod Immunol* 1994; 31:230 (abstract).
24. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E. Natural inhibitor of transforming growth factor- β protects against scarring in experimental kidney disease. *Nature* 1992; 360:361-364.
25. Abramson SR, Woessner JF Jr. cDNA sequence for rat dermatan sulfate proteoglycan-II (decorin). *Biochem Biophys Acta* 1992; 1132:225-227.
26. Clark DA, Chaput A, Tutton D. Active suppression of host-vs-graft reaction in pregnant mice. VII. Spontaneous abortion of allogeneic CBA/J \times DBA/2 fetuses in the uterus of CBA/J mice correlates with deficient non-T suppressor cell activity. *J Immunol* 1986; 136:1668-1675.
27. Clark DA, Chaput A, Walker C, Rosenthal KL. Active suppression of host-vs-graft reaction in pregnant mice. VI Soluble suppressor activity obtained from decidua of allopregnant mice. *J Immunol* 1985; 134:1659-1664.
28. Slapsys RM, Younglai E, Clark DA. A novel suppressor cell develops in uterine decidua in response to fetal trophoblast-type cells. *Reg Immunol* 1988; 1:182-189.
29. Schmin P, Cox D, Bilbe G, Maier R, McMaster GK. Differential expression of TGF- β 1, β 2, and β 3 genes during mouse embryogenesis. *Development* 1991; 111:117-130.
30. Miller DA, Lee A, Pelton RW, Chen EY, Moses HL, Derynck R. Murine transforming growth factor β 2 cDNA sequence and expression in adult tissues and embryos. *Mol Endocrinol* 1989; 3:1108-1114.
31. Das SK, Paria BC, Andrews GK, Dey SK. Effects of 9-ene-tetrahydrocannabinol on expression of β -type transforming growth factors, insulin-like growth factor-I and *c-myc* genes in the mouse uterus. *J Steroid Biochem Mol Biol* 1993; 45:459-465.
32. Pelton RW, Nomura S, Moses HL, Hogan BL. Expression of transforming growth factor β 2 RNA during murine embryogenesis. *Development* 1989; 106:759-767.
33. Cheng HL, Schneider SL, Kane CM, Gollnick SO, Grande C, Thompson D, Pietrzak E, Tomasi TB. TGF- β 2 gene and protein expression in maternal and fetal tissues at various stages of murine development. *J Reprod Immunol* 1993; 25:133-148.
34. Das SK, Flanders KC, Andrews GK, Dey SK. Expression of transforming growth factor- β isoforms (β 2 and β 3) in the mouse uterus: analysis of the periimplantation period and effects of ovarian steroids. *Endocrinology* 1992; 130:3459-3466.
35. Charnock-Jones DS, Sharkey AM, Rajput-Williams J, Burch D, Schofield JP, Fountain SA, Boock CA, Smith SK. Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. *Biol Reprod* 1993; 48:1120-1128.
36. Imai K, Maeda M, Fujiwara H, Okamoto N, Kariya M, Emi N, Takakura K, Kanzaki H, Mori T. Human endometrial stromal cells and decidual cells express cluster of differentiation (CD) 13 antigen/aminopeptidase N and CD10 antigen/neuronal endopeptidase. *Biol Reprod* 1992; 46:328-334.
37. Bodmer S, Huber D, Heid I, Fontana A. Human glioblastoma cell derived transforming growth factor- β 2: evidence for secretion of both high and low molecular weight biologically active forms. *J Neuroimmunol* 1991; 34:33-42.
38. King RJB, Wang DY, Daly RJ, Darbre PD. Approaches to studying the role of growth factors in the progression of breast tumours from the steroid sensitive to insensitive state. *J Steroid Biochem* 1989; 34:133-138.
39. Mustoe TA, Pierce GF, Thomason A, Gramates P, Sporn MB, Deuel TF. Accelerated healing of incisional wounds in rats induced by transforming growth factor- β . *Science* 1987; 237:1333-1336.
40. Wahl S. Transforming growth factor beta (TGF- β) in inflammation: a cause and cure. *J Clin Immunol* 1992; 12:61-74.
41. Roberts AB, Sporn MB. Regulation of endothelial cell growth, architecture, and matrix synthesis by TGF- β . *Am Rev Resp Dis* 1989; 140:1126-1128.
42. Nathan C, Sporn M. Cytokines in context. *J Cell Biol* 1991; 113:981-986.
43. Paralkar VM, Vukicevic S, Reddi AH. Transforming growth factor β type 1 binds to collagen IV of basement membrane matrix: implications for development. *Dev Biol* 1991; 143:303-308.
44. Huang SS, O'Grady P, Huang JS. Human transforming growth factor β - α 2-macroglobulin complex is a latent form of transforming growth factor β . *J Biol Chem* 1988; 263:1535-1541.
45. Ohta M, Greenberger JS, Anklesaria P, Bassols A, Massague J. Two forms of transforming growth factor- β distinguished by multipotent haematopoietic progenitor cells. *Nature* 1987; 329:539-541.
46. Jennings JC, Mohan S, Linkhart TA, Widstrom R, Baylink DJ. Comparison of the biological actions of TGF beta-1 and TGF beta-2: differential activity in endothelial cells. *J Cell Physiol* 1988; 137:167-172.
47. Madri JA, Bell L, Merwin JR. Modulation of vascular cell behaviour by transforming growth factors β . *Mol Reprod Dev* 1992; 32:121-126.
48. Burmester JK, Qian SW, Roberts AB, Huang A, Amatayakul-Chantler S, Suardet L, Odartchenko N, Madri JA, Sporn MB. Characterization of distinct functional domains of transforming growth factor β . *Proc Natl Acad Sci USA* 1993; 90:8628-8632.

that detect the 6.0-, 5.0-, and/or the 3.5-kb-sized mRNAs hybridize with placental and/or uterine epithelial cells rather than with the decidual natural suppressor cells we have described [3, 29–34]. Further, different sizes of mRNA transcripts for vascular endothelial growth factor (VEGF) produce molecules of different molecular mass [35]. Cloning and expressing particular mRNA transcripts for decidual TGF β 2 could generate the types of TGF β 2-like molecules we have described in this paper. However, TGF β s are translated into a large precursor molecule within the cell, and this is modified by processing mechanisms prior to release from the cell surface [18]. It is therefore possible that the molecules of interest would be produced only if the particular mRNA were expressed in the 1E5.B5.1 subset of decidual lymphomyeloid cells. Since these have not yet been cloned, such an experiment would not likely be feasible (it has been suggested that uterine epithelium in pregnant mice may produce TGF β 2 [3, 33], but the types of molecules illustrated in Figure 3 can be obtained from the implantation site described, where there is no epithelium (Clark et al., unpublished results). The second approach is to purify each component to homogeneity for microsequencing and assay of biologic activities. Development of antibodies specific for the different sizes/types of the molecule will likely be required for a proper understanding of events in situ, and this may be possible once the molecular sequence is known [6, 20]. Enzymatic modification may play an important role in rendering the doublet more active. If enzymatic processing by decidual-associated enzymes does prove important in altering the biological activity of these TGF β 2-related molecules in situ, it will also be necessary to characterize the regulation of the enzyme in order to come to a full understanding of the biology of the TGF β 2-related activity. A variety of enzymes are known to be present at the fetomaternal interface [36].

Support for the existence of TGF β species that do not have a molecular mass of 25 kDa, as does conventional TGF β , is provided by studies of "successful neoplasms" other than the fetus. Glioblastoma cells have been reported to secrete an 80–100-kDa immunoprecipitable and bioactive TGF β 2, and breast cancer cells may contain a 30–32-kDa doublet as well as a 40-kDa TGF β [37, 38]. Anomalous-sized bioactive TGF β s may not show the typical 12.5-kDa band on exposure to reducing agents [18]. Recombinant TGF β 2 of the conventional 25-kDa molecular mass injected into the peritoneal cavity of pregnant mice at 1–2 μ g/day to produce immunosuppression generates thick adhesions and a sick animal (Clark et al., unpublished results). Fibrosis and inflammation (i.e., monocyte recruitment) seen with injection of the active recombinant TGF β [39, 40] are not evident in histological sections of decidua where our putatively active TGF β 2-like factor is being produced [3]. Although the basis for this may lie in the binding of active TGF β by matrix components (i.e., α -2 macroglobulin-pregnancy zone protein, PP14, α -fetoprotein, type IV collagen, and decorin) or

by presence of other cytokines, which may modify TGF β bioactivity [24, 25, 41–44], it is also possible that the TGF β 2 molecules produced in pregnancy decidua that have anomalous molecular mass are also biologically different from conventional TGF β 2. Figure 9 suggests that our molecules are less potent in stimulating collagen synthesis compared to immunosuppressive activity. It is known that TGF β 2 is less potent than TGF β 1 in inhibiting lymphomyeloid and endothelial cells [45–47], so variation in the potency of the many different effects of TGF β s [18] might be expected to arise with variation in molecular structure. Indeed, distinct functional domains have recently been identified on conventional 25-kDa TGF β [48]. Whether our anomalous-sized TGF β 2-like molecules arise from a different gene than that coding for conventional 25-kDa TGF β 2, or arise by alternate splicing and posttranscriptional modification of mRNA from the known TGF β 2 gene, remains uncertain. Further studies of the novel decidual TGF β 2-related molecules will likely provide valuable insights into their role in successful reproduction.

REFERENCES

- Clark DA, Flanders KC, Banwatt D, Millar-Book W, Manuel J, Stedronska-Clark J, Rowley B. Murine pregnancy produces a unique immunosuppressive molecule related to transforming growth factor β 2. *J Immunol* 1990; 144:3008–3014.
- Clark DA, Lea RG, Flanders KC, Banwatt D, Chaouat G. Role of a unique species of TGF- β in preventing rejection of the conceptus during pregnancy. In: Gergely J, Benczur M, Erdei A, Falus A, Füst Gy, Medgyesi G, Petranyi Gy, Rajnavölgyi E (eds.), *Progress in Immunology VIII*. Budapest: Springer-Verlag; 1992: 841–847.
- Lea RG, Flanders KC, Harley CB, Manuel J, Banwatt D, Clark DA. Release of a transforming growth factor (TGF)- β 2-related suppressor factor from postimplantation murine decidual tissue can be correlated with the detection of a subpopulation of cells containing RNA for TGF- β 2. *J Immunol* 1992; 148:778–787.
- Wollenberger AW. Cytokine antagonistic functions of α -2 macroglobulin. University of Guelph: Guelph, Ontario, Canada; 1992. Ph.D. Thesis.
- Flanders KC, Roberts AB, Ling N, Fleurdelys BE, Sporn MB. Antibodies to peptide determinants in transforming growth factor-beta and their application. *Biochemistry* 1988; 27:739–746.
- Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L. Monoclonal antibodies recognizing transforming growth factor- β . Bioactivity neutralization and transforming growth factor β 2 affinity. *J Immunol* 1989; 142:1536–1541.
- Hamburger AW, White CP, Dunn FE. Secretion of transforming growth factors by primary human tumor cells. *Br J Cancer* 1985; 51:9–14.
- Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. *J Immunol Methods* 1989; 119:203–210.
- Hirte H. A quantitative colony-forming bioassay for TGF- β using a colorimetric endpoint. *Proc Am Assoc Cancer Res* 1993; 34:240 (abstract).
- McAnulty RJ, Campa JS, Cambrey AD, Laurent GJ. The effects of transforming growth factor beta on rates of procollagen synthesis and degradation *in vitro*. *Biochem Biophys Acta* 1991; 1091:231–235.
- Sha X, Brunner AM, Purchio AF, Gentry LE. Transforming growth factor β 1: importance of glycosylation and acidic protease for processing and secretion. *Mol Endocrinol* 1989; 3:1090–1098.
- Brown PD, Wakefield LM, Levinson AD, Sporn MB. Physicochemical activation of recombinant latent transforming growth factor-beta's 1, 2, and 3. *Growth Factors* 1990; 3:35–43.
- Miyazono K, Heldin CH. Latent forms of TGF- β : molecular structure and mechanisms of activation. In: *Clinical Applications of TGF- β* , Ciba Foundation Symposium #157. Chichester: Wiley; 1991: 81–92.
- Lawrence DA. Identification and activation of latent transforming growth factor β . *Methods Enzymol* 1991; 198:327–336.
- Dennis PA, Rifkin DB. Cellular activation of latent transforming growth factor β requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. *Proc Natl Acad Sci USA* 1991; 88:580–584.




FIG. 9. Comparison of potency of TGFβ₂ standards and purified decidual suppressor factor in the CTL suppression assay and the procollagen stimulation assay. **A)** Effects expressed as percentage of maximal for CTL suppression with TGFβ₂ standard (solid circles) or HPLC fraction (open circles) with superimposition of the latter to allow readout of approximate effective concentration of TGFβ₂. Solid diamonds show dose-response curve obtained with TGFβ₂ standard in the procollagen stimulation assay and the effect of HPLC fraction (open diamonds) based on effective TGFβ₂ concentration determined in the CTL suppression assay. Values represent mean \pm 1 SEM. For procollagen stimulation assay, SEM values of points on standard curve were $<$ 2%. **B)** Comparison of activity of HPLC-fractionated decidual factor in the CTL and procollagen stimulation assay after correction for differing sensitivities. The two standard curves (solid diamonds, solid circles) have been superimposed (i.e., the ED₅₀% values have been superimposed); consequently, the HPLC titration curve from the procollagen stimulation assay has moved to the right.

sitive than the CTL suppression assay, but the opposite was suggested by the purified decidual material. Correcting for differences in assay sensitivity by superimposing the two dose-response curves obtained with conventional TGFβ₂ (Fig. 9B) created a more striking separation of potency of the decidual material in the two assays. The purified decidual material appeared to have only half of the expected potency in the procollagen synthesis stimulation assay. By simple inspection it is evident that one could have a significant level of immunosuppression at concentrations that did not significantly promote collagen synthesis.

DISCUSSION

The data in this paper show that the TGFβ₂-like molecule released by murine pregnancy decidua has components that are higher as well as components that are lower in molecular mass than conventional 25-kDa bioactive TGFβs. The existence of a higher molecular mass doublet was overlooked in earlier studies because we used 48-h supernatants (generated in 10% FBS-supplemented medium). However, scrutiny of the published figure suggests that at least one component of the doublet was probably present as a faint band [1], consistent with Figure 3. The doublet appears to possess intrinsic biological activity in the absence of modification by proteases, low pH, or other factors

involved in generating the lower molecular mass activity at 20–23 kDa. Further, affinity separation using solid-phase 3C7 anti-TGFβ₂ suggested that part of the doublet did not adhere to the antibody and this component did possess suppressive activity. While part of the doublet present in t0 supernatant behaved similarly and did not bind to 3C7, most of the t0 activity was retained on the column and could not be eluted under the conditions used in these experiments; the latter phenomenon is currently under investigation. The ability of 3C7 to react with t0 activity was confirmed by neutralization of t0 activity *in vitro*. These data suggest that the molecules constituting the doublet in the t18 supernatant differed from those present at t0 due to alteration during the process of generation of the lower molecular mass species during the 18-h incubation. Alteration in TGFβ during processing may have precedent in that antibodies have been developed that distinguish between the intracellular and the extracellular form of TGFβ₁ [20].

The origin of the activity in t0 supernatant (wash medium) is uncertain. It could represent molecules free in interstitial fluid or loosely bound to matrix, or it could represent intracellular TGFβ₂-related peptides released during the disaggregation procedure (viability is approximately 60% [1]). Availability of antibodies specific for the different molecular mass species that could readily resolve this issue are not yet available. The increase in bioactivity during the first 18-h incubation at 37°C could represent release of additional activity due to cell death or synthesis and secretion of new molecules by viable cells. Sequential viability determinations during incubation would not likely distinguish between these alternatives because the cells responsible for TGFβ-mediated suppressive activity *in vitro* appear to be a minor subset of the lymphomyeloid cells present in the decidual cell preparation carrying the 1E5.B5.1 determinant of bone marrow-derived natural suppressor cells [3, 21, 22]. Preliminary pulse-chase studies using radiolabeled amino acids *in vitro* suggest that the doublet is actively synthesized [23], and this will be the subject of a future report. Cessation of net increase in active factor after 18–24-h incubation could be due to increased rates of degradation, cessation of synthesis, production of molecules such as decorin that may bind and antagonize the activity of TGFβs [24, 25], or a combination of some of these. Some decrease in synthesis would be expected due to cell death and due to the dependence of decidual suppressor cell function *in vivo* on soluble signals from fetal trophoblast cells that are absent in our *in vitro* culture system [26–28].

The demonstration that pregnancy-associated TGFβ₂ may be composed of a spectrum of molecules of differing molecular mass not attributable to glycosylation suggests that achieving full understanding of their molecular structure and their individual properties will require one of two possible strategies. It is known that uterine TGFβ₂ mRNA on Northern blots may have molecular sizes of 6.0, 5.0, 4.2, 3.5, and 1.5 kb; and there is some evidence to suggest that probes




FIG. 7. Western blot study of TGF β 2-related decidual factor after treatment of t0 supernatant in vitro. **A)** From left to right: TGF β 2 standard, 25 ng (see arrow; note that downward slope is artifact at edge of gel); t0 supernatant incubated at pH 4.5 for 18 h; t0 supernatant incubated at pH 7.5 for 18 h; t0 supernatant incubated at pH 7.5 with *N*-glycanase (Genzyme) or *N* glycanase (Sigma) for 18 h. **B)** From left to right: TGF β 2 standard, 50 ng; t0 supernatant incubated at pH 7.5 for 18 h; t0 supernatant incubated at 80°C for 10 min and then incubated at pH 7.5, 37°C, for 18 h; t0 supernatant incubated at pH 4.5; t0 supernatant incubated at pH 4.5 at 37°C for 18 h after an initial heating to 80°C for 10 min. Note that there is some variation in intensity of bands due to variation in resolubilization of concentrated lyophilized samples in the SDS sample buffer and due to the small amounts of biologically active molecules present. A higher concentration of standard was used, as detection efficiency of the rabbit anti-TGF β 2 was lower with later bleeds postimmunization.

TGF β 2 band was *not* generated in response to heat. Further, the shift in the band at pH 4.5 from high to low molecular mass was completely abrogated. Nevertheless, the heat-treated t0 supernatant retained its activity in the immunosuppression assay (Fig. 8), and the activity of both heated and unheated t0 supernatant could be neutralized by the 3C7 monoclonal anti-TGF β antibody. The activity of heat-treated t0 supernatant was also retained when examined in the NRK colony-forming assay (data not shown).

Procollagen Synthesis Stimulation

A known effect of TGF β 1 is stimulation of collagen synthesis, which may then result in fibrosis [18]. The precise roles of the two mammalian TGF β 2 and TGF β 3 are not yet well understood. However, we have recently reported that TGF β 2 shares the ability of TGF β 1 to stimulate procollagen synthesis by fibroblasts in vitro [19]. Affinity column-purified decidual immunosuppressive activity was further pu-




FIG. 8. Effect of monoclonal (3C7) anti-TGF β 2 antibody on immunosuppressive activity in serum-free supernatants; t0^H = t0 supernatant heated to 80°C for 10 min. The 3C7 monoclonal is known to neutralize activity in FBS-containing supernatants whereas the 2G1 monoclonal binds but does not neutralize [1], and did not neutralize t0 or t0^H activity (data not shown). All antibodies were used at a final concentration of 10 μ g/ml and test supernatant at the dilution shown. *Denotes significant suppression; **significant abrogation of suppression.

rified by HPLC separation as described in *Materials and Methods*. The immunosuppressive activity of 1/10 and 1/20 dilutions was compared to the recombinant TGF β 2 standard curve, and by superimposition the relative amount of TGF β present was determined. The purified immunosuppressive peak was also tested at 1/10 and 1/20 dilutions on fetal human fibroblasts [10]. Net procollagen synthesis was expressed as a percentage of maximum achieved with the TGF β standard, and the result is illustrated in Figure 9A. The 1/10 but not the 1/20 dilution of the HPLC peak stimulated procollagen formation to a significant degree. However, when plotted as a function of TGF β 2 concentration in the assay, the potency of the decidual material was less than expected from the standard curve (activity of our recombinant TGF β 2 standard was not diminished by presence of the HPLC buffer [data not shown]). From the standard curve, the procollagen synthesis assay was more sen-




FIG. 5. Elution of decidual suppressor activity from 3C7 solid-phase affinity column. A t18 supernatant was used to saturate the column; * and ** indicate reproducible peaks of nonadherent activity. Solid circles: PBS eluate; open circles: acid glycine eluate.

Further evidence that the molecules detected by Western blotting in Figure 3 were related to TGF β 2 was sought by affinity column separations using beads coated with the 3C7 monoclonal anti-TGF β 2 antibody. As can be seen in Figure 5, most of the activity in the t18 supernatant was bound, and the eluted activity showed both high and low molecular mass bands on Western blotting (Fig. 6). The activity (denoted by two asterisks) that was washed from the column by PBS pH 7.2 was also analyzed, and it appeared to be of the higher molecular mass form (data not shown); this could be explained by the column's having < 100% binding efficiency for the molecules. Surprisingly, little if any t0 supernatant activity could be recovered from the affinity column either in the wash phase or with acid glycine




FIG. 6. Western blot analysis of TGF β 2-like material eluted by acid glycine from the 3C7 affinity column. The immunosuppressive activity peak eluted as shown in Figure 5 was collected and analyzed by Western blot assay using rabbit anti-TGF β 2 peptide. The arrowhead shows the location of the TGF β 2 standard (50, 25, or 10 ng). (Note that a lighter band at 43 kDa is not uncommon where higher concentrations of TGF β 2 standard are used.)

(data not shown), and this was reproducible with use of two separate preparations of 3C7-coated Reactibeads. It was not possible to separate the components of the doublet from each other or to separate the doublet from the lower molecular mass material by aqueous phase sieving HPLC in KCl-acetic acid buffer (data not shown).

Enzyme Treatment

The inactive TGF β precursor is known to be glycosylated [14], and TGF β 2 possesses amino acids that could in theory act as glycosylation sites if accessible [18]. If lower molecular mass factors were produced by cleavage of carbohydrate (during incubation in vitro), such sites would need to be accessible to glycosylases. Several sets of experiments were done to try to modify the apparent molecular mass of the doublet shown in t0 supernatant in Figure 3. Figure 7A shows that *N*-glycanase treatment failed to shift the bands, but incubation in pH 4.5 buffer alone generated the lower molecular mass band; this made it impossible to determine whether endoglycosidase H had any effect (and indeed, no additional effect was seen; data not shown). When the t0 supernatant was first heat-inactivated at 80°C for 10 min and then incubated at pH 4.5, the result was as illustrated in Figure 7B. A conventional (i.e., authentic) 25-kDa




FIG. 2. Kinetics of release of suppressive activity from murine pregnancy decidua in serum-free medium. Increment in activity per unit time interval (6 h) shown as open triangle $\Delta s/\Delta t$. Error bars represent ± 1 SEM, 4 replicates per point.

at 37°C. Activity was present at t0 and peaked at t18 (18 h). Thereafter there was some decrease in activity, but this was not statistically significant. There was no increase in activity when t0 supernatants were incubated at 37°C for 18 h in the absence of cells (data not shown). When the supernatants were analyzed by PAGE-Western blotting, a surprising result was obtained. Figure 3 shows that at t0, TGF β 2 antigenic activity was present as a doublet that migrated more slowly and at an apparent molecular mass greater than that of the 25-kDa porcine TGF β 2 standard. By 18 h of incubation, the lower molecular mass band previously described in the HPLC peak of 48-h decidua supernatants (prepared in medium with 10% FBS) [1] appeared, and the doublet became less intense. By 48 h, the doublet was even less evident, as was the lower molecular mass band; this is compatible with a small net decrease in activity as measured in the immunosuppression assay. These findings were confirmed in two additional independent experiments. With reference to the TGF β 2 and prestained standards, the doublet had an estimated molecular mass of 26 and 27 kDa, and the lower band had an estimated molecular mass of 20–23 kDa.

To determine whether bioactive TGF β was being observed in the supernatants rather than a latent TGF β that was being activated in vitro by low pH or enzymes (free or cell associated) [12–17] in the MLC-CTL assay, the supernatants were tested for the ability to stimulate NRK fibroblasts to form colonies in agar in the presence of EGF. It can be seen from the data in Figure 4 that active TGF β




FIG. 3. Western blotting of serum-free medium for TGF β 2. t0 = Zero time wash fluid; t18 = supernatant after incubation for 18 h; t48 = supernatant after incubation for 48 h. Arrowhead denotes position of TGF β 2 standard (10 ng). MW $\times 10^{-3}$ is equivalent to molecular mass in kDa.

was present at both t0 and t18. Activity was increased by exposure of the t0 supernatant to low pH, and this suggested that some latent TGF β may also have been present.




FIG. 4. Bioassay for TGF β activity in serum-free media supernatants using NRK fibroblast assay (100% = 1.286 ± 0.023 o.d.; 0% = 0.116 ± 0.008 o.d. units). Time zero supernatants without treatment (open bar) or after acidification (hatched bar) to pH 2 and neutralization. *Denotes significant increase in suppressive activity, $p < 0.05$. Eighteen-hour supernatant (without treatment, open bar) or after acidification (hatched bar). Control medium (MC; solid bar) showed less than 0.01 $\mu\text{g/ml}$ TGF β ($1.97 \pm 0.8\%$ OD) response; in an independent experiment, no TGF β activity was generated by acid treatment of control medium. Purified TGF β 1 was used as the standard. Error bars represent ± 1 SEM, 4 replicates per point.